Patent Publication Number: US-2017360920-A1

Title: Method and compositions for the prevention and treatment of a hiv infection

Description:
RELATED APPLICATIONS 
     This Application claims the benefit of U.S. Provisional Application 62/082,387, filed Nov. 20, 2014, and U.S. Provisional Application 62/091,392, filed Dec. 12, 2014, the contents of which are incorporated herein by reference. 
    
    
     BACKGROUND 
     Despite antiretroviral therapy (ART), HIV-1 persists in a stable latent reservoir 1,2 , primarily in resting memory CD4 +  T cells 3, 4 . This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed 5  and tested both in vitro and in vivo 6-8 . A key remaining question is whether virus-specific immune mechanisms including cytolytic T lymphocytes (CTL) can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (&gt;98%) of latent viruses carry CTL escape mutations that render infected cells insensitive to CTLs directed at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes from latent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived from the latent reservoir, both in vitro and in patient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir. 
     HIV-1 establishes latent infection in resting CD4 +  T cells 3, 4 . Recent efforts to eradicate HIV-1 infection have focused on reversing latency without global T cell activation 5 . However, inducing HIV-1 gene expression in latently infected cells is not sufficient to cause the death of these cells if they remain in a resting state 9 . Boosting HIV-1-specific immune responses including CTL responses may be required for clearance of the latent reservoir 9 . CTLs play a significant role in suppressing HIV-1 replication in acute infection 10-14 . Because of this strong selective pressure, HIV-1 quickly acquires mutations to evade CTL recognition 12, 13, 15-18 . CTL escape has been studied primarily through the analysis of plasma virus 12, 13, 16, 18-20 , and CTL-based vaccines have been designed based on conserved epitopes 21, 22 . A systematic investigation of CTL escape in the latent reservoir will be of great importance to the ongoing CTL-based eradication efforts, because latent HIV-1 likely represents the major source of viral rebound after treatment interruption. Earlier studies have suggested the presence of CTL escape mutations in proviral DNA 15, 17 , but it still remains unclear to what extent the latent reservoir in resting CD4 +  T cells is affected by CTL escape, whether mutations detected in proviral DNA are representative of the very small fraction of proviruses that are replication-competent, and most importantly, whether the CTL response can recognize and clear infected cells after latency is reversed. Provided herein, in part, is a CD8 +  T cell vaccine or therapy for use against latent HIV-1 infection. 
     SUMMARY OF THE INVENTION 
     Provided herein are methods of preventing or treating a HIV infection in a mammal, such as a human. The methods involve administrating to a mammal in need thereof, a therapeutically effective amount of a CD8+ T cell vaccine composition. Such methods comprise using a CD8 +  T cell vaccine composition which has been pre-stimulated with at least one HIV epitope, such as a HIV-1 Gag epitope, or a pool or mixture of HIV epitopes. The vaccine induces and enhances a CD8 +  T cell immune response against HIV/AIDS in said mammal. 
     One aspect of the invention relates to a method of preventing or treating a HIV infection comprising administering to a mammal in need thereof, a therapeutically effective amount of a CD8 +  T cell vaccine composition, wherein the CD8 +  T cell has been pre-stimulated with at least one HIV epitope, to thereby enhance a CD8 +  T cell immune response against HIV. 
     In certain embodiments, the pre-stimulation occurs ex-vivo. 
     In certain embodiments, the CD8 +  T cell has been pre-stimulated with at least two, three, four, five, six, seven, eight, nine, or ten HIV epitopes. 
     In certain embodiments, the at least one HIV epitope is a subdominant epitope. 
     In certain embodiments, the at least one HIV epitope is a dominant epitope. 
     In certain embodiments, the HIV epitopes comprise subdominant and dominant epitopes. 
     In certain embodiments, the at least one HIV epitope is from HIV-1. 
     In certain embodiments, the at least one HIV epitope is selected from an epitope in the HIV-1 Gag, HIV-1 Nef, HIV-1 Rev, HIV-1 Tat, or HIV-1 Env, or combination thereof. 
     In certain embodiments, the at least one HIV epitope is provided in a pool or mixture of HIV epitopes. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Gag, HIV-1 Nef, HIV-1 Rev, HIV-1 Tat, HIV-1 Env, or combination thereof. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Gag represented by the peptide sequences set forth in Table 2, Table 4, or both. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Nef represented by the peptide sequences set forth in Table 3. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Rev represented by the peptide sequences set forth in Table 5. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Tat represented by the peptide sequences set forth in Table 7. 
     In certain embodiments, the pool or mixture of HIV epitope is a pool or mixture of HIV-1 Env represented by the peptide sequences set forth in Table 6. 
     In certain embodiments, the at least one HIV epitope is an epitope in the HIV-1 Gag. 
     In certain embodiments, the epitope in the HIV-1 Gag is selected from any one of SEQ ID NOs: 1-17, or combination thereof. 
     In certain embodiments, the HIV-1 Gag is from proviral HIV-1 DNA in resting CD4+ T cells from mammals during the acute phase or chronic phase of infection. 
     In certain embodiments, the at least one HIV epitope is synthetic. 
     In certain embodiments, the at least one HIV epitope is unmutated. 
     In certain embodiments, the at least one HIV epitope is mutated. 
     In certain embodiments, the CD8 +  T cell immune response is to subdominant epitope in HIV-1. 
     In certain embodiments, the CD8 +  T cell is from CP36 or CP39. 
     In certain embodiments, the CD8 +  T cell is autologous. 
     In certain embodiments, the CD8 +  T cell has been pre-stimulated with at least one HIV epitope and at lease one cytokine. 
     In certain embodiments, the at least one cytokine is interleukin-2 (IL-2). 
     In certain embodiments, the CD8 +  T cell to CD4 +  T cell ratio is enhanced. 
     In certain embodiments, the CD8 +  T cell response targets latent or reactivated HIV-1 infected cells. 
     In certain embodiments, the CD8 +  T cell immune response is greater in magnitude than a CD8 +  T cell immune response induced by administration of an unstimulated CD8 +  T cell composition. 
     In certain embodiments, the CD8 +  T cell immune response is greater in magnitude than a CD8 +  T cell immune response induced by administration of the HIV epitope alone. 
     In certain embodiments, the efficacy of the immune response against HIV results in a reduction of the levels of HIV viral replication. 
     In certain embodiments, the reduction of levels of HIV viral replication is decreased in log 10  reductions of about 2-logs, 3-logs, 4-logs, 5-logs, 6-logs, 7-logs, 8-logs, or 9-logs. 
     In certain embodiments, the efficacy of the immune response against HIV results in a reduction of levels of plasma HIV-1 RNA. 
     In certain embodiments, the reduction of the levels of plasma HIV-1 RNA is in log 10  reductions of about 2-logs, 3-logs, 4-logs, 5-logs, 6-logs, 7-logs, 8-logs, or 9-logs. 
     In certain embodiments, the efficacy of the immune response against HIV results in a reduction of levels of proviral HIV-1 DNA. 
     In certain embodiments, the levels of provrial HIV-1 DNA is decreased 100-, 200-, 300-, 400-, 500-, 600-, 700-, 800-, 900-, 1000-, 1500-, or 2000-fold. 
     In certain embodiments, the efficacy of the immune response against HIV results in a reduction of the HIV-1 latent reservoir. 
     In certain embodiments, the HIV-1 latent reservoir is decreased 100-, 200-, 300-, 400-, 500-, 600-, 700-, 800-, 900-, 1000-, 1500-, or 2000-fold when compared to the resting CD4 +  T cell population in any healthy or infected individual or total latently infected resting CD4 +  T cell population. 
     In certain embodiments, the resting CD4 +  T cell population in any healthy or infected individual about 10 12  cells. 
     In certain embodiments, the total latently infected resting CD4+T cell population is from about 10 6  to about 10 7  cells. 
     In certain embodiments, the efficacy of the immune response against HIV results in a delay in rebound of HIV viremia after cessation of antiretroviral therapy. 
     In certain embodiments, the delay is measured in months of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months. 
     In certain embodiments, the mammal is a human. 
     In certain embodiments, the human is afflicted with HIV-1. 
     In certain embodiments, the human is chronically infected with HIV-1. 
     In certain embodiments, the human is acutely infected with HIV-1. 
     In certain embodiments, the CD8 +  T cell vaccine composition is administered to a human on suppressive antiretroviral therapy. 
     In certain embodiments, the CD8 +  T cell vaccine composition is administered to the antiretroviral-treated human followed by antiretroviral treatment interruption. 
     In certain embodiments, the CD8 +  T cell vaccine composition is administered to the antiretroviral-treated human in combination with latency reversing therapy. 
     In certain embodiments, the composition is administered to the mammal more than one time over the course of treating or preventing. 
     In certain embodiments, the composition is administered to the mammal in need thereof at about weeks two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, and sixteen post-HIV infection. 
     In certain embodiments, the therapeutically effective amount is about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12  prestimulated CD8 +  T cells per infusion into a patient. 
     In certain embodiments, the effective amount is between about 10 7  to 10 9  prestimulated CD8 +  T cells per infusion into a patient. 
     Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIGS. 1 a   - 1   e.  CTL escape variants dominate the latent reservoir of CP-treated but not AP-treated patients. a, Frequency of variants in Gag CTL epitopes in proviruses from resting CD4 +  T cells. Representative results of 6 patients are shown. Only optimal CTL epitopes relevant to each patient&#39;s HLA type are listed. Results from both Pacbio (left bar) and MiSeq (right bar) sequencing are shown. The effect on CTL recognition (denoted by color) is determined from information in the Los Alamos National Laboratory (LANL) HIV Molecular Immunology Database. b, CTL escape variants identified by sequencing are specific to HLA type. Frequencies of documented escape-associated variants in four well-characterized epitopes are shown for all 15 CP-treated patients. Median and P value from Mann-Whitney test are shown. c, Comparison of CTL escape variant frequency in proviruses between CP- and AP-treated patients. Only well-characterized epitopes are shown. Median and P value from Mann-Whitney test are shown. d, Characterization of CTL responses against HIV-1 Gag epitopes by interferon-γ ELISpot. The peptides tested are listed below the x-axis (black type, epitopes in which sequence variation was detected; blue type, no variation). The observed mutation is underlined in red, and CTL escape (defined by the lost of positive response) is denoted by * above the bar. The peptide concentration was 10 μg/ml. Error bars represent s.e.m., n=3. e, Sequences in Gag CTL epitopes for proviral DNA and outgrowth virus from resting CD4 +  T cells in CP39. CTL epitopes with no observed variation are highlighted in blue. Epitopes with documented escape mutations are shaded in red. 
         FIGS. 2 a   - 2   c.  CD8 +  T cells pre-stimulated with a mixture of Gag peptides eliminate autologous CD4 +  T cells infected with autologous HIV-1 from resting CD4 +  T cells. a, Pre-stimulated CD8 +  T cells (sCD8) eliminate autologous infected CD4 +  T cells more efficiently than unstimulated CD8 +  T cells (uCD8). Each symbol represents the mean of 3 replicates. Median and P value from Mann-Whitney test are shown. b, sCD8 inhibit viral growth in autologous infected CD4 +  T cells with higher efficacy than uCD8. c, sCD8 pre-stimulated by different viral peptides eliminate autologous CD4 +  T cells infected with viruses derived from resting CD4 +  T cells. For b and c, results are compared with CD4 only using paired t tests. Error bars represent s.e.m., n=3. *: p&lt;0.05; **: p&lt;0.01; ***: p&lt;0.001; ns: p&gt;0.05. 
         FIGS. 3 a   - 3   d.  CD8 +  T cells targeting unmutated epitopes, not epitopes with identified escaped mutations, eliminate CTL escape variants. a, Frequency of variants in Gag CTL epitopes in proviruses from resting CD4 +  T cells of CP36 and CP39. Epitopes tested with single peptide stimulation herein are denoted in colors (red or pink, epitopes with escape observed; blue, no escape observed). b, Epitope-specific CD8 +  T cells proliferate significantly after single peptide stimulation. Only CD8 +  cells are shown. Percentages of CFSE low , pentamer-positive cells are indicated for unstimulated cultures (uCD8) with or without IL2, for cultures stimulated with Gag peptide mixture (sCD8) and IL2, and for cultures stimulated with the indicated single peptides and IL2. Wild type versions of peptides were used for all single peptide stimulations. c, CD8 +  T cell proliferative responses after single peptide stimulation. Only CD8 +  cells are shown. Percentages of CFSE low  cells are indicated. d, CD8 +  T cells targeting unmutated epitopes, not epitopes with identified escaped mutations, eliminate autologous CD4 +  T cells infected with CTL escape variants. uCD8: unstimulated CD8 +  T cells; sCD8: Gag peptide mixture stimulated CD8 +  T cells. Error bars represent s.e.m., n=3. *: p&lt;0.05; **: p&lt;0.01; ***: p&lt;0.001; ns: p&gt;0.05, paired t test. 
         FIGS. 4 a   - 4   h.  Broad-spectrum cytotoxic T lymphocytes suppress in vivo replication of HIV-1 from the latent reservoir of the same patients in patient-derived humanized mice. a, Experimental design. b and c, Efficient engraftment of patient CP18-derived hematopoietic cells in MIS( K I)TRG mice at week 6. Representative flow cytometry analysis (b) and summary (c) of human CD45 +  cells, human T-lymphocyte and monocyte subsets. 11 out of 15 mice (enclosed in the rectangle) were used for HIV-1 infection. d, Correlation between frequency of peripheral human CD45 +  cells (6 weeks after engraftment) and plasma HIV-1 RNA levels (14 days after infection). e, Depletion of peripheral CD4 +  T cells after HIV-1 infection. *: p&lt;0.05, paired t-test, n=11. f and g, Reduction of levels of plasma HIV-1 RNA and copies of peripheral blood HIV-1 DNA after injection of viral-specific CTLs. Filled: above detection limit; open: below detection limit. *: p&lt;0.05, unpaired t test. h, Effect of CTL on the level of viral replication in vivo. The area under the curve of the viremia vs. time plot for each mouse in f and g before (AUC1) or after (AUC2) injection of CD8 +  T cells was calculated to quantitatively represent viral replication over time. *: p&lt;0.05, unpaired t test. 
         FIG. 5 . CTL escape variants dominate the latent reservoir of CP-treated HIV-1-positive individuals, but not AP-treated individuals. Frequency of variants in Gag CTL epitopes in proviruses from resting CD4 +  T cells. Results of all 25 patients tested are shown. Only optimal CTL epitopes relevant to each patient&#39;s HLA type are listed in linear positional order on the X axis. Results from both Pacbio (left bar) and MiSeq (right bar) sequencing platforms are shown for each epitope. The absence of bars above a listed epitope indicates that only wild type sequences were detected. For each mutation in a CTL epitope, information regarding the effect of the mutation on CTL recognition from the Los Alamos National Laboratory (LANL) HIV Molecular Immunology Database or from ELISpot assays described herein was used to assign the mutation to one of the categories indicated at the bottom. See Methods for definitions of these categories. 
         FIG. 6 . Characterization of CTL responses against HIV-1 Gag epitopes by interferon-γ ELISpot. Results of 7 patients tested are shown. The peptides tested are listed for each patient in each graph. Error bars represent s.e.m., n=3. 
         FIG. 7 . Partial Gag sequences from proviral DNA and outgrowth virus from resting CD4 +  T cells of 8 CP-treated patients (following  FIG. 1 e   ). CTL epitopes with no observed variation are highlighted in blue. Documented escape mutations (red shading), inferred escape mutations (yellow shading), diminished response (pink shading), susceptible form (green shading) or undetermined variations (gray shading) in relevant optimal epitopes are indicated. See Methods for definitions of these types of mutations. 
         FIGS. 8 a   - 8   d.  CD8 +  T cells pre-stimulated with a mixture of consensus B Gag peptides eliminate autologous CD4 +  T cells infected with autologous HIV-1 from resting CD4 +  T cells. a, HIV-1 isolated from ART-treated individuals replicates as well as lab strain virus BaL. p24 values represent mean of 3 replicates. Error bars represent s.e.m., n=3. b, CD8 +  T cells are not stimulated after co-cultured with PHA-activated CD4 +  T cells. c, A representative flow cytometric analysis of CTL-mediated killing after co-culture of infected CD4 +  T cells with autologous CD8 +  T cells. CTL activity is measured by the percentage of Gag-positive, CD8-negative cells after 3 days of co-culture relative to cultures without CD8 +  T cells. d, Pre-stimulated CD8 +  T cells eliminate autologous infected CD4 +  T cells more efficiently than non-stimulated CD8 +  T cells. All results were normalized to the CD4 only control group. Error bars represent s.e.m., n=3. *: p&lt;0.05; **: p&lt;0.01; ***: p&lt;0.001; ns: p&gt;0.05, paired t test. 
         FIGS. 9 a   - 9   b.  The elimination of infected CD4 +  T cells is mediated by direct killing by autologous CD8 +  T cells. a, Killing of infected CD4 +  T cells is enhanced by increased E:T ratios for both pre-stimulated and non-stimulated CD8 +  T cells. b, Killing of the infected CD4 +  T cells depends on direct cell-cell contact between CD4 +  T cells and CTLs. All results were normalized to the CD4 only control group. Error bars represent s.e.m., n=3. *: p&lt;0.05; **: p&lt;0.01; ***: p&lt;0.001; ns: p&gt;0.05, paired t test. 
         FIGS. 10 a   - 10   d.  Viral dynamics and depletion of CD4 +  T cells in humanized mice. a, Viral dynamics in CP18-infected MIS (KI) TRG mice. CP18-derived MIS (KI) TRG mice were infected with autologous HIV-1. Plasma HIV-1 RNA levels were measured from day 0 to day 56. b, Depletion of CD4 T cells in peripheral blood of HIV-1 BaL-infected mice. MIS (KI) TRG mice engrafted with fetal liver CD34 cells were infected with HIV-1 BaL. CD4 to CD8 ratio in peripheral blood was measured by FACS from day 0 to day 29 after infection. c, Depletion of CD4 T cells in spleen of HIV-1 BaL-infected mice. MIS (KI) TRG mice engrafted with fetal liver CD34 cells were infected with HIV-1 BaL. CD4 to CD8 ratio in spleen was measured by FACS 20 days after infection. Median and P value from Mann-Whitney test are shown. d, Detection of cell-associated HIV-1 RNA in T cells and macrophages/monocytes. CD3 +  and CD14 +  human cells from HIV-1-infected MIS (KI) TRG mice from spleen and lung were purified by FACS. CD3 − CD14 −  cells were also collected as controls. Cell associated HIV-1 RNA was quantified by gag-specific qPCR. *: p&lt;0.05, unpaired t test. 
         FIGS. 11 a   - 11   c.  HIV-1 infection occurs in peripheral blood and tissues in humanized mice. a, Engraftment levels of MIS (KI) TRG mice with fetal liver or patient CD34 cells. b, Memory CD4 +  T cells are detected in MIS (KI) TRG mice after infection. MIS (KI) TRG mice were infected with HIV-1 BaL. Peripheral blood and indicated tissues from infected mice were collected at 20 dpi. Memory CD4 T cells were determined by CD45RO staining. c, Total number of cell associated HIV-1 DNA in blood and tissues. DNA Leukocytes from peripheral blood or indicated tissues were isolated for the measurement of total amount of cell-associated HIV-1 DNA by real-time PCR. For b and c, median and P value from Mann-Whitney test are shown. 
         FIG. 12 . Broad-spectrum cytotoxic T lymphocytes suppress in vivo infection of patient-derived humanized mice with autologous latent HIV-1. Generation of patient CP36-derived humanized mice was described in  FIG. 4 . Mice were infected with autologous viruses at 6 weeks old. CD8 T cells from CP36 were pre-stimulated with the mixture of Gag peptides or left untreated for 6 days in vitro and were injected into mice by i.v. 9 days after infection. Plasma HIV-1 RNA and HIV-1 DNA in peripheral blood were measured by real-time PCR. 
     
    
    
     DETAILED DESCRIPTION 
     A. Definitions 
     For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. 
     The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. 
     The term “administering” includes any method of delivery of a compound of the present invention, including but not limited to, a pharmaceutical composition, therapeutic agent, or CD8 +  T cell vaccine composition into a subject&#39;s system or to a particular region in or on a subject. The phrases “systemic administration,” “administered systemically,” “peripheral administration,” “administered peripherally,” “infusion,” and “reinfusion” as used herein mean the administration of a compound, drug, CD8 +  T cell vaccine composition, or other material other than directly into the central nervous system, such that it enters the patient&#39;s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. “Parenteral administration” and “administered parenterally” means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. 
     The term “amino acid” is known in the art. In general the abbreviations used herein for designating the amino acids and the protective groups are based on recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochemistry (1972) 11:1726-1732). In certain embodiments, the amino acids used in the application of this invention are those naturally occurring amino acids found in proteins, or the naturally occurring anabolic or catabolic products of such amino acids which contain amino and carboxyl groups. Particularly suitable amino acid side chains include side chains selected from those of the following amino acids: glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan. 
     Also included are the (d) and (l) stereoisomers of such amino acids when the structure of the amino acid admits of stereoisomeric forms. The configuration of the amino acids and amino acid residues herein are designated by the appropriate symbols (d), (l) or (dl). Furthermore, when the configuration is not designated the amino acid or residue can have the configuration (d), (l) or (dl). It is to be understood accordingly that the isomers arising from such asymmetry are included within the scope of this invention. Such isomers can be obtained in substantially pure form by classical separation techniques and by sterically controlled synthesis. For the purposes of this application, unless expressly noted to the contrary, a named amino acid shall be construed to include both the (d) or (l) stereoisomers. 
     The terms “comprise” and “comprising” are used in the inclusive, open sense, meaning that additional elements may be included. 
     The term “HIV” is known to one skilled in the art to refer to Human Immunodeficiency Virus. There are two types of HIV: HIV-1 and HIV-2. There are many different strains of HIV-1. The strains of HIV-1 can be classified into three groups: the “major” group M, the “outlier” group O and the “new” group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Within the M-group there are at least ten subtypes or clades: e.g., clade A, B, C, D, E, F, G, H, I, J, and K. A “clade” is a group of organisms, such as a species, whose members share homologous features derived from a common ancestor. Any reference to HIV-1 in this application includes all of these strains. 
     The term “including” is used to mean “including but not limited to”. “Including” and “including but not limited to” are used interchangeably. 
     A “patient” or “subject” or “mammal” refers to either a human or non-human animal. 
     The term “pharmaceutical delivery device” refers to any device that may be used to administer a therapeutic agent or agents to a subject. Non-limiting examples of pharmaceutical delivery devices include hypodermic syringes, multichamber syringes, stents, catheters, transcutaneous patches, microneedles, microabraders, and implantable controlled release devices. 
     The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. 
     The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer&#39;s solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; and (22) other non-toxic compatible substances employed in pharmaceutical formulations. 
     The terms “polypeptide”, “peptide” and “epitope” are used interchangeably herein to refer to polymers of amino acids. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. 
     In certain embodiments, peptides of the invention may be synthesized chemically, ribosomally in a cell free system, or ribosomally within a cell. Chemical synthesis of polypeptides of the invention may be carried out using a variety of art recognized methods, including stepwise solid phase synthesis, semi-synthesis through the conformationally-assisted re-ligation of peptide fragments, enzymatic ligation of cloned or synthetic peptide segments, and chemical ligation. Native chemical ligation employs a chemoselective reaction of two unprotected peptide segments to produce a transient thioester-linked intermediate. The transient thioester-linked intermediate then spontaneously undergoes a rearrangement to provide the full length ligation product having a native peptide bond at the ligation site. Full length ligation products are chemically identical to proteins produced by cell free synthesis. Full length ligation products may be refolded and/or oxidized, as allowed, to form native disulfide-containing protein molecules (see e.g., U.S. Pat. Nos. 6,184,344 and 6,174,530; and T. W. Muir et al., Curr. Opin. Biotech. (1993): vol. 4, p 420; M. Miller, et al., Science (1989): vol. 246, p 1149; A. Wlodawer, et al., Science (1989): vol. 
     245, p 616; L. H. Huang, et al., Biochemistry (1991): vol. 30, p 7402; M. Schnolzer, et al., Int. J. Pept. Prot. Res. (1992): vol. 40, p 180-193; K. Rajarathnam, et al., Science (1994): vol. 264, p 90; R. E. Offord, “Chemical Approaches to Protein Engineering”, in Protein Design and the Development of New therapeutics and Vaccines, J. B. Hook, G. Poste, Eds., (Plenum Press, New York, 1990) pp. 253-282; C. J. A. Wallace, et al., J. Biol. Chem. (1992): vol. 267, p 3852; L. Abrahmsen, et al., Biochemistry (1991): vol. 30, p 4151; T. K. Chang, et al., Proc. Natl. Acad. Sci. USA (1994) 91: 12544-12548; M. Schnlzer, et al., Science (1992): vol., 3256, p 221; and K. Akaji, et al., Chem. Pharm. Bull. (Tokyo) (1985) 33: 184). 
     As known to one skilled in the art, “retroviruses” are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate (proviral DNA). In particular, upon infection by the RNA virus, the lentiviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus. The viral DNA is then integrated pseudo-randomly into the host cell genome of the infecting cell, forming a “provirus” which is inherited by daughter cells. The retrovirus genome contains at least three genes: Gag codes for core and structural proteins of the virus; Pol codes for reverse transcriptase, protease and integrase; and Env codes for the virus surface proteins. Within the retrovirus family, HIV is classified as a lentivirus, having genetic and morphologic similarities to animal lentiviruses such as those infecting cats (feline immunodeficiency virus), sheep (visna virus), goats (caprine arthritis-encephalitis virus), and non-human primates (simian immunodeficiency virus). 
     B. Methods of Preventing or Treating a HIV Infection 
     Provided are methods of preventing or treating a lentiviral infection, such as a HIV infection, comprising administering to a mammal in need thereof, a therapeutically effective amount of a CD8 +  T cell vaccine composition, wherein the CD8 +  T cell has been pre-stimulated with at least one HIV epitope, to thereby enhance a CD8 +  T cell immune response against HIV. 
     The term “effective amount” as used herein means an amount effective and at dosages and for periods of time necessary to achieve the desired result. The term “mammal” as used herein includes all members of the animal kingdom including non-humans and humans. In certain embodiments, the mammal may be a human. The human may be afflicted with HIV-1. The human may be chronically infected or acutely infected with HIV-1. The human may be on suppressive antiretroviral therapy. In certain embodiments, the pre-stimulated CD8+ T cell vaccine composition can be reinfused only in antiretroviral therapy (ART)-treated individuals, reinfused only in untreated individuals, reinfused only in ART-treated individuals, followed by antiretroviral treatment interruption, or reinfused combined with latency reversing therapy in ART-treated individuals. 
     In certain embodiments, the CD8 +  T cell vaccine composition is administered to the patient more than one time over the course of treating or preventing. 
     In certain embodiments, the efficacy of the CD8 +  T cell vaccine composition may relate to HIV latency and the ability to remain off of antiretroviral therapy without HIV rebound. In certain embodiments, these measures include reduction in proviral DNA. The estimated number of HIV proviruses per infected person on therapy are 10 8  to 10 9 . In certain embodiments, the reductions in proviral DNA that result in a delay in rebound may be on the order of about 100- to 1000-fold reductions. In other embodiments, these measures included reduction in the total number of resting CD4 +  T cells in any healthy or infected individual would be approximately 10 12  using well-known methods in the art of measuring reservoir size. In other embodiments, these measures included reduction in the total latently infected resting CD4 T cell population appears to be between 10 6  and 10 7  cells. In certain embodiments, a 1000-fold reduction would result in significant delay in rebound when off antiretroviral therapy. In other embodiments, efficacy is measured in delay in rebound of HIV viremia after cessation of antiretroviral therapy measured in months. 
     C. Therapeutically Effective CD8 +  T Cell Vaccine Compositions 
     A therapeutically effective amount of a CD8 +  T cell vaccine composition comprises CD8 +  T cells which have been pre-stimulated with at least one HIV epitope, to thereby enhance a CD8 +  T cell immune response. 
     The pre-stimulation occurs ex-vivo and may include incubating the CD8 +  T cells with at least one cytokine in addition to the at least one HIV epitope. The CD8 +  T cell may be derived from CP36 or CP39. The CD8 +  T cell may be autologous to the mammal. 
     The HIV epitopes may include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 HIV epitopes. The at least one HIV epitope may be a subdominant or dominant epitope. The at least two HIV epitopes may comprise subdominant and dominant epitopes. 
     In certain embodiments, the CD8 +  T cell response may target latent or reactivated HIV-1 infected cells. In certain embodiments, the CD8 +  T cell immune response may be greater in magnitude than a CD8 +  T cell immune response induced by administration of an unstimulated CD8 +  T cell composition. In other embodiments, the CD8 +  T cell immune response is greater in magnitude than a CD8 +  T cell immune response induced by administration of the HIV epitope alone. The CD8 +  T cell immune response may be in response to a subdominant epitope(s) in HIV-1. 
     In certain embodiments, the at least one HIV epitope may be from HIV-1. In certain embodiments, the at least one HIV epitope may be from HIV-2. In certain embodiments, the at least one HIV epitope may be selected from an epitope in the HIV-1 Gag, HIV-1 Nef, HIV-1 Rev, HIV-1 Tat, or HIV-1 Env. In certain embodiments, the HIV epitope may be provided singly, or in combination as a mixture or pool of HIV peptides. In certain embodiments, the pool or mixture of HIV peptides are defined by the Gag peptides in Table 2 and Table 4 (i.e., NIH AIDS Reagent 8117). In certain embodiments, the pool or mixture of HIV peptides are defined by the Nef peptides in Table 3 (i.e., NIH AIDS Reagent 5189). In certain embodiments, the pool or mixture of HIV peptides are defined by the Rev peptides in Table 5 (i.e., NIH AIDS Reagent 6445). In certain embodiments, the pool or mixture of HIV peptides are defined by the Tat peptides in Table 7 (i.e., NIH AIDS Reagent 5138). In certain embodiments, the pool or mixture of HIV peptides are defined by the Env peptides in Table 6 (i.e., NIH AIDS Reagent 9480). Said mixtures or pools of HIV peptides may comprise different combinations of the HIV peptides set for the in Tables 2-7. In certain embodiments, the at least one HIV epitope is an epitope in HIV-1 Gag. In certain embodiments, the HIV-1 Gag epitopes may be selected from ISPRTLNAW (SEQ ID NO: 1), LSPRTLNAW (SEQ ID NO: 2), TSTLQEQIGW (SEQ ID NO: 3), TSNLQEQIGW (SEQ ID NO: 4), QASQEVKNW (SEQ ID NO: 5), QSTQEVKNW(SEQ ID NO: 6), KAFSPEVIPMF (SEQ ID NO: 7), SLYNTVATL (SEQ ID NO: 8), SLFNTVAVL (SEQ ID NO: 9), WASRELERF (SEQ ID NO: 10), TLNAWVKVV (SEQ ID NO: 11), RLRPGGKKK (SEQ ID NO: 12), RLRPGGKKS (SEQ ID NO: 13), LYNTVATLY (SEQ ID NO: 14), LFNTIAALF (SEQ ID NO: 15), TPQDLNTML (SEQ ID NO: 16), or GPGHKARVL (SEQ ID NO: 17). In certain embodiments, the HIV Env epitope is found in the consensus Subtype B sequence as follows: 
     
       
         
           
               
            
               
                 (SEQ ID NO: 18) 
               
            
           
           
               
            
               
                 MRVKGIRKNYQHLWRWGTMLLGMLMICSAAEKLWVTVYYGVPVWKEATTT 
               
               
                   
               
               
                 LFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLENVTENFNMWKNNMV 
               
               
                   
               
               
                 EQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLMNATNTTNSSSGEKMEK 
               
               
                   
               
               
                 GEIKNCSFNITTSIRDKVQKEYALFYKLDVVPIDNDNTSSYRLISCNTSV 
               
               
                   
               
               
                 ITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGTGPCTNVSTVQCTHG 
               
               
                   
               
               
                 IRPVVSTQLLLNGSLAEEEVVIRSENFTNNAKTIIVQLNESVEINCTRPN 
               
               
                   
               
               
                 NNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNISRAKWNNTLKQIVKKLRE 
               
               
                   
               
               
                 QFGNKTIVFNQSSGGDPEIVMHSFNCGGEFFYCNTTQLFNSTWNVNGTWN 
               
               
                   
               
               
                 NNTEGNDTITLPCRIKQIINMWQEVGKAMYAPPIRGQIRCSSNITGLLLT 
               
               
                   
               
               
                 RDGGNNNTNETEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRR 
               
               
                   
               
               
                 VVQREKRAVGIGAMFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNN 
               
               
                   
               
               
                 LLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLIC 
               
               
                   
               
               
                 TTTVPWNASWSNKSLDEIWDNMTWMEWEREIDNYTSLIYTLIEESQNQQE 
               
               
                   
               
               
                 KNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFAVLSI 
               
               
                   
               
               
                 VNRVRQGYSPLSFQTRLPAPRGPDRPEGIEEEGGERDRDRSGRLVDGFLA 
               
               
                   
               
               
                 LIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEVLKYWWNLLQYWS 
               
               
                   
               
               
                 QELKNSAVSLLNATAIAVAEGTDRVIEVVQRACRAILHIPRRIRQGLERA 
               
               
                   
               
               
                 LL. 
               
            
           
         
       
     
     In certain embodiments, the HIV epitope may be synthetic and may be chemically synthesized as described in section “A” above. In other embodiments, the HIV epitopes may be mutated or unmutated. Other HIV epitopes may be deep sequences from from proviral HIV-1 DNA in resting CD4 +  T cells from mammals during the acute phase or chronic phase of infection (see examples section of instant specification). 
     The present invention further features methods comprising the administration of an effective amount a CD8 +  T cell vaccine composition, wherein the composition comprises CD8 +  T cells which have been pre-stimulated with at least one HIV epitope, or a pool or mixure of HlVepitodes set forth in Tables 2-7, to thereby enhance a CD8 +  T cell immune response, as described above. Dosage levels of between about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12  cells per infusion into a patient may be useful as a vaccine injection in the methods described herein. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. The dose of the vaccine may vary according to factors such as the infection state, age, sex, and weight of the individual, and the ability of CD8 +  T cell vaccine composition to elicit a desired response in the individual. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The dose of the vaccine may also be varied to provide optimum preventative or treatment dose response depending upon the circumstances. 
     In certain embodiments, the dosage may enhance the CD8 +  T cell to CD4 +  T cell ratio. The efficacy of the prevention or treatment of the methods of the present invention may be determined from samples obtained from the mammal after treatment has began using the following. In certain embodiments, the efficacy is determined comparing a sample of a mammal obtained during the course of treatment to a sample which has been previously obtained from the patient, such as at the start of treatment or in an initial sample obtained two, three, or four weeks post HIV infection but prior to treatment. In certain embodiments, the levels of HIV viral replication is decreased in a plasma sample when compared to a plasma sample previously obtained from the mammal prior to initiation of treatment. The levels of HIV viral replication may be decreased in terms of log 10  reductions of about 2-logs, 3-logs, 4-logs, 5-logs, 6-logs, 7-logs, 8-logs, or 9-logs. In certain embodiments, the levels of plasma HIV-1 RNA may be decreased in a plasma sample when compared to a plasma sample previously obtained from the mammal prior to initiation of treatment. The levels of plasma HIV-1 RNA may be decreased in terms of log 10  reductions of about 2-logs, 3-logs, 4-logs, 5-logs, 6-logs, 7-logs, 8-logs, or 9-logs. In other embodiments, the levels of proviral HIV-1 DNA may be decreased 100-, 200-, 300-, 400-, 500-, 600-, 700-, 800-, 900-, 1000-, 1500-, or 2000-fold. The fold reduction may be calculated as a reduction from an estimated 10 8  or 10 9  HIV provirus per infected person on antiretroviral therapy. In other embodiments, the efficacy of the CD8 +  T cell vaccine composition can be determined when the HIV-1 latent reservoir is decreased 100-, 200-, 300-, 400-, 500-, 600-, 700-, 800-, 900-, 1000-, 1500-, or 2000-fold when compared to the resting CD4+ T cell population in any healthy or infected individual or total latently infected resting CD4+ T cell population using well known methods in the art to measure the reservoir size. In certain embodiments, the resting CD4 +  T cell population in any healthy or infected individual is about 10 12  cells. In certain embodiments, the total latently infected resting CD4 +  T cell population is from about 10 6  to about 10 7  cells. Such fold reductions may result in significant delay in rebound when off of antiretroviral therapy. In other embodiments, the efficacy of the CD8 +  T cell vaccine composition relate to HIV latency and the ability of the patient to remain off of antiretroviral therapy without HIV rebound. In certain embodiments, efficacy of the CD8 +  T cell vaccine composition can be determined by the delay in rebound of HIV viremia after cessation of antiretroviral therapy. Typically, a rebound of HIV viremia may occur in a couple of weeks in patients who have stopped antiretroviral therapy. In certain embodiments a significant delay may be measured in months of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months. 
     The compositions of the invention are suitable for administration to subjects in a biologically compatible form in vivo. The expression “biologically compatible form suitable for administration in vivo” as used herein means a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to any animal, preferably humans. 
     The CD8 +  T cell vaccine composition of the present invention may additionally contain suitable diluents, adjuvants and/or carriers. Preferably, the vaccines contain an adjuvant which can enhance the immunogenicity of the vaccine in vivo. The adjuvant may be selected from many known adjuvants in the art including the lipid-A portion of gram negative bacteria endotoxin, trehalose dimycolate of mycobacteria, the phospholipid lysolecithin, dimethyldictadecyl ammonium bromide (DDA), certain linear polyoxypropylene-polyoxyethylene (POP-POE) block polymers, aluminum hydroxide, liposomes and CpG (cytosine-phosphate-guanidine) polymers. The vaccines may also include cytokines that are known to enhance the immune response including GM-CSF, IL-2, IL-12, TNF and IFNγ. 
     The vaccines of the instant invention may be formulated and introduced as a vaccine through oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and intravaginal, or any other standard route of immunization. 
     In formulations of the subject vaccines, wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may be present in the formulated agents. 
     Subject compositions may be suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of composition that may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated, and the particular mode of administration. 
     Methods of preparing these formulations include the step of bringing into association compositions of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association agents with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. 
     Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a subject composition thereof as an active ingredient. Compositions of the present invention may also be administered as a bolus, electuary, or paste. 
     In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. 
     A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. 
     Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. 
     Suspensions, in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. 
     Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent. Formulations, which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. 
     Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants, which may be required. 
     The ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. 
     Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. 
     Compositions of the present invention may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions. 
     Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions. 
     In addition, vaccines may be administered parenterally as injections (intravenous, intramuscular or subcutaneous). The vaccine compositions of the present invention may optionally contain one or more adjuvants. Any suitable adjuvant can be used, such as CpG polymers, aluminum hydroxide, aluminum phosphate, plant and animal oils, and the like, with the amount of adjuvant depending on the nature of the particular adjuvant employed. In addition, the anti-infective vaccine compositions may also contain at least one stabilizer, such as carbohydrates such as sorbitol, mannitol, starch, sucrose, dextrin, and glucose, as well as proteins such as albumin or casein, and buffers such as alkali metal phosphates and the like. 
     Pharmaceutical compositions of this invention suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. 
     Examples of suitable aqueous and non-aqueous carriers, which may be employed in the pharmaceutical compositions of the invention, include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Further, the CD8 +  T cell vaccine compositions may be encapsulated in liposomes and administered via injection. 
     All references cited herein are all incorporated by reference herein, in their entirety, whether specifically incorporated or not. All publications, patents, or patent applications cited herein are hereby expressly incorporated by reference for all purposes. In case of conflict, the definitions within the instant application govern. 
     Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. 
     The present description is further illustrated by the following examples, which should not be construed as limiting in any way. 
     EXAMPLES 
     Methods 
     
         
         Human subjects. Peripheral blood or bone marrow for the isolation of primary CD4 + , CD8 +  or CD34 +  T cells was obtained from 30 HIV-1-infected patients (Table 1) and 7 healthy adult volunteers. All patients had been on antiretroviral therapy (ART) for at least 2 years and had maintained undetectable plasma HIV-1 RNA levels (&lt;50 copies/ml) for at least 1 year prior to study. 10 AP-treated patients were recruited from the OPTIONS cohort at the University of California San Francisco (UCSF). This study was approved by the Johns Hopkins Internal Review Board and by the UCSF Committee on Human Research. Written informed consent was provided by all study participants. HLA typing for each patient was performed by the Johns Hopkins University Immunogenetics Laboratory. 
         Sample preparation for deep sequencing. Peripheral blood mononuculear cells (PBMCs) were isolated from whole blood by Ficoll gradient separation. CD4 +  T cells were purified from PBMCs by negative selection using CD4 +  Isolation Kit II (Miltenyi). Resting CD4 +  T cells were then purified from CD4 +  T cells by negative selection using CD25, CD69 and HLA-DR microbeads (Miltenyi). Genomic DNA was extracted from 5 million resting CD4 +  T cells from each patient using QlAamp DNA Mini Kit (Qiagen). The gag gene was amplified from genomic DNA by a two-round nested PCR using these primers: 5′ outer primer (5′-TTGACTAGCGGAGGCTAGAAGG-3′); 3′ outer primer (5′-GATAAAACCTCCAATTCCCCCTATC-3); 5′inner primer (5′-GAGAGATGGGTGCGAGAGCGTC-3′); 3′ inner primer (5′-CTGCTCCTGTATCTAATAGAGC-3′). For each patient, the entire genomic DNA from 5 million of resting CD4 +  T cells was evenly distributed as template into 80 PCR reactions. The reactions were performed by using High Fidelity Plantinum Taq Polymerase (Life Technologies) following manufacturer&#39;s instruction. PCR amplicons were purified by gel extraction after gel electrophoresis. 
         Deep sequencing. For PacBio RS single molecule sequencing, amplicons were barcoded with a group of 10 bp indexes and then multiple samples were pooled together to generate smrtbell sequencing library following Pacific Biosciences template preparation and sequencing-C2 user guide for 2 kb insert size and using Pacific Bioscience DNA template preparation kit. For MiSeq Sequencing, the pooled amplicon DNA was end repaired, adenylated, and ligated to Illumina TruSeq adaptors and PCR enriched for 10 cycles. The resulting library was then run on bioanalyzer high sensitivity DNA chip for size and concentration determination. The library was then sequenced on MiSeq for paired end 250 bp reads. The sequence reads from PacBio and MiSeq were demultiplexed using Fastx-Toolkit. 
         Data analysis for deep sequencing results. For the paired MiSeq reads, the two reads were first merged using FLASH 31 . MiSeq and PacBio reads from each individual were then aligned to the reference HIV-1 consensus B Gag sequence using Bowtie2 32 . Custom program was written using perl scripts to identify and compute the frequency of all sequence variants that caused non-synonymous amino acid changes in each individual&#39;s relevant optimal Gag epitopes (based on reported information in the HIV Molecular 
       
    
     Immunology Database, Los Alamos National Laboratory, http://www.hiv.lanl.gov/content/immunology/index.html) according to their HLA type. For each individual, variants that occurred at a frequency &gt;3% were retained. Additional for PacBio reads, sequences with identified premature stop codons were eliminated from the analyzed results. For each identified variation, the mutation type regarding CTL recognition was determined by matching with the information in the above-mentioned database. The five mutation types adopted in this paper are: Documented Escape (no CTL response when patient cells are challenged with the variant peptide), Inferred Escape (variant is predicted to be an escape mutant by longitudinal study or transmission study, but the reactivity of the variant is not tested experimentally), Diminished Response (experimental data suggest partial escape as evidenced by decreased CTL response), Susceptible Form (CTL response is elicited when patient cells are challenged with the variant peptide) and Mutation Type Not Determined (no experimental data on CTL recognition of this variant).
     Elispot essays. The Elispot assays were performed using Human IFN-γ ELISpot PLUS kit (Mabtech) according to previously described 33  and manufacturer&#39;s instructions. PBMCs were added at 200,000 cells per well and synthetic peptides were added in a final concentration of 0.1, 1 or 10 μg/ml. A response is considered positive if it was 3 fold higher than the mean background (cell only control) and greater than 55 SFC/million cells. The number of specific T cells was calculated by subtracting the mean background values.   Recovery and sequencing of patient viruses from resting CD4 +  T cells. Co-culture assays were performed to recover and amplify replication-competent viruses as previously described 34 . The viruses were recovered from five to ten million resting CD4 +  T cells. The concentration of outgrowth viruses was determined by p24 ELISA (PerkinElmer). Total RNA of outgrowth viruses was extracted using Trizol LS reagent (Life Technologies). Residual DNA was then removed by TURBO DNase (Life Technologies) treatment. First strand cDNA was synthesized using SuperScript III Reverse Transcriptase (Life Technologies) and the gag gene was amplified from cDNA using the gag outer primer pair mentioned above. The PCR amplicons were then purified by gel extraction and sequenced by regular Sanger sequencing.   In vitro HIV-1 infection. PBMCs from HIV-1-infected patients and healthy donors were stimulated by adding 0.5 μg/ml Phytohaemagglutinin (PHA) and IL-2 (100 U/ml) to basal media (RPMI with 10% heat-inactivated fetal bovine serum and antibiotics) for three days prior to isolation of CD4 +  T cells. Each patient&#39;s activated CD4 +  T cells were infected with viruses recovered from the same patient&#39;s resting CD4 +  T cells. Healthy donor&#39;s CD4 +  cells were infected with a lab strain virus, BaL. Virus concentration used in infection was equivalent to the p24 concentration of 200 ng/ml. All infections were performed by centrifugation of target cells with virus at 1,200 g for 2 hours.   Stimulation of CD8 +  T cells. PBMCs from CP-treated patients were cultured in the presence of IL-2 (100 U/ml) with a mixture of consensus B Gag (or Nef, Rev, Tat, Env) peptides (800 ng/ml for each) (NIH AIDS Reagent Program), or with individual synthetic peptide (0.5 μ/ml) (Genemed Synthesis). CD8 +  T cells were purified after six days of incubation by positive selection using human CD8 microbeads (Miltenyi). To monitor CTL proliferation, PBMCs were stained with CFSE (Life Technologies) prior to incubation and with relevant pentamer (Proimmune) after incubation. PBMCs were then stained with CD8-APC (Becton Dickson, BD) and analyzed by flow cytometry using FACS Canto II (BD).   Co-culture of autologous CD4 +  and CD8 +  T cells. Three hours after infection, CD4 +  T cells were mixed with autologous unstimulated or stimulated CD8 +  T cells at 1:1 ratio in basal media at 5 million cells per ml. Two days after co-culture, enfuvirtide (T-20, Roche) was added into the culture at 10 μM to prevent further infection events except if the measurement was p24 ELISA. Three days after co-culture, cells were stained with CD8-APC (BD) first, fixed and permeabilized with Cytoperm/Cytofix (BD pharmingen), then stained for intracellular p24 Gag (PE, Coulter). Cells were analyzed by flow cytometry using FACS Canto II (BD). For measurement of viral growth, 5 μl of supernatant was taken from the co-culture at Days 0, 3 and 6, and subjected to p24 ELISA. For analysis of cell contact dependence, CD4 +  and CD8 +  T cells were placed in separate chambers of trans-well plates (0.4 μm, Costar).   Generation and infection of patient-derived humanized mice. The previously reported MISTRG mouse in the Rag2 −/−  Il2rg −/−  129×Balb/c (N2) genetic background harbors knock-in replacement of the endogenous mouse Csf1, Csf2, Il3 and Tpo genes with humanized version and a BAC transgene encoding human SIRPα 25 . We generate Sirpa (KI)  mouse which harbors a knock-in replacement of the endogenous mouse Sirpa gene with a humanized version. Sirpa (KI)  mouse will be thoroughly described elsewhere. The improved MIS (KI) TRG mouse was generated by breeding Sirpa (KI)  mice to MITRG mice. All animal experimentations were performed in compliance with Yale Institutional Animal Care and Use Committee protocols. MIS (KI) TRG mice were maintained with continuous treatment with enrofloxacin in the drinking water (Baytril, 0.27 mg/ml). Patient bone marrow or fetal liver CD34 +  cells were isolated by CD34 microbeads selection (miltenyi). Newborn mice (within first 3 days of life) were sublethally irradiated (X-ray irradiation with X-RAD 320 irradiator, PXi; 1×150 cGy) and 100,000 fetal liver or 250,000 patient CD34 +  cells in 20 μl of PBS were injected into the liver with a 22-gauge needle (Hamilton Company). 6-8 weeks after engraftment, mice engrafted with patient CD34 +  cells were infected by i.v. with HIV-1 (100 ng p24) which was recovered and expanded from the resting CD4 +  T cells of the same patient (CD34 +  cell donor), as mentioned above. Mice engrafted with fetal liver CD34 +  cells were infected by i.v. with HIV-1 BaL (100 ng p24). Mice with less than 5% human CD45 +  cells in the peripheral blood were excluded from the infection study. Mice with more than 70% human CD45  +  cells in the peripheral blood were also excluded because they were unhealthy due to human macrophage/monocytes caused anemia 33 . 20 million autologous CD8 +  T cells with or without pre-stimulation were injected by i.v. 9 or 14 days after infection. Group allocation was blinded. Peripheral blood samples were collected by retro-orbital bleeding at different time points before and after injection of CD8 +  T cells. Engraftment of human CD45 +  cells as well as lymphoid and myeloid subsets was determined by flow cytometry. Plasma HIV-1 RNA in peripheral blood was measured by one-step reverse transcriptase (Invitrogen) real-time PCR using the following primers and probe, described previously 8 : forward (5′→3′) ACATCAAGCAGCCATGCAAAT, reverse (5′→3′) TCTGGCCTGGTGCAATAGG and probe (5′→3′) VIC-CTATCCCATTCTGCAGCTTCCTCATTGATG-TAMRA. Assay sensitivity is 200 RNA copies per ml of plasma. HIV-1 DNA in peripheral blood was also measured by real time PCR using the same primers and probe mentioned above, with assay sensitivity at 5 copies per 100 μl of blood. Total viral DNA in PBMCs was determined by measuring copies of viral DNA/100 μl blood and blood volume per mouse (80 μl blood/1 g body weight). To quantitate total viral DNA in tissues, spleens, livers and lungs of infected mice were collected. For the spleen, single-cell suspensions were treated with ACK lysis buffer. Liver and lung leukocytes were isolated by digesting tissues with 100 U/ml collagenase IV and 0.02 mg/ml DNase I (Sigma), followed by density gradient centrifugation.   Statistical analysis. For comparison of HIV-1 variant frequency ( FIGS. 1 b  and  c   ) and viral infection in HIV-1 BaL-infected mice ( FIGS. 10 and 11 ), we applied Mann-Whitney tests. For comparison of inhibitory effect of autologous CTLs ( FIG. 2 a   ), we applied a Wilcoxon matched pairs test. For comparison of viral replication in humanized mice ( FIGS. 4 f, g  and  h   ), we applied an unpaired t test. For all other comparisons, paired t tests were applied. All tests were calculated by the GraphPad Prism 6 software, and conducted as two-tailed tests with a type I error rate of 5%.   

     To investigate CTL escape variants in the latent reservoir, the proviral HIV-1 DNA in resting CD4 +  T cells from 25 patients was deep sequenced (Table 2). Among them, 10 initiated ART during the acute phase (AP, within 3 months of infection) while the other 15 initiated ART during the chronic phase (CP) of infection. The sequencing was focused on Gag because it is an important target of the CTL response 23  and is highly conserved, which facilitates detection of escape variants. Prior data from our lab showed that previously documented CTL escape variants completely dominated the viral reservoirs of nearly all CP-treated patients ( FIG. 5  and Table 2). This trend is especially obvious for several well characterized CTL epitopes: the HLA-A2-restricted epitope SLYNTVATL (SL9), the HLA-A3-restricted epitope RLRPGGKKK (RK9) and the HLA-B57/58-restricted epitope TSTLQEQIGW (TW10) ( FIG. 1 a    and  FIG. 5 ). In these epitopes, close to 100% of the sequences harbored escape mutations. Comparison of mutation frequencies between HLA allele-relevant and -irrelevant epitopes in CP-treated patients suggests these CTL escape mutations identified are specific to patient&#39;s HLA type ( FIG. 1 b   ). By contrast, except for SL9 from AP01 and RK9 from AP08, few if any CTL escape mutations were archived in AP-treated patients ( FIG. 1 c    and  FIG. 5 ). The striking difference between AP- and CP-treated patients ( FIG. 1 c   ) indicates that unless treatment is initiated within the first several months of infection, the latent reservoir becomes almost completely dominated by variants resistant to dominant CTL responses. 
     To confirm variants detected at high frequency in the latent reservoir represent functional CTL escape mutants, cells from 7 CP-treated subjects were tested for reactivity to synthetic peptides representing wild-type and mutant versions of the relevant epitopes. As expected, there were only minimal responses to previously documented CTL escape mutants by patient CD8 +  T cells, and no de novo response was detected ( FIG. 1 d    and  FIG. 6 ). In contrast, all tested subjects retained a strong response to peptides representing the wild-type epitopes, suggesting wild-type virus was initially transmitted, with subsequent evolution of CTL escape variants. Most HIV-1 proviruses detected in patients are defective 24 . Therefore, to determine whether these CTL escape variants can be reactivated and lead to viral rebound if therapy is stopped, replication-competent viruses were isolated from the latent reservoirs of 9 CP-treated patients. It was found that all dominant CTL escape mutations identified in proviruses in resting CD4 +  T cells were also present in the replication-competent viruses that grew out after T cell activation ( FIG. 1 e    and  FIG. 7 ), indicating that these CTL escape variants not only dominate the population of proviruses, but can also be released and replicate once latency is reversed. 
     Whether the host CTL response could recognize and eliminate the cells infected with these escape variants were investigated next. A ctivated CD4 +  T cells from these patients were infected with autologous, replication-competent virus derived from the latent reservoir ( FIG. 8 a   ). The infected cells were then co-cultured with autologous CD8 +  T cells, either unstimulated or pre-stimulated, to assess HIV-1-specific cytolytic activity. Non-specific activation of CD8 +  T cells was not observed after co-cultured with PHA-activated CD4 +  T cells ( FIG. 8 b   ). From all 13 CP-treated subjects tested, CD8 +  T cells pre-stimulated by a Gag peptide mixture efficiently killed autologous infected CD4 +  T cells (median 61% elimination), while unstimulated CD8 +  T cells from most subjects had significantly less effect (median 23% elimination) ( FIG. 2 a    and  FIGS. 8 c  and 8 d   ). CD8 +  T cells from 7/7 healthy donors completely failed to eliminate autologous infected cells (FIG.  2   a ), confirming the observed killing was HIV-1-specific. The killing effect was enhanced by increasing the effector to target (E:T) ratio ( FIG. 9 a   ), and was cell-cell contact dependent ( FIG. 9 b   ). When the co-culture was maintained over time in the absence of ART, viral replication was significantly reduced, but not completely inhibited by pre-stimulated CD8 +  T cells ( FIG. 2 b   ). Itwas found that peptide mixtures from other HIV-1 proteins (Nef, Tat, Rev, and Env) could also boost CTL responses and facilitate the elimination of infected cells ( FIG. 2 c   ) and that CTLs pre-stimulated by Gag peptides generally had the highest activity. Together, these results demonstrate that chronically infected patients retain CTL clones that can recognize and eliminate autologous infected CD4 +  T cells, despite the presence of CTL escape mutations in dominant epitopes. However, these clones require stimulation with antigen for optimal activity. 
     To further characterize which CTL population contributed to the elimination of cells infected by CTL escape variants, the killing activity of two specific CTL populations were compared: the one that targets epitopes in which escape has been identified and the one that targets unmutated epitopes ( FIG. 3 a   ). CD8 +  T cells from CP36 and CP39 were pre-stimulated with IL-2 and different synthetic peptides representing the wild-type forms of the relevant epitopes. After incubation for 6 days, each CTL population exhibited significant proliferation compared to no treatment or IL-2 alone ( FIGS. 3 b  and  c   ). Pentamer staining for three available epitopes revealed that the number of epitope-specific CD8 +  T cells increased dramatically after stimulation with wild-type peptides ( FIG. 3 b   ). After co-culture with autologous target cells infected with latent reservoir-derived viruses, CTLs targeting unmutated epitopes clearly showed stronger cytolytic activity than the IL-2 only controls, while CTLs targeting epitopes with identified escaped mutations showed no significant killing ( FIG. 3 d   ). CTLs pre-stimulated by the Gag peptide mixture exhibited stronger killing than all single peptide-stimulated populations ( FIG. 3 d   ). 
     To test whether CTL that recognize unmutated viral epitopes can inhibit HIV-1 replication and clear infected cells in vivo, patient-derived humanized mice using an improved version of a recently reported mouse system named MISTRG 25  were generated. Whereas the previously reported MISTRG mice bear a BAC transgene encoding human SIRPα, the newly generated MIS (KI) TRG mice harbor a knock-in replacement of the endogenous mouse Sirpa gene with a humanized version. With humanization by knock-in replacement of the Csf1, Csf2, Il3, Tpo and Sirpa genes in the Rag2 −/−  Il2rg −/−  genetic background, MIS (KI) TRG mice are highly permissive for human hematopoiesis and support the reconstitution of robust human lymphoid and myelomonocytic systems. With the demonstrated development of functional T-lymphocytes and monocytes/macrophages, MIS (KI) TRG mice provide a useful humanized mouse host for HIV-1 infection studies. Bone marrow biopsies were obtained from study participants and purified CD34 +  cells were used to reconstitute the MIS (KI) TRG mice. These patient-derived humanized mice were infected with primary HIV-1 isolates grown from resting CD4 +  T cells of the same patient and then evaluated antiviral effect of autologous CD8 +  T cells ( FIG. 4 a   ). MIS (KI) TRG mice engrafted with CP18 bone marrow CD34 +  cells successfully developed human T-lymphocyte and monocyte/macrophage subsets ( FIGS. 4 b  and  c   ), which were sufficient to support HIV-1 infection ( FIG. 4 d   ). Plasma HIV-1 RNA levels peaked 20-30 days after infection ( FIG. 10 a   ). Depletion of CD4 +  T cells was clearly evident 12 days after infection in peripheral blood and spleen ( FIG. 4 e    and  FIGS. 10 b  and 10 c   ). Cell-associated HIV-1 RNA was detected in both T cells and macrophages/monocytes ( FIG. 10 d   ). Viral infection was also observed in various tissues where a large number of memory CD4 +  T cells were detected ( FIG. 11 ). In control mice or mice that received autologous patient CD8 +  T cells pre-stimulated with a peptide representing the unmutated dominant SL9 epitope, levels of plasma HIV-1 RNA and proviral DNA in peripheral blood continued to increase from day 14 to day 29 after infection ( FIG. 40 . In sharp contrast, mice that received CD8 +  T cells pre-stimulated with unmutated epitopes (Gag mix or WF9) had a significantly lower level of viral replication ( FIG. 4 g    and h). Dramatic decreases in plasma HIV-1 RNA of 100- to 1,000-fold were observed in all three mice that received CD8 +  T cells pre-stimulated with the mixture of Gag peptides including dominant and subdominant epitopes. Two of three mice had undetectable levels of plasma HIV-1 RNA and proviral DNA in peripheral blood measured at three time points ( FIG. 4 g   ). The same experiments were performed using patient CP36-derived humanized mice and reduction of peripheral HIV-1 RNA and DNA levels was also observed in mice that received CP36 CD8 +  T cells pre-stimulated with the mixture of Gag peptides ( FIG. 12 ). Since the post-engraftment lifespan of MIS (KI) TRG mice is only 10-12 weeks 33 , the acute phase of HIV-linfection and demonstrate the in vivo functionality of patient CD8 +  T cells was only investigated. Future developments of the MIS (KI) TRG model will prolong the post-engraftment lifespan of the mice and will allow the studies of establishment and clearance of HIV-1 latent reservoir in vivo. Together, these in vitro and in vivo experiments demonstrate that only the CTL clones targeting unmutated epitopes are effective against cells infected with the viral variants that are likely to represent the major source of rebound HIV-1 after reversal of latency. 
     The seeding of the HIV-1 latent reservoir starts just a few days after infection 26 , prior to the development of robust CTL response 14 . This is consistent with the finding that patients who initiated treatment early in acute infection have few if any CTL escape variants archived in the latent reservoir. However, if treatment was initiated in chronic infection, CTL escape variants became dominant in the latent reservoir, indicating a complete replacement of the initially established ‘wild-type’ reservoir. The mechanism behind this replacement warrants further investigation, but likely reflects the dynamic nature of the reservoir in untreated infection. In any event, the overwhelming presence of escape variants in the latent reservoir of chronic patients certainly presents an additional barrier to eradication efforts. The striking difference between AP- and CP-treated patients presents another argument for early treatment of HIV-1 infection; early treatment not only reduces the size of the latent reservoir 27 , but also alters the composition of the reservoir, as shown here, in a way that may enhance the efficacy of potential CTL-based eradication therapies. 
     The hierarchy of HIV-1-specific CTL response in acute infection appears to play a significant role in initial viral suppression as demonstrated by the fact that certain immunodominant CTL populations are frequently linked to lower set point viremia later in infection 17,28 . These immunodominant responses in acute infection have been identified as the major selection force driving the development of CTL escape mutations 13, 20 . Here it was shown that these immunodominant response-driven mutations are not only archived in the latent reservoir, but also in fact dominate the latent provirus population in CP-treated patients. Therefore, directing CTL responses to unmutated viral epitopes is essential to clear latent HIV-1. Due to bias in antigen presentation or recognition 29 , common vaccination strategies will likely re-stimulate immunodominant CTL clones which do not kill infected cells after reversal of latency. Stimulation of CTL responses with viral peptides circumvents antigen processing and is able to elicit broad-spectrum CTL responses against unmutated regions of viral proteins. These study suggests that latent HIV-1 can be eliminated in chronically infected patients despite the overwhelming presence of CTL escape variants. Future directions in therapeutic vaccine design need to focus on boosting broad CTL responses as also reported elsewhere 30  and/or manipulating immuno dominance. 
     REFERENCES 
     
         
         1. Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.  Nat Med  9, 727-8 (2003). 
         2. Strain, M. C. et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.  Proc Natl Acad Sci USA  100, 4819-24 (2003). 
         3. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.  Science  278, 1295-300 (1997). 
         4. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.  Nature  387, 183-8 (1997). 
         5. Richman, D. D. et al. The challenge of finding a cure for HIV infection.  Science  323, 1304-7 (2009). 
         6. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.  AIDS Res Hum Retroviruses  25, 207-12 (2009). 
         7. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.  J Biol Chem  284, 6782-9 (2009). 
         8. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.  Nature  487, 482-5 (2012). 
         9. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.  Immunity  36, 491-501 (2012). 
         10. Walker, B. D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals.  Nature  328, 345-8 (1987). 
         11. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.  J Virol  68, 4650-5 (1994). 
         12. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.  Nat Med  3, 205-11 (1997). 
         13. Goonetilleke, N. et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.  J Exp Med  206, 1253-72 (2009). 
         14. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. &amp; Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development.  Nat Rev Immunol  10, 11-23 (2010). 
         15. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.  Nature  354, 453-9 (1991). 
         16. Koup, R. A. Virus escape from CTL recognition.  J Exp Med  180, 779-82 (1994). 
         17. Goulder, P. J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.  Nat Med  3, 212-7 (1997). 
         18. Goulder, P. J. &amp; Watkins, D. I. HIV and SIV CTL escape: implications for vaccine design.  Nat Rev Immunol  4, 630-40 (2004). 
         19. Henn, M. R. et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.  PLoS Pathog  8, e1002529 (2012). 
         20. Liu, M. K. et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.  J Clin Invest  123, 380-93 (2013). 
         21. Rolland, M., Nickle, D. C. &amp; Mullins, J. I. HIV-1 group M conserved elements vaccine.  PLoS Pathog  3, e157 (2007). 
         22. Letourneau, S. et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine.  PLoS One  2, e984 (2007). 
         23. Yu, X. G. et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.  J Virol  76, 8690-701 (2002). 
         24. Ho, Y. C. et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure.  Cell  155, 540-51 (2013). 
         25. Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model.  Nat Biotechnol  32, 364-72 (2014). 
         26. Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.  Nature,  74-77 (2014). 
         27. Ananworanich, J. et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.  PLoS One  7, e33948 (2012). 
         28. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection.  Nature  412, 334-8 (2001). 
         29. Le Gall, S., Stamegna, P. &amp; Walker, B. D. Portable flanking sequences modulate CTL epitope processing.  J Clin Invest  117, 3563-75 (2007). 
         30. Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.  Science  340, 1237874 (2013). 
         31. Magoc, T. &amp; Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies.  Bioinformatics  27, 2957-63 (2011). 
         32. Langmead, B. &amp; Salzberg, S. L. Fast gapped-read alignment with Bowtie 2.  Nat Methods  9, 357-9 (2012). 
         33. Streeck, H., Frahm, N. &amp; Walker, B. D. The role of IFN-gamma Elispot assay in HIV vaccine research.  Nat Protoc  4, 461-9 (2009). 
         34. Siliciano, J. D. &amp; Siliciano, R. F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.  Methods Mol Biol  304, 3-15 (2005). 
       
    
     EQUIVALENTS 
     Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention may become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. Such equivalents are intended to be encompassed by the following claims. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Peripheral blood or bone marrow for the isolation of primary 
               
               
                 CD4+, CD8+ or CD34+ T cells was obtained from 
               
               
                 30 HIV-1-infected patients and 7 healthy adult volunteers. 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                   
                   
                 Plasma 
                   
                 Treatment 
               
               
                   
                   
                 CD4 
                 HIV-1 
                 Time on 
                 start time 
               
               
                   
                 Year of 
                 count* 
                 RNA †   
                 ART 
                 after infection 
               
               
                 Patient 
                 Diagnosis 
                 (cells/μl) 
                 (copies/ml) 
                 (years) 
                 (days) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 AP01 
                 2006 
                 1251 
                 &lt;50 
                 7 
                 64 
               
               
                 AP03 
                 2004 
                 595 
                 &lt;50 
                 9 
                 34 
               
               
                 AP04 
                 1998 
                 953 
                 &lt;50 
                 15 
                 77 
               
               
                 AP05 
                 2002 
                 618 
                 &lt;50 
                 11 
                 39 
               
               
                 AP07 
                 2012 
                 592 
                 &lt;50 
                 1.5 
                 67 
               
               
                 AP08 
                 2008 
                 780 
                 &lt;50 
                 6 
                 28 
               
               
                 AP09 
                 2012 
                 1069 
                 &lt;50 
                 2 
                 39 
               
               
                 AP10 
                 2006 
                 513 
                 &lt;50 
                 7 
                 50 
               
               
                 AP11 
                 2007 
                 874 
                 &lt;50 
                 6 
                 10 
               
               
                 AP12 
                 2007 
                 629 
                 &lt;50 
                 6 
                 15 
               
               
                 CP05 
                 2001 
                 500 
                 &lt;50 
                 10 
                 &gt;180 
               
               
                 CP12 
                 1997 
                 1074 
                 &lt;50 
                 15 
                 &gt;180 
               
               
                 CP18 
                 1998 
                 773 
                 &lt;50 
                 &gt;4 
                 &gt;180 
               
               
                 CP19 
                 2006 
                 620 
                 &lt;50 
                 6 
                 &gt;180 
               
               
                 CP26 
                 1994 
                 640 
                 &lt;50 
                 16 
                 &gt;180 
               
               
                 CP27 
                 1987 
                 784 
                 &lt;50 
                 4 
                 &gt;180 
               
               
                 CP28 
                 1998 
                 614 
                 &lt;50 
                 6 
                 &gt;180 
               
               
                 CP31 
                 2000 
                 619 
                 &lt;50 
                 10 
                 &gt;180 
               
               
                 CP32 
                 1999 
                 780 
                 &lt;50 
                 2 
                 &gt;180 
               
               
                 CP35 
                 2002 
                 738 
                 &lt;50 
                 10 
                 &gt;180 
               
               
                 CP36 
                 2003 
                 1119 
                 &lt;50 
                 4 
                 &gt;180 
               
               
                 CP37 
                 1999 
                 730 
                 &lt;50 
                 12 
                 &gt;180 
               
               
                 CP38 
                 1986 
                 870 
                 &lt;50 
                 3 
                 &gt;180 
               
               
                 CP39 
                 1996 
                 1552 
                 &lt;50 
                 10 
                 &gt;180 
               
               
                 CP40 
                 2002 
                 544 
                 &lt;50 
                 7 
                 &gt;180 
               
               
                 CP42 
                 1987 
                 684 
                 &lt;50 
                 16 
                 &gt;180 
               
               
                 CP47 
                 1986 
                 792 
                 &lt;50 
                 14 
                 &gt;180 
               
               
                 CP48 
                 1998 
                 641 
                 &lt;50 
                 8 
                 &gt;180 
               
               
                 CP49 
                 1992 
                 864 
                 &lt;50 
                 5 
                 &gt;180 
               
               
                 CP50 
                 2001 
                 964 
                 &lt;50 
                 4 
                 &gt;180 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Deep sequencing results for viral variants archived in the latent reservoir. 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 Variation 
                 Variation 
                   
               
               
                   
                   
                 Epitope 
                   
                   
                 Frequency 
                 Frequency 
                 Mutation 
               
               
                 Patient 
                 HLA Type 
                 Name 
                 Epitope 1   
                 Variant 2   
                 (%) (PacBio) 
                 (%) (MiSeq) 
                 Type 3   
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 CP05 
                 A*29:02 
                 RY11 
                 RSLYNTVATLY (A30) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*30:01 
                 LY9 
                 LYNTVATLY (A29:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*42:01 
                 IW9 
                 ISPRTLNAW (B57:01) 
                 I147L 
                 89.4 
                 92.3 
                 E 
               
               
                   
                 B*57:01 
                 KF11 
                 KAFSPEVIPMF (B57:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*06:02 
                 TL9 
                 TPQDLNTML (B42:01) 
                 Q182A 
                 86.6 
                 88.1 
                 MTND 
               
               
                   
                 Cw*17:01 
                 TW10 
                 TSTLQEQIGW (B57:01) 
                 T242N 
                 98.4 
                 98.7 
                 E 
               
               
                   
                   
                 QW9 
                 QASQEVKNW (B57:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP12 
                 A*01:01 
                 LY9 
                 LYNTVATLY (A29:02, B44:03) 
                 T81A, V82I 
                 67.1 
                 68.6 
                 MTND 
               
               
                   
                 A*29:02 
                 IW9 
                 ISPRTLNAW (B57:01) 
                 I147L 
                 93 
                 97.3 
                 E 
               
               
                   
                 B*44:03 
                 KF11 
                 KAFSPEVIPMF (B57:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*57:01 
                 TW10 
                 TSTLQEQIGW (B57:01) 
                 T242N 
                 91.3 
                 99.1 
                 B 
               
               
                   
                 Cw*06:02 
                 QW9 
                 QASQEVKNW (B57:01) 
                 S310T 
                 69.8 
                 72.8 
                 MTND 
               
               
                   
                 Cw*16:01 
               
               
                   
               
               
                 CP18 
                 A*02:01 
                 WF9 
                 WASRELERF (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*33:03 
                 SL9 
                 SLYNTVATL (A02:01) 
                 Y79F, V82I, 
                 97.4 
                 98.8 
                 E 
               
               
                   
                 B*35:01 
                   
                   
                 T84V 
               
               
                   
                 B*81:01 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*04:01 
                 TL9 
                 TPQDLNTML (B81:01) 
                 Q182G/A/V 
                 87.6 
                 93.4 
                 MTND 
               
               
                   
                 Cw*18:01 
                 HA9 
                 HPVHAGPIA (B35:01) 
                 I223V 
                 53.7 
                 66.6 
                 MTND 
               
               
                   
                   
                 PY9 
                 PPIPVGEIY (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A0201) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP19 
                 A*23:01 
                 RY11 
                 RSLYNTVATLY (B58) 
                 V82I, T84V 
                 35.9 
                 24.6 
                 MTND 
               
               
                   
                 A*68:02 
                 VF9 
                 VKVVEEKAF (B15:03) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*15:03 
                 GHL9 
                 GHQAAMQML (B15) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*58:01 
                 TW10 
                 TSTLQEQIGW (B58:01) 
                 T242N, G248T 
                 82.9 
                 98.3 
                 E 
               
               
                   
                 Cw*02:10 
                 QW9 
                 QASQEVKNW (B58:01) 
                 E312D 
                 78.1 
                 97.9 
                 MTND 
               
               
                   
                 Cw*07:18 
               
               
                   
               
               
                 CP31 
                 A*23:01 
                 RY11 
                 RSLYNTVATLY (B58) 
                 R76K, T81A 
                 99.5 
                 92.3 
                 E 
               
               
                   
                 A*66:02 
                 KF11 
                 KAFSPEVIPMF (B58:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*41:01 
                 TL9 
                 TPQDLNTML (C08:02) 
                 Q182G, T186L 
                 0 
                 22.9 
                 MTND 
               
               
                   
                 B*58:01 
                 EW10 
                 ETINEEAAEW (B58) 
                 E203D 
                 95.1 
                 69.2 
                 SF 
               
               
                   
                 Cw*07:18 
                 TW10 
                 TSTLQEQIGW (B58:01) 
                 T242N, G248A 
                 99.1 
                 71.7 
                 E 
               
               
                   
                 Cw*08:02 
                 QW9 
                 QASQEVKNW (B58:01) 
                 E312D 
                 99 
                 70.4 
                 MTND 
               
               
                   
               
               
                 CP32 
                 A*34:02 
                 LY9 
                 LYNTVATLY (B44:03) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*68:01 
                 TL9 
                 TPQDLNTML (B53:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*44:03 
                 QW9 
                 QASQEVKNW (B53:01) 
                 S310T 
                 97.2 
                 98.8 
                 E 
               
               
                   
                 B*53:01 
               
               
                   
                 Cw*04:01 
               
               
                   
               
               
                 CP36 
                 A*02:02 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28S 
                 94.5 
                 97.5 
                 MTND 
               
               
                   
                 B*35:01 
                 WF9 
                 WASRELERF (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*53:01 
                 SL9 
                 SLYNTVATL (A02:02) 
                 T84V 
                 98.2 
                 99 
                 E 
               
               
                   
                 Cw*04:01 
                 TV9 
                 TLNAWVKVV (A02:02) 
                 V159I 
                 81.6 
                 83.4 
                 DR 
               
               
                   
                   
                 EW10 
                 ETINEEAAEW (B53) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 HA9 
                 HPVHAGPIA (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 QW9 
                 QASQEVKNW (B53:01) 
                 S310T 
                 70.9 
                 78 
                 MTND 
               
               
                   
               
               
                 CP38 
                 A*03:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 K26R 
                 10.4 
                 13.1 
                 E 
               
               
                   
                 A*24:02 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K26R, K28Q 
                 75.4 
                 78.7 
                 E 
               
               
                   
                 B*44:02 
                 KW9 
                 KYKLKHIVW (A24:02) 
                 K28Q, K30R, I34L 
                 98.3 
                 99.4 
                 E 
               
               
                   
                 B*81:01 
                 TL9 
                 TPQDLNTML (B81:01) 
                 Q182G/S, T186L 
                 95.7 
                 99.4 
                 MTND 
               
               
                   
                 Cw*05:01 
                 RL11 
                 RDYVDRFYKTL (B44:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*18:01 
                 AW11 
                 AEQASQEVKNW (B44:02, Cw5) 
                 S310T 
                 12.5 
                 12.3 
                 MTND 
               
               
                   
               
               
                 CP39 
                 A*03:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*29:02 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28Q 
                 94.7 
                 98.6 
                 E 
               
               
                   
                 B*07:02 
                 LY9 
                 LYNTVATLY (A29:02) 
                 Y79F, V82I, 
                 99 
                 98.6 
                 E 
               
               
                   
                 B*15:16 
                   
                   
                 T84V, Y86F 
               
               
                   
                 Cw*07:02 
                 SV9 
                 SPRTLNAWV (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*14:02 
                 TL9 
                 TPQDLNTML (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 HA9 
                 HPVHAGPIA (B7) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 GL9 
                 GPGHKARVL (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP40 
                 A*02:02 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 K18R 
                 39.8 
                 40.4 
                 MTND 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28T/R 
                 89.5 
                 91.1 
                 DR 
               
               
                   
                 B*15:16 
                 RL10 
                 RPGGKKKYKL (B51:01) 
                 K28T/R, K30R 
                 91.8 
                 92.4 
                 MTND 
               
               
                   
                 B*51:01 
                 SL9 
                 SLYNTVATL (A02:02, Cw14) 
                 Y79F, T81A, 
                 99.4 
                 99.3 
                 E 
               
               
                   
                 Cw*14:02 
                   
                   
                 V82I, T84V 
               
               
                   
                   
                 TV9 
                 TLNAWVKVV (A02:02) 
                 V159I 
                 3.4 
                 4.2 
                 DR 
               
               
                   
               
               
                 CP42 
                 A*02:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28Q 
                 97.5 
                 98.9 
                 E 
               
               
                   
                 B*07:02 
                 SL9 
                 SLYNTVATL (A02:01) 
                 Y79F, V82I 
                 98.3 
                 98.7 
                 E 
               
               
                   
                 B*38:01 
                 SV9 
                 SPRTLNAWV (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07:02 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*12:03 
                 TL9 
                 TPQDLNTML (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 HA9 
                 HPVHAGPIA (B7) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 GL9 
                 GPGHKARVL (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP47 
                 A*02:01 
                 SL9 
                 SLYNTVATL (A02:01) 
                 Y79F, T81A, 
                 92.3 
                 96.4 
                 E 
               
               
                   
                   
                   
                   
                 V82I, T84V 
               
               
                   
                 A*25:01 
                 QW11 
                 QAISPRTLNAW (A25:01) 
                 I147L 
                 96.5 
                 96.5 
                 DR 
               
               
                   
                 B*18;01 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07:01 
                 EW10 
                 ETINEEAAEW (A25:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*12:03 
                 FRK10 
                 FRDYVDRFYK (B18:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP48 
                 A*33:03 
                 LY9 
                 LYNTYATLY (B44:03) 
                 T81A, V82I, T84V 
                 94.2 
                 98.7 
                 MTND 
               
               
                   
                 A*37:01 
                 RL11 
                 RDYVDRFYKTL (B44) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*44:03 
                 AW11 
                 AEQASQEVKNW (B44) 
                 S310T 
                 24.5 
                 27.8 
                 MTND 
               
               
                   
                 Cw*06:02 
               
               
                   
                 Cw*07:06 
               
               
                   
               
               
                 CP49 
                 A*01:01 
                 GK9 
                 GGKKKYKLK (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*02:01 
                 EV9 
                 ELRSLYNTV (B08:01) 
                 R76K, Y79F 
                 99.2 
                 98.5 
                 MTND 
               
               
                   
                 B*08:01 
                 SL9 
                 SLYNTVATL (A02:01) 
                 Y79F 
                 99.2 
                 98.5 
                 E 
               
               
                   
                 B*13:02 
                 VQV9 
                 VQNLQGQMV (B13) 
                 L138M 
                 97 
                 97.3 
                 MTND 
               
               
                   
                 Cw*06:02 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07:01 
                 GI11 
                 GQMKFPRGSD1 (B13) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 EI8 
                 EIYKRWII (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 DL9 
                 DCKTILKAL (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 R19 
                 RQANFLGKI (B13) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 CP50 
                 A*03:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*30:04 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28Q 
                 91.8 
                 94 
                 E 
               
               
                   
                 B*35:01 
                 WF9 
                 WASRELERF (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*49:01 
                 RY11 
                 RSLYNTVATLY (A30) 
                 R76K 
                 97.4 
                 98.5 
                 IE 
               
               
                   
                 Cw*04:01 
                 HA9 
                 HPVHAGPIA (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07:01 
                 PY9 
                 PPIPVGEIY (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 AP01 
                 A*02:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 K28Q 
                 3.4 
                 4.3 
                 E 
               
               
                   
                 B*35:01 
                 WF9 
                 WASRELFRF (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*44:02 
                 SL9 
                 SLYNTVATL (A02:01) 
                 T84V 
                 94.4 
                 98.7 
                 E 
               
               
                   
                 Cw*04:01 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*05:01 
                 HA9 
                 HPVHAGPIA (B35:01) 
                 I223P 
                 95.2 
                 94.7 
                 MTND 
               
               
                   
                   
                 PY9 
                 PP1PVGEIY (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 RL11 
                 RDYVDRFYKTL (B44:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 AW11 
                 AEQASQEVKNW (B44:02, Cw5) 
                 N315G 
                 96.5 
                 94.9 
                 MTND 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 1 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 AP03 
                 A*24:02 
                 IK9 
                 IRLRPGGKK (B27:05) 
                 K26N 
                 66.1 
                 61.5 
                 MTND 
               
               
                   
                 A*24:07 
                 KW9 
                 KYKLKHIVW (A24:02) 
                 K28Q 
                 29.5 
                 36.4 
                 E 
               
               
                   
                 B*15:02 
                 VL8 
                 VIPMFSAL (C01:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*27:05 
                 KK10 
                 KRWIILGLNK (B27:05) 
                 R264K, L268M 
                 25 
                 25.8 
                 E 
               
               
                   
                 Cw*01:02 
                 YL9 
                 YVDRFYKTL (C03:03) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*03:03 
               
               
                   
               
               
                 AP04 
                 A*02:01 
                 KW9 
                 KYKLKHIVW (A24::02) 
                 K30Q/R 
                 50.4 
                 52.9 
                 MTND 
               
               
                   
                 A*24:02 
                 WF9 
                 WASRELFRF (B35:01) 
                 F44Y 
                 7.7 
                 7 
                 MTND 
               
               
                   
                 B*14:01 
                 SL9 
                 SLYNTVATL (A02:01) 
                 V82I 
                 11.7 
                 12.3 
                 E 
               
               
                   
                 B*35:01 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 V1591 
                 7.6 
                 6.9 
                 DR 
               
               
                   
                 Cw*04:01 
                 HA9 
                 HPVHAGPIA (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*15:05 
                 PY9 
                 PPIPVGEIY (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 CC9 
                 CRAPRKKGC (B14) 
                 K411R 
                 70.5 
                 79.2 
                 MTND 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 1437L 
                 7.7 
                 6.9 
                 MTND 
               
               
                   
               
               
                 AP05 
                 A*02:01 
                 RL10 
                 RPGGKKKYKL, (B51:01) 
                 K28Q 
                 95.8 
                 98.7 
                 MTND 
               
               
                   
                 B*07:02 
                 SL9 
                 SLYNTVATL (A02:03) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*51:01 
                 SV9 
                 SPRTLNAWV (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*01:02 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 V159I 
                 99.2 
                 98.5 
                 DR 
               
               
                   
                 Cw*07:02 
                 VL8 
                 VIPMFSAL (Cw01:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 TL9 
                 TPQDLNTML (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 HA9 
                 HPVHAGPIA (B7) 
                 H219P, I223V 
                 99.4 
                 98.7 
                 MTND 
               
               
                   
                   
                 GL9 
                 GPGHKARVL (B07:02) 
                 R361K 
                 6.1 
                 18.3 
                 MTND 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 H441N 
                 97.2 
                 98.1 
                 MTND 
               
               
                   
               
               
                 AP07 
                 A*02:07 
                 RY11 
                 RSLYNTVATLY(B58) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*33:03 
                 VL8 
                 VIPMFSAL(Cw01:02) 
                 S173T 
                 96.6 
                 97.2 
                 DR 
               
               
                   
                 B*46:01 
                 TW10 
                 TSTLQEQIGW(B58:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*58:01 
                 YL9 
                 YVDRFYKTL(A02:07) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*01:02 
                 QW9 
                 QASQEVKNW(B58) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*03:02 
               
               
                   
               
               
                 AP08 
                 A*02:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 R28Q 
                 96.1 
                 98.7 
                 E 
               
               
                   
                 B*07:02 
                 SL9 
                 SLYNTVATL (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07:02 
                 SV9 
                 SPRTLMAWV (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 TL9 
                 TPQDLNTML (B07:02) 
                 Q182S 
                 93.1 
                 96.5 
                 MTND 
               
               
                   
                   
                 HA9 
                 HPVIIAGPIA (B7) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 GL9 
                 GPGHKARVL (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 AP09 
                 A*03:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*11:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*08:01 
                 GK9 
                 GGKKKYKLK (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*14:02 
                 EV9 
                 ELRSLYNTV (B08:01) 
                 R76K, V82I 
                 98.9 
                 98.9 
                 IE 
               
               
                   
                 Cw*07 
                 EI8 
                 EIYKRWII (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*08 
                 DA9 
                 DRFYKTLRA(B14:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 DL9 
                 DCKTILKAL (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 AK11 
                 ACQGVGGPGHK(A11:01) 
                 G357S 
                 98 
                 99.1 
                 SF 
               
               
                   
                   
                 CC9 
                 CRAPRKKGC (B14) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                 AP10 
                 A*01:01 
                 GK9 
                 GGKKKYKLK (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*02:01 
                 EV9 
                 ELRSLYNTV (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*08:01 
                 SL9 
                 SLYNTVATL (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*15:01 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*03 
                 EI8 
                 EIYKRWII (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*07 
                 GLY9 
                 GLNKIVRMY(B15:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 DL9 
                 DCKTILKAL (B08:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 G435R 
                 31.7 
                 51.6 
                 MTND 
               
               
                   
               
               
                 AP11 
                 A*02:01 
                 RL10 
                 RPGGKKKYKL (B51:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*35:01 
                 WF9 
                 WASRELERF (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*51:01 
                 SL9 
                 SLYNTVATL (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*02:02 
                 TV9 
                 TLNAWVKVV (A02:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 Cw*04:01 
                 HA9 
                 HPVHAGPIA (B7) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 PY9 
                 PPIPVGEIY (B35:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 FK10 
                 FLGKIWPSHK (A02:01) 
                 G435R 
                 2.1 
                 6.7 
                 MTND 
               
               
                   
               
               
                 AP12 
                 A*01:01 
                 KK9 
                 KIRLRPGGK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 A*03:01 
                 RK9 
                 RLRPGGKKK (A03:01) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                 B*07:02 
                 SV9 
                 SPRTLNAWV (B07:02) 
                 R150K 
                 2.7 
                 5.6 
                 MTND 
               
               
                   
                 Cw*07 
                 TL9 
                 TPQDLNTML (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 HA9 
                 HPVHAGPIA (B7) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
                   
                 GL9 
                 GPGHKARVL (B07:02) 
                 — 
                 0 
                 0 
                 — 
               
               
                   
               
               
                   1 Each patient&#39;s relevant optimal Gag epitopes are based: on reported information in the HIV Molecular Immunology Database, Los Alamos National Laboratory (http://www.luv.lanl.gov/content/immunology/index.html) according to the HLA type. 
               
               
                   2 Sequences from each subject were aligned to the reference HIV-1 clade B consensus Gag sequence. Variants were determined by the differences from the reference sequence. 
               
               
                   3 Mutation Type abbreviations: MTND: mutation type not determined; E: documented escape; IE: inferred escape; DR: diminished response; SF: susceptible form. 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
               
                   
               
               
                 Consensus Subtype 8 Nef (NIH AIDS Reagent 5189) 
               
               
                 DATA SHEET 
               
               
                 HIV-1 Consensus Subtype B Nef (15-mer) Peptides - Complete Set 
               
               
                 (Cat# 5189, Lot# 10 - NOTE solubility data is from lot#9) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                   
                 Solubility Data 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Molecular 
                   
                 Peptide 
                   
                   
                 10% 
                   
               
               
                   
                   
                   
                 Wt. 
                 Purity 
                 Content 
                   
                   
                 Acetic 
               
               
                 CAT # 
                 Peptide Name 
                 SEQUENCE 
                 Amu 
                 [%] 
                 [%] 
                 Water 
                 PBS 
                 Acid 
                 DMSO 
               
               
                   
               
               
                 5139 
                 HIV-1 Consensus Subtype B Nef 
                 MGGKWSKRSVVGWPT 
                 1676.0 
                 96.0 
                 71.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5140 
                 HIV-1 Consensus Subtype B Nef 
                 WSKRSVVGWPTVRER 
                 1843.1 
                 91.5 
                 69.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5141 
                 HIV-1 Consensus Subtype B Nef 
                 SVVGWPTVRERMRRA 
                 1800.1 
                 95.9 
                 69.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5142 
                 HIV-1 Consensus Subtype B Nef 
                 WPTVRERMRRAEPAA 
                 1826.1 
                 95.2 
                 71.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5143 
                 HIV-1 Consensus Subtype B Nef 
                 RERMRRAEPAADGVG 
                 1670.9 
                 97.4 
                 70.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5144 
                 HIV-1 Consensus Subtype B Nef 
                 RRAEPAADGVGAVSR 
                 1511.7 
                 94.8 
                 74.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5145 
                 HIV-1 Consensus Subtype B Nef 
                 PAADGVGAVSRDLEK 
                 1484.6 
                 98.4 
                 80.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5146 
                 HIV-1 Consensus Subtype B Nef 
                 GVGAVSRDLEKHGAI 
                 1508.7 
                 96.6 
                 74.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5147 
                 HIV-1 Consensus Subtype B Nef 
                 VSRDLEKHGAITSSN 
                 1613.8 
                 90.8 
                 71.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5148 
                 HIV-1 Consensus Subtype B Nef 
                 LEKHGAITSSNTAAN 
                 1513.6 
                 96.0 
                 76.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5149 
                 HIV-1 Consensus Subtype B Nef 
                 GAITSSNTAANNADC 
                 1409.4 
                 96.2 
                 80.0 
                 − 
                 − 
                 − 
                 − 
               
               
                   
               
               
                 5150 
                 HIV-1 Consensus Subtype B Nef 
                 SSNTAANNADCAWLE 
                 1566.6 
                 95.0 
                 84.0 
                 − 
                 − 
                 − 
                 − 
               
               
                   
               
               
                 5151 
                 HIV-1 Consensus Subtype B Nef 
                 AANNADCAWLEAQEE 
                 1634.7 
                 98.1 
                 90.0 
                 + 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 5152 
                 HIV-1 Consensus Subtype B Nef 
                 ADCAWLEAQEEEEVG 
                 1678.8 
                 94.4 
                 87.0 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 5153 
                 HIV-1 Consensus Subtype B Nef 
                 WLEAQEEEEVGFPVR 
                 1813.0 
                 97.7 
                 82.0 
                 + 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5154 
                 HIV-1 Consensus Subtype B Nef 
                 QEEEEVGFPVRPQVP 
                 1739.9 
                 91.7 
                 88.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5155 
                 HIV-1 Consensus Subtype B Nef 
                 EVGFPVRPQVPLRPM 
                 1722.1 
                 96.6 
                 76.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5156 
                 HIV-1 Consensus Subtype B Nef 
                 PVRPQVPLRPMTYKA 
                 1753.1 
                 96.9 
                 72.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5157 
                 HIV-1 Consensus Subtype B Nef 
                 QVPLRPMTYKAAVDL 
                 1702.1 
                 92.4 
                 77.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
            
           
           
               
            
               
                 NOTE: Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once 
               
               
                 a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be 
               
               
                 taken to ensure that the peptide does not begin to precipitate out of solution. 
               
            
           
           
               
               
            
               
                   
                 Solubility Data 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 Peptide 
                   
                   
                 10% 
                   
               
               
                   
                   
                   
                 M W 
                 Purity 
                 Content 
                   
                   
                 Acetic 
               
               
                 CAT # 
                 Peptide Name 
                 SEQUENCE 
                 g/mol 
                 [%] 
                 [%] 
                 Water 
                 PBS 
                 Acid 
                 DMSO 
               
               
                   
               
               
                 5158 
                 HIV-1 Consensus Subtype B Nef 
                 RPMTYKAAVDLSHFL 
                 1749.1 
                 91.0 
                 73.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5159 
                 HIV-1 Consensus Subtype B Nef 
                 YKAAVDLSHFLKEKG 
                 1706.0 
                 95.9 
                 69.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5160 
                 HIV-1 Consensus Subtype B Nef 
                 VDLSHFLKEKGGLEG 
                 1628.8 
                 95.1 
                 76.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5161 
                 HIV-1 Consensus Subtype B Nef 
                 HFLKEKGGLEGLIYS 
                 1691.0 
                 95.5 
                 75.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5162 
                 HIV-1 Consensus Subtype B Nef 
                 SKGGLEGLIYSQKRQ 
                 1705.9 
                 97.0 
                 74.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5163 
                 HIV-1 Consensus Subtype B Nef 
                 LEGLIYSQKRQDILD 
                 1791.0 
                 94.8 
                 79.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5164 
                 HIV-1 Consensus Subtype B Nef 
                 IYSQKRQDILDLWVY 
                 1940.2 
                 96.8 
                 74.0 
                 + 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5165 
                 HIV-1 Consensus Subtype B Nef 
                 KRQDILDLWVYHTQG 
                 1872.1 
                 95.9 
                 75.0 
                 + 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5166 
                 HIV-1 Consensus Subtype B Nef 
                 ILDLWVYHTGGYFPD 
                 1867.1 
                 96.0 
                 81.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5167 
                 HIV-1 Consensus Subtype B Nef 
                 WVYHTQGYFPDWQNY 
                 2004.0 
                 95.1 
                 75.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5168 
                 HIV-1 Consensus Subtype B Nef 
                 TQGYFPDWQNYTPGP 
                 1770.9 
                 95.5 
                 78.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5169 
                 HIV-1 Consensus Subtype B Nef 
                 FPDWQNYTPGPGIRY 
                 1811.0 
                 95.3 
                 74.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5170 
                 HIV-1 Consensus Subtype B Nef 
                 QNYTPGPGIRYPLTF 
                 1723.9 
                 97.2 
                 76.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5171 
                 HIV-1 Consensus Subtype B Nef 
                 PGPGIRYPLTFGWCF 
                 1711.0 
                 96.9 
                 79.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5172 
                 HIV-1 Consensus Subtype B Nef 
                 IRYPLTFGWCFKLVP 
                 1840.3 
                 96.6 
                 80.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5173 
                 HIV-1 Consensus Subtype B Nef 
                 LTFGWCFKLVPVEPE 
                 1765.1 
                 95.9 
                 82.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5174 
                 HIV-1 Consensus Subtype B Nef 
                 WCFKLVPVEPEKVEE 
                 1832.2 
                 97.6 
                 81.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5175 
                 HIV-1 Consensus Subtype B Nef 
                 LVPVEPEKVEEANEG 
                 1638.8 
                 96.4 
                 84.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5176 
                 HIV-1 Consensus Subtype B Nef 
                 EPEKVEEANEGENNS 
                 1674.7 
                 96.1 
                 83.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5177 
                 HIV-1 Consensus Subtype B Nef 
                 VEEANEGENNSLLHP 
                 1651.7 
                 97.2 
                 82.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5178 
                 HIV-1 Consensus Subtype B Nef 
                 NEGENNSLLHPMSLH 
                 1691.9 
                 95.5 
                 77.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5179 
                 HIV-1 Consensus Subtype B Nef 
                 NNSLLHPMSLHGMDD 
                 1680.9 
                 96.4 
                 70.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5180 
                 HIV-1 Consensus Subtype B Nef 
                 LHPMSLHGMDDPERE 
                 1764.0 
                 94.9 
                 66.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5181 
                 HIV-1 Consensus Subtype B Nef 
                 SLHGMDDPEREVLEW 
                 1813.0 
                 96.1 
                 74.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5182 
                 HIV-1 Consensus Subtype B Nef 
                 MDDPEREVLEWKFDS 
                 1896.1 
                 95.5 
                 74.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5183 
                 HIV-1 Consensus Subtype B Nef 
                 EREVLEWKFDSRLAF 
                 1925.2 
                 98.5 
                 74.0 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5184 
                 HIV-1 Consensus Subtype B Nef 
                 LEWKFDSRLAFHHMA 
                 1888.2 
                 96.3 
                 74.0 
                 + 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5185 
                 HIV-1 Consensus Subtype B Nef 
                 FDSRLAFHHMARELH 
                 1867.1 
                 93.0 
                 71.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5186 
                 HIV-1 Consensus Subtype B Nef 
                 LAFHHMARELHPEYY 
                 1914.2 
                 96.6 
                 72.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5187 
                 HIV-1 Consensus Subtype B Nef 
                 HMARELHPEYYKDC 
                 1792.0 
                 97.0 
                 67.0 
                 + 
                 + 
                 + 
                 + 
               
               
                   
               
            
           
           
               
            
               
                 Determination of solubility: appr, 0.25 mg of the respective peptide was incubated with 1 ml of 
               
               
                 solvent. 
               
               
                 Solubility was assessed by visual inspection of the resulting solution/suspension. 
               
               
                 “+”: complete dissolution 
               
               
                 “−”: incomplete dissolution 
               
            
           
         
       
     
     
       
         
           
               
             
               
                   
               
               
                 Brown 20232 delivery list 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 MW (1) 
                   
                 MW (2) 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 detected 
                 MW (1) 
                 detected 
                 MW (2) 
                 MW (3) detected 
                 MW (3) 
               
               
                 Index 
                 JPT-4 
                 Sequence 
                 Peptide Name 
                 Batch# 
                 [g/mol] 
                 label 
                 [g/mol] 
                 label 
                 [g/mol] 
                 label 
               
               
                   
               
               
                 1 
                 20232_001 
                 H-MGARASVLSGGELDR-OH 
                 7872_HIV-1 Consensus B Gag_001 
                 070213R-06 
                 — 
                 — 
                 759.9 
                 [M + 2H]2+ 
                 507 
                 [M + 3H]3+ 
               
               
                   
               
               
                 2 
                 20232_002 
                 H-ASVLSGGELDRNEKI-OH 
                 7872_HIV-1 Consensus B Gag_002 
                 070213R-07 
                 — 
                 — 
                 830.4 
                 [M + 2H]2+ 
                 554.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 3 
                 20232_003 
                 H-SGGKLDRWEKIRLRP-OH 
                 7872_HIV-1 Consensus B Gag_003 
                 190213F-02 
                 — 
                 — 
                 906.8 
                 [M + 2H]2+ 
                 604.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 4 
                 20232_004 
                 H-LURWEKIRLRPGGKK-OH 
                 7872_HIV-1 Consensus B Gag_004 
                 070213R-08 
                 — 
                 — 
                 927 
                 [M + 2H]2+ 
                 616.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 5 
                 20232_005 
                 H-EKIRLRPGGKKKYKL-OH 
                 7872_HIV-1 Consensus B Gag_005 
                 070213R-09 
                 — 
                 — 
                 906 
                 [M + 2H]2+ 
                 605.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 6 
                 20232_006 
                 H-LRPGGKKKYKLKHTV-OH 
                 7872_HIV-1 Consensus B Gag_006 
                 190213F-04 
                 1765.6 
                 [M + H]+ 
                 883.4 
                 [M + 2H]2+ 
                 589.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 7 
                 20232_007 
                 H-GKKKYKLKHIVWASR-OH 
                 7872_HIV-1 Consensus B Gag_007 
                 190213F-06 
                 — 
                 — 
                 921.9 
                 [M + 2H]2+ 
                 814.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 8 
                 20232_008 
                 H-YKLKHIVWASREKER-OH 
                 7872_HIV-1 Consensus B Gag_008 
                 190213F-08 
                 — 
                 — 
                 964.9 
                 [M + 2H]2+ 
                 643.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 9 
                 20232_009 
                 H-HIVWASRELKRFAVH-OH 
                 7872_HIV-1 Consensus B Gag_009 
                 190213F-10 
                 — 
                 — 
                 913.9 
                 [M + 2H]2+ 
                 609.0 
                 [M + 3H]3+ 
               
               
                   
               
               
                 10 
                 20232_010 
                 H-ASRELERFAVNPGLL-OH 
                 7872_HIV-1 Consensus B Gag_010 
                 190213K-01 
                 — 
                 — 
                 836.4 
                 [M + 2H]2+ 
                 658.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 11 
                 20232_011 
                 H-LERFAVNPGLLETSE-OH 
                 7872_HIV-1 Consensus B Gag_011 
                 190213K-03 
                 1874.9 
                 [M + H]+ 
                 838.1 
                 [M + 2H]2+ 
                 659 
                 [M + 3H]3+ 
               
               
                   
               
               
                 12 
                 20232_012 
                 H-AVNPGLLETSEGCRQ-OH 
                 7872_HIV-1 Consensus B Gag_012 
                 190213K-05 
                 1575.2 
                 [M + H]+ 
                 787.8 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 13 
                 20232_013 
                 H-GLLETSEGCRQILGQ-OH 
                 7872_HIV-1 Consensus B Gag_013 
                 190213K-07 
                 1604.4 
                 [M + H]+ 
                 802.4 
                 [M + 2H]2+ 
                 535.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 14 
                 20232_014 
                 H-TSEGCRQILGQLQPS-OH 
                 7872_HIV-1 Consensus B Gag_014 
                 190213K-09 
                 1816.4 
                 [M + H]+ 
                 806.9 
                 [M + 2H]2+ 
                 539.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 15 
                 20232_015 
                 H-CRQILGQLQPSLQTG-OH 
                 7872_HIV-1 Consensus B Gag_015 
                 190213K-11 
                 1642.8 
                 [M + H]+ 
                 821.5 
                 [M + 2H]2+ 
                 548.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 16 
                 20232_016 
                 H-LGQLQPSLQTGSRHL-OH 
                 7872_HIV-1 Consensus B Gag_016 
                 190213K-13 
                 1000.4 
                 [M + H]+ 
                 800.4 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 17 
                 20232_017 
                 H-QPSLQTGSEHLRSLY-OH 
                 7872_HIV-1 Consensus B Gag_017 
                 190213K-15 
                 — 
                 — 
                 854.4 
                 [M + 2H]2+ 
                 570.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 18 
                 20232_018 
                 H-QTGSEELRSLYNTVA-OH 
                 7872_HIV-1 Consensus B Gag_018 
                 190213K-17 
                 — 
                 — 
                 834.5 
                 [M + 2H]2+ 
                 556.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 19 
                 20232_019 
                 H-EKLRSLYMTVATLYC-OH 
                 7872_HIV-1 Consensus B Gag_019 
                 190213K-19 
                 1775.4 
                 [M + H]+ 
                 886.4 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 20 
                 20232_020 
                 H-SLYNTVATLYCVHQR-OH 
                 7872_HIV-1 Consensus B Gag_020 
                 190213K-21 
                 — 
                 — 
                 885 
                 [M + 2H]2+ 
                 590.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 21 
                 20232_021 
                 H-TVATLYCVHQRIEVK-OH 
                 7872_HIV-1 Consensus B Gag_021 
                 190213K-23 
                 1762.3 
                 [M + H]+ 
                 680.8 
                 [M + 2H]2+ 
                 587.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 22 
                 20232_022 
                 H-LYCVHQRIEVKDTKE-OH 
                 7872_HIV-1 Consensus B Gag_022 
                 190213K-25 
                 1552.4 
                 [M + H]+ 
                 931.4 
                 [M + 2H]2+ 
                 621.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 23 
                 20232_023 
                 H-HQRIEVKDTKEALEK-OH 
                 7872_HIV-1 Consensus B Gag_023 
                 190213K-27 
                 — 
                 — 
                 912.4 
                 [M + 2H]2+ 
                 606.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 24 
                 20232_024 
                 H-EVKDTKEALEKIERH-OH 
                 7872_HIV-1 Consensus B Gag_024 
                 190213K-29 
                 — 
                 — 
                 895.3 
                 [M + 2H]2+ 
                 597.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 25 
                 20232_025 
                 H-TKEALEKIEEEQNKS-OH 
                 7872_HIV-1 Consensus B Gag_025 
                 190213K-31 
                 — 
                 — 
                 888.8 
                 [M + 2H]2+ 
                 592.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 26 
                 20232_026 
                 H-LEKIEEEQNKSKKKA-OH 
                 7872_HIV-1 Consensus B Gag_026 
                 190213K-33 
                 1603.3 
                 [M + H]+ 
                 901.8 
                 [M + 2H]2+ 
                 601.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 27 
                 20232_027 
                 H-KEEQNKSKKKAQQAA-OH 
                 7872_HIV-1 Consensus B Gag_027 
                 190213K-35 
                 1717.8 
                 [M + H]+ 
                 859.1 
                 [M + 2H]2+ 
                 573.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 28 
                 20232_028 
                 H-NKSKKKAQQAAADTG-OH 
                 7872_HIV-1 Consensus B Gag_028 
                 190213K-37 
                 1547.1 
                 [M + H]+ 
                 773.7 
                 [M + 2H]2+ 
                 516.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 29 
                 20232_029 
                 H-KKAQQAAADTGGSSQ-OH 
                 7872_HIV-1 Consensus B Gag_029 
                 190213K-39 
                 1505.2 
                 [M + H]+ 
                 753.1 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 30 
                 20232_030 
                 H-QAAADTGGSSQVSQN-OH 
                 7872_HIV-1 Consensus B Gag_030 
                 190213K-41 
                 1477.7 
                 [M + H]+ 
                 739.5 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 31 
                 20232_031 
                 H-DTGNSSQVSQNYPIV-OH 
                 7872_HIV-1 Consensus B Gag_031 
                 190213K-43 
                 1610.1 
                 [M + H]+ 
                 805.2 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 32 
                 20232_032 
                 H-SSQVSQNTPIVQNLQ-OH 
                 7872_HIV-1 Consensus B Gag_032 
                 190213K-45 
                 1707.8 
                 [M + H]+ 
                 853.1 
                 [M + 2H]2+ 
                 560 
                 [M + 3H]3+ 
               
               
                   
               
               
                 33 
                 20232_033 
                 H-SQNYPTVQNLQGQMV-OH 
                 7872_HIV-1 Consensus B Gag_033 
                 190213K-47 
                 — 
                 — 
                 859.8 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 34 
                 20232_034 
                 H-PIVQNLQGQMVRQAI-OH 
                 7872_HIV-1 Consensus B Gag_034 
                 220213Z-10 
                 1675.5 
                 [M + H]+ 
                 838.4 
                 [M + 2H]2+ 
                 559.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 35 
                 20232_035 
                 H-NLQGQMVEQAISPRT-OH 
                 7872_HIV-1 Consensus B Gag_035 
                 220213Z-12 
                 1682.2 
                 [M + H]+ 
                 840.8 
                 [M + 2H]2+ 
                 561.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 36 
                 20232_036 
                 H-QMVHQAISPRTLNAW-OH 
                 7872_HIV-1 Consensus B Gag_036 
                 220213Z-14 
                 — 
                 — 
                 876.8 
                 [M + 2H]2+ 
                 564.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 37 
                 20232_037 
                 H-QAISPRTLNAMVKVV-OH 
                 7872_HIV-1 Consensus B Gag_037 
                 220213Z-16 
                 — 
                 — 
                 841.5 
                 [M + 2H]2+ 
                 561.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 38 
                 20232_038 
                 H-PRTLNAWVKVVEEKA-OH 
                 7872_HIV-1 Consensus B Gag_038 
                 220213Z-18 
                 — 
                 — 
                 870.8 
                 [M + 2H]2+ 
                 580.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 39 
                 20232_039 
                 H-NAWVKVVEEKAFSPE-OH 
                 7872_HIV-1 Consensus B Gag_039 
                 220213Z-20 
                 1732.5 
                 [M + H]+ 
                 866.9 
                 [M + 2H]2+ 
                 578.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 40 
                 20232_040 
                 H-KVVEEKAFSFEVIPM-OH 
                 7872_HIV-1 Consensus B Gag_040 
                 220213Z-22 
                 1703.5 
                 [M + H]+ 
                 851.9 
                 [M + 2H]2+ 
                 568.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 41 
                 20232_041 
                 H-EKAPSPEVIPNFSAL-OH 
                 7872_HIV-1 Consensus B Gag_041 
                 220213Z-24 
                 1666.5 
                 [M + H]+ 
                 833.3 
                 [M + 2H]2+ 
                 556.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 42 
                 20232_042 
                 H-SPEVIPMFSALSEGA-OH 
                 7872_HIV-1 Consensus B Gag_042 
                 220213Z-26 
                 1535.7 
                 [M + H]+ 
                 768 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 43 
                 20232_043 
                 H-IPMFSALSEGATPQD-OH 
                 7872_HIV-1 Consensus B Gag_043 
                 220213Z-28 
                 1565.2 
                 [M + H]+ 
                 762.8 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 44 
                 20232_044 
                 H-SALSEGATPQDLNTM-OH 
                 7872_HIV-1 Consensus B Gag_044 
                 220213Z-30 
                 1535.2 
                 [M + H]+ 
                 768.2 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 45 
                 20232_045 
                 H-EGATPQDLNTMLNTV-OH 
                 7872_HIV-1 Consensus B Gag_045 
                 220213Z-32 
                 1604.3 
                 [M + H]+ 
                 802.7 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 46 
                 20232_046 
                 H-PQDLNTNLNTVGGHQ-OH 
                 7872_HIV-1 Consensus B Gag_046 
                 220213Z-34 
                 1625.4 
                 [M + H]+ 
                 812.8 
                 [M + 2H]2+ 
                 542.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 47 
                 20232_047 
                 H-NTNLNTVGGHQAAHQ-OH 
                 7872_HIV-1 Consensus B Gag_047 
                 220213Z-36 
                 1574.2 
                 [M + H]+ 
                 787.2 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 48 
                 20232_048 
                 H-NTVGGHQAAMQMLKE-OH 
                 7872_HIV-1 Consensus B Gag_048 
                 220213Z-38 
                 1615.4 
                 [M + H]+ 
                 807.8 
                 [M + 2H]2+ 
                 539 
                 [M + 3H]3+ 
               
               
                   
               
               
                 49 
                 20232_049 
                 H-GHQAAMQMLKETINE-OH 
                 7872_HIV-1 Consensus B Gag_049 
                 220213Z-40 
                 1701.8 
                 [M + H]+ 
                 851 
                 [M + 2H]2+ 
                 567.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 50 
                 20232_050 
                 H-AMQMLKETINEEAAE-OH 
                 7872_HIV-1 Consensus B Gag_050 
                 220213Z-42 
                 1709.3 
                 [M + H]+ 
                 854.8 
                 [M + 2H]2+ 
                 — 
                 — 
               
               
                   
               
               
                 51 
                 20232_051 
                 H-LKETINEEAAENDRL-OH 
                 7872_HIV-1 Consensus B Gag_051 
                 220213Z-44 
                 — 
                 — 
                 909.3 
                 [M + 2H]2+ 
                 606.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 52 
                 20232_052 
                 H-INBEAAEWDRLHPVH-OH 
                 7872_HIV1 Consensus B Gag_052 
                 220213R-01 
                 — 
                 — 
                 908.4 
                 [M + 2H]2+ 
                 506 
                 [M + 3H]3+ 
               
               
                   
               
               
                 53 
                 20232_053 
                 H-AAEWDRLHFVHAGPI-OH 
                 7872_HIV1 Consensus B Gag_053 
                 040313Y-01 
                 — 
                 — 
                 834.9 
                 [M + 2H]2+ 
                 557.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 54 
                 20232_054 
                 H-DRLHPVHAGPIAPGO-OH 
                 7872_HIV1 Consensus B Gag_054 
                 040313Y-03 
                 1565.4 
                 [M + H]+ 
                 782.9 
                 [M + 2H]2+ 
                 522.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 55 
                 20232_055 
                 H-PVHAGPIAPGQMREP-OH 
                 7872_HIV1 Consensus B Gag_055 
                 040313Y-05 
                 1658.8 
                 [M + H]+ 
                 779 
                 [M + 2H]2+ 
                 519.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 56 
                 20232_056 
                 H-GPIAPGQMREPRGSD-OH 
                 7872_HIV1 Consensus B Gag_056 
                 040313Y-07 
                 1568.3 
                 [M + H]+ 
                 784.7 
                 [M + 2H]2+ 
                 523.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 57 
                 20232_057 
                 H-PGOMREPRGSDIAGT-OH 
                 7872_HIV1 Consensus B Gag_057 
                 040313Y-09 
                 1572.2 
                 [M + H]+ 
                 766.7 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 58 
                 20232_058 
                 H-REPRGSDIAGTTSTL-OH 
                 7872_HIV1 Consensus B Gag_058 
                 040313Y-11 
                 — 
                 — 
                 780.9 
                 [M + 2H]2+ 
                 521 
                 [M + 3H]3+ 
               
               
                   
               
               
                 59 
                 20232_059 
                 H-GSDIAGTTSTLQEQI-OH 
                 7872_HIV1 Consensus B Gag_059 
                 040313Y-13 
                 1521.3 
                 [M + H]+ 
                 760.8 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 60 
                 20232_060 
                 H-AGITSTLOEOIGWWT-OH 
                 7872_HIV1 Consensus B Gag_060 
                 040313Y-15 
                 1625.2 
                 [M + H]+ 
                 612.7 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 61 
                 20232_061 
                 H-STLQEQIGWMTNNPP-OH 
                 7872_HIV1 Consensus B Gag_061 
                 06021306 
                 1716.3 
                 [M + H]+ 
                 858.8 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 62 
                 20232_062 
                 H-EQIGWMTNNPPIPVG-OH 
                 7872_HIV1 Consensus B Gag_062 
                 040313Y-17 
                 1653.4 
                 [M + H]+ 
                 826.8 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 63 
                 20232_063 
                 H-MMTNNPPIPVGEIYK-OH 
                 7872_HIV1 Consensus B Gag_063 
                 040313Y-19 
                 1761.2 
                 [M + H]+ 
                 880.5 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 64 
                 20232_064 
                 H-NPPIPVGEIYKRWIT-OH 
                 7872_HIV1 Consensus B Gag_064 
                 040313Y-21 
                 — 
                 — 
                 898.3 
                 [M + 2H]2+ 
                 599.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 65 
                 20232_065 
                 H-PVGEIYKRWIILGLN-OH 
                 7872_HIV1 Consensus B Gag_065 
                 040313Y-23 
                 1770.3 
                 [M + H]+ 
                 886.4 
                 [M + 2H]2+ 
                 591.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 66 
                 20232_066 
                 H-IYKRWIILGLNKIVR-OH 
                 7872_HIV1 Consensus B Gag_066 
                 040313Y-25 
                 — 
                 — 
                 943.5 
                 [M + 2H]2+ 
                 629.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 67 
                 20232_067 
                 H-WIILGLWKIVRMYSP-OH 
                 7872_HIV1 Consensus B Gag_067 
                 040313Y-27 
                 1805.2 
                 [M + H]+ 
                 902.5 
                 [M + 2H]2+ 
                 601.9 
                 [M + 3H]3+ 
               
               
                   
               
               
                 68 
                 20232_068 
                 H-GLNKIVRNYSPTSIL-OH 
                 7872_HIV1 Consensus B Gag_068 
                 040313Y-29 
                 1692.7 
                 [M + H]+ 
                 846.8 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 69 
                 20232_069 
                 H-IVRMYSPTSILDIRQ-OH 
                 7872_HIV1 Consensus B Gag_069 
                 040313Y-31 
                 1792.5 
                 [M + H]+ 
                 896.8 
                 [M + 2H]2+ 
                 598.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 70 
                 20232_070 
                 H-ISPTSILOIRQGPKE-OH 
                 7872_HIV1 Consensus B Gag_070 
                 040313Y-33 
                 — 
                 — 
                 852.4 
                 [M + 2H]2+ 
                 588.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 71 
                 20232_071 
                 H-SILDIRDGPKEPPRD-OH 
                 7872_HIV1 Consensus B Gag_071 
                 040313Y-35 
                 — 
                 — 
                 885.9 
                 [M + 2H]2+ 
                 591.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 72 
                 20232_072 
                 H-IRQGPKEPPRDYVDR-OH 
                 7872_HIV1 Consensus B Gag_072 
                 040313Y-37 
                 — 
                 — 
                 938.9 
                 [M + 2H]2+ 
                 626.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 73 
                 20232_073 
                 H-PKEPPRDIVDRFYET-OH 
                 7872_HIV1 Consensus B Gag_073 
                 040313Y-39 
                 — 
                 — 
                 980.9 
                 [M + 2H]2+ 
                 654.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 74 
                 20232_074 
                 H-PRDYVDRFYKTLRAE-OH 
                 7872_HIV1 Consensus B Gag_074 
                 270213M-17 
                 — 
                 — 
                 990.8 
                 [M + 2H]2+ 
                 660.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 75 
                 20232_075 
                 H-VDRFYKTLRAEQASQ-OH 
                 7872_HIV1 Consensus B Gag_075 
                 270213M-19 
                 — 
                 — 
                 906.9 
                 [M + 2H]2+ 
                 604.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 76 
                 20232_076 
                 H-YKTLRASQASQEVEN-OH 
                 7872_HIV1 Consensus B Gag_076 
                 270213M-21 
                 — 
                 — 
                 862.9 
                 [M + 2H]2+ 
                 589.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 77 
                 20232_077 
                 H-RAEQASQIVQNWMTE-OH 
                 7872_HIV1 Consensus B Gag_077 
                 270213M-23 
                 1807.3 
                 [M + H]+ 
                 904.2 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 78 
                 20232_078 
                 H-ASQEVKNWMTETLLV-OH 
                 7872_HIV1 Consensus B Gag_078 
                 270213M-25 
                 1750.3 
                 [M + H]+ 
                 875.3 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 79 
                 20232_079 
                 H-VONWMTETLLVQNAN-OH 
                 7872_HIV1 Consensus B Gag_079 
                 270213M-27 
                 1763.2 
                 [M + H]+ 
                 861.4 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 80 
                 20232_080 
                 H-MTETLLVQNANPDCK-OH 
                 7872_HIV1 Consensus B Gag_080 
                 270213M-29 
                 1678.4 
                 [M + H]+ 
                 838.8 
                 [M + 2H]2+ 
                 558.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 81 
                 20232_081 
                 H-LLVQNANPDCKTILK-OH 
                 7872_HIV1 Consensus B Gag_081 
                 270213M-31 
                 1672.4 
                 [M + H]+ 
                 835.9 
                 [M + 2H]2+ 
                 557.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 82 
                 20232_082 
                 H-NANPDCKIILKALGP-OH 
                 7872_HIV1 Consensus B Gag_082 
                 270213M-33 
                 1555.8 
                 [M + H]+ 
                 778 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 83 
                 20232_083 
                 H-DCKTLLKALGPAATL-OH 
                 7872_HIV1 Consensus B Gag_083 
                 270213M-35 
                 1515.5 
                 [M + H]+ 
                 757.9 
                 [M + 2H]2+ 
                 505.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 84 
                 20232_084 
                 H-ILKALGPAATLEEMN-OH 
                 7872_HIV1 Consensus B Gag_084 
                 270213M-37 
                 1588.5 
                 [M + H]+ 
                 794.4 
                 [M + 2H]2+ 
                 530 
                 [M + 3H]3+ 
               
               
                   
               
               
                 85 
                 20232_085 
                 H-LGPAATLEEMNTACQ-OH 
                 7872_HIV1 Consensus B Gag_085 
                 270213M-39 
                 1566.3 
                 [M + H]+ 
                 783.8 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 86 
                 20232_086 
                 H-ATLEEMMTACQGVGG-OH 
                 7872_HIV1 Consensus B Gag_086 
                 270213M-41 
                 1498.2 
                 [M + H]+ 
                 749.7 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 87 
                 20232_087 
                 H-EMNTACQGVGGPGHK-OH 
                 7872_HIV1 Consensus B Gag_087 
                 270213M-43 
                 1504.3 
                 [M + H]+ 
                 751.8 
                 [M + 2H]2+ 
                 501.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 88 
                 20232_088 
                 H-ACQGVGGPGHKARVL-OH 
                 7872_HIV1 Consensus B Gag_088 
                 270213M-45 
                 1450.4 
                 [M + H]+ 
                 725.4 
                 [M + 2H]2+ 
                 464 
                 [M + 3H]3+ 
               
               
                   
               
               
                 89 
                 20232_089 
                 H-VGGPGHKARVLAEAM-OH 
                 7872_HIV1 Consensus B Gag_089 
                 270213M-47 
                 1493.4 
                 [M + H]+ 
                 746.9 
                 [M + 2H]2+ 
                 498.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 90 
                 20232_090 
                 H-GHKARVLAEAMSQVT-OH 
                 7872_HIV1 Consensus B Gag_090 
                 08031307 
                 1599.3 
                 [M + H]+ 
                 799.7 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 91 
                 20232_091 
                 H-RVLAEAHSQVTNSAT-OH 
                 7872_HIV1 Consensus B Gag_091 
                 150313812 
                 — 
                 — 
                 789.6 
                 [M + 2H]2+ 
                 526.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 92 
                 20232_092 
                 H-EAMSQVTMSATIMMO-OH 
                 7872_HIV1 Consensus B Gag_092 
                 18031387 
                 1642   
                 [M + H]+ 
                 821.5 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 93 
                 20232_093 
                 H-QVTNSATIMMQRGNF-OH 
                 7872_HIV1 Consensus B Gag_093 
                 18031388 
                 1697.2 
                 [M + H]+ 
                 846.5 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 94 
                 20232_094 
                 H-SATIKMQKGNFRNQR-OH 
                 7872_HIV1 Consensus B Gag_094 
                 14031387 
                 — 
                 — 
                 906.2 
                 [M + 2H]2+ 
                 804.3 
                 [M + 3H]3+ 
               
               
                   
               
               
                 95 
                 20232_095 
                 H-MMQRGNFRNQRKTVK-OH 
                 7872_HIV1 Consensus B Gag_095 
                 080313C11 
                 — 
                 — 
                 947.6 
                 [M + 2H]2+ 
                 632.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 96 
                 20232_096 
                 H-GNFRNQRKTVKCFMC-OH 
                 7872_HIV1 Consensus B Gag_096 
                 070313C4 
                 1815.4 
                 [M + H]+ 
                 907.5 
                 [M + 2H]2+ 
                 605.3 
                 [M + 3H]3+ 
               
               
                   
               
               
                 97 
                 20232_097 
                 H-HORKTVKCFNCGKRG-OH 
                 7872_HIV1 Consensus B Gag_097 
                 070313C5 
                 — 
                 — 
                 856.5 
                 [M + 2H]2+ 
                 571.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 98 
                 20232_098 
                 H-TVKCFNOGKEGHIAK-OH 
                 7872_HIV1 Consensus B Gag_098 
                 070313C6 
                 — 
                 — 
                 817.8 
                 [M + 2H]2+ 
                 545.8 
                 [M + 3H]3+ 
               
               
                   
               
               
                 99 
                 20232_099 
                 H-FNCGKEGHIAKNCRA-OH 
                 7872_HIV1 Consensus B Gag_099 
                 070313C8 
                 1648.2 
                 [M + H]+ 
                 824.7 
                 [M + 2H]2+ 
                 550.3 
                 [M + 3H]3+ 
               
               
                   
               
               
                 100 
                 20232_100 
                 H-KEGHIAKNCRAPRKK-OH 
                 7872_HIV1 Consensus B Gag_100 
                 070313C9 
                 — 
                 — 
                 860.1 
                 [M + 2H]2+ 
                 579.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 101 
                 20232_101 
                 H-IAKNCRAPKKKGCWK-OH 
                 7872_HIV1 Consensus B Gag_101 
                 070313C10 
                 1759.8 
                 [M + H]+ 
                 880.4 
                 [M + 2H]2+ 
                 587.3 
                 [M + 3H]3+ 
               
               
                   
               
               
                 102 
                 20232_102 
                 H-CRAPRKKGCWKCGKE-OH 
                 7872_HIV1 Consensus B Gag_102 
                 25021384 
                 1750.5 
                 [M + H]+ 
                 876.8 
                 [M + 2H]2+ 
                 584.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 103 
                 20232_103 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_103 
                 250213B5 
                 — 
                 — 
                 8  .4 
                 [M + 2H]2+ 
                 582.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 104 
                 20232_104 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_104 
                 250213B6 
                 — 
                 — 
                 877.3 
                 [M + 2H]2+ 
                 585.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 105 
                 20232_105 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_105 
                 250213B7 
                 — 
                 — 
                 859.3 
                 [M + 2H]2+ 
                 573.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 106 
                 20232_106 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_106 
                 250213B8 
                 — 
                 — 
                 859.3 
                 [M + 2H]2+ 
                 593.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 107 
                 20232_107 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_107 
                 250213B9 
                    .2 
                 [M + H]+ 
                 893 
                 [M + 2H]2+ 
                 593.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 108 
                 20232_108 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_108 
                 250213B10 
                 — 
                 — 
                 869.6 
                 [M + 2H]2+ 
                 
                   
                 
                 [M + 3H]3+ 
               
               
                   
               
               
                 109 
                 20232_109 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_109 
                 260213C2 
                 16  .2 
                 [M + H]+ 
                 847.8 
                 [M + 2H]2+ 
                 585.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 110 
                 20232_110 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_110 
                 260213C3 
                 1728.2 
                 [M + H]+ 
                 852.8 
                 [M + 2H]2+ 
                 575.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 111 
                 20232_111 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_111 
                 260213C4 
                 — 
                 — 
                 860.4 
                 [M + 2H]2+ 
                 574.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 112 
                 20232_112 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_112 
                 260213C5 
                 1619.2 
                 [M + H]+ 
                 8  .0 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 113 
                 20232_113 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_113 
                 260213C6 
                 1658.2 
                 [M + H]+ 
                 843.2 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 114 
                 20232_114 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_114 
                 260213C7 
                    .3 
                 [M + H]+ 
                 848.   
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 115 
                 20232_115 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_115 
                 040313C3 
                    .1 
                 [M + H]+ 
                    8.7 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 116 
                 20232_116 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_116 
                 040313C4 
                 — 
                 — 
                 872.4 
                 [M + 2H]2+ 
                 562.1 
                 [M + 3H]3+ 
               
               
                   
               
               
                 117 
                 20232_117 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_117 
                 040313C5 
                 — 
                 — 
                 848.3 
                 [M + 2H]2+ 
                 564.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 118 
                 20232_118 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_118 
                 
                   
                 
                 — 
                 — 
                 857.9 
                 [M + 2H]2+ 
                 577.4 
                 [M + 3H]3+ 
               
               
                   
               
               
                 119 
                 20232_119 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_119 
                 280213C8 
                 1761.3 
                 [M + H]+ 
                 860.4 
                 [M + 2H]2+ 
                 587.5 
                 [M + 3H]3+ 
               
               
                   
               
               
                 120 
                 20232_120 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_120 
                 280213C9 
                 — 
                 — 
                 865.9 
                 [M + 2H]2+ 
                 577.7 
                 [M + 3H]3+ 
               
               
                   
               
               
                 121 
                 20232_121 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_121 
                 280213C10 
                 — 
                 — 
                 854.4 
                 [M + 2H]2+ 
                 576.2 
                 [M + 3H]3+ 
               
               
                   
               
               
                 122 
                 20232_122 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_122 
                 11031384 
                 1861.3 
                 [M + H]+ 
                 781.2 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
               
                 123 
                 20232_123 
                 H-  -OH 
                 7872_HIV1 Consensus B Gag_123 
                 280213C11 
                 1821.1 
                 [M + H]+ 
                    81.1 
                 [M + 2H]2+ 
                 — 
                 [M + 3H]3+ 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                 Theor. MW 
                   
                   
                   
                   
                   
                   
               
               
                   
                   
                 (average) 
                 Theor. MW + TFA 
                 Exp. MW vs. 
               
               
                   
                 Index 
                 [g/mol] 
                 [g/mol] 
                 Theor. MW 
                 Purity [%] 
                 Amount [mg] 
                 Purified 
                 Comment 
               
               
                   
                   
               
               
                   
                  1 
                 1518.72 
                 1860.72 
                 pass 
                 96.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  2 
                 1659.87 
                 2001.87 
                 pass 
                 90.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  3 
                 1812.08 
                 2382.08 
                 pass 
                 93.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  4 
                 1852.21 
                 2850.21 
                 pass 
                 90.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  5 
                 1814.25 
                 2726.25 
                 pass 
                 87.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  6 
                 1785.21 
                 2677.21 
                 pass 
                 81.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  7 
                 1842.25 
                 2754.25 
                 pass 
                 91.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  8 
                 1928.28 
                 2612.26 
                 pass 
                 88.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                  9 
                 1827.09 
                 2283.09 
                 pass 
                 85.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 10 
                 1671.94 
                 2013.94 
                 pass 
                 96.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 11 
                 1674.9 
                 1902.8 
                 pass 
                 81.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 12 
                 1573.78 
                 1801.76 
                 pass 
                 81 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 13 
                 1603.83 
                 1831.83 
                 pass 
                 90.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 14 
                 1616.83 
                 1844.83 
                 pass 
                 90.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 15 
                 1641.92 
                 1669.92 
                 pass 
                 88.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 16 
                 1599.78 
                 1713.78 
                 pass 
                 93.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 17 
                 1707.89 
                 1935.69 
                 pass 
                 80.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 18 
                 1667.82 
                 1895.82 
                 pass 
                 86.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 19 
                 1775.04 
                 2003.84 
                 pass 
                 82 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 20 
                 1768.04 
                 2110.04 
                 pass 
                 82.2 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 21 
                 1760.1 
                 2216.1 
                 pass 
                 85.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 22 
                 1861.16 
                 2431.16 
                 pass 
                 80.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 23 
                 1824.08 
                 2508.08 
                 pass 
                 91.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 24 
                 1789.98 
                 2245.98 
                 pass 
                 94 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 25 
                 1775.95 
                 2231.95 
                 pass 
                 94.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 26 
                 1802.06 
                 2486.06 
                 pass 
                 81.9 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 27 
                 1716.87 
                 2286.67 
                 pass 
                 50.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 28 
                 1545.71 
                 2115.71 
                 pass 
                 87.5 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 29 
                 1504.58 
                 1846.58 
                 pass 
                 81.9 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 30 
                 1477.47 
                 1591.47 
                 pass 
                 86.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 31 
                 1508.69 
                 1722.69 
                 pass 
                 89.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 32 
                 1704.86 
                 1818.86 
                 pass 
                 84.3 
                 50 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 33 
                 1716.94 
                 1632.94 
                 pass 
                 89 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 34 
                 1675.96 
                 1903.96 
                 pass 
                 82.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 35 
                 1679.92 
                 2021.92 
                 pass 
                 93.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 36 
                 1752.03 
                 2094.03 
                 pass 
                 85.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 37 
                 1682 
                 2024 
                 pass 
                 84.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 38 
                 1740.04 
                 2196.04 
                 pass 
                 95.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 39 
                 1732.96 
                 2074.96 
                 pass 
                 93.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 40 
                 1703.04 
                 2045.04 
                 pass 
                 86.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 41 
                 1665.99 
                 1893.99 
                 pass 
                 58.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 42 
                 1534.77 
                 1546.77 
                 pass 
                 83.8 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 43 
                 1563.77 
                 1677.77 
                 pass 
                 81.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 44 
                 1534.68 
                 1646.68 
                 pass 
                 81.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 45 
                 1603.78 
                 1717.78 
                 pass 
                 81.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 46 
                 1624.79 
                 1652.79 
                 pass 
                 81.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 47 
                 1572.77 
                 1800.77 
                 pass 
                 84.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 48 
                 1614.85 
                 1956.85 
                 pass 
                 83.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 49 
                 1700.95 
                 2042.95 
                 pass 
                 95.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 50 
                 1707.95 
                 1935.95 
                 pass 
                 88.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 51 
                 1817.01 
                 2158.01 
                 pass 
                 88.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 52 
                 1815.98 
                 2271.98 
                 pass 
                 96 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 53 
                 1668.80 
                 2124.89 
                 pass 
                 93.85 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 54 
                 1564.78 
                 2020.78 
                 pass 
                 94.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 55 
                 1656.62 
                 1896.82 
                 pass 
                 84.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 56 
                 1567.76 
                 1909.76 
                 pass 
                 84.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 57 
                 1571.75 
                 1913.75 
                 pass 
                 84.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 58 
                 1560.72 
                 1902.72 
                 pass 
                 82.3 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 59 
                 1520.64 
                 1634.64 
                 pass 
                 81.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 60 
                 1623.82 
                 1737.82 
                 pass 
                 81.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 61 
                 1715.91 
                 1829.91 
                 pass 
                 85.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 62 
                 1852.89 
                 1766.89 
                 pass 
                 89.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 63 
                 1759.06 
                 1987.06 
                 pass 
                 91 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 64 
                 1795.17 
                 2137.17 
                 pass 
                 83.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 65 
                 1771.14 
                 2113.14 
                 pass 
                 92.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 66 
                 1885.37 
                 2455.37 
                 pass 
                 90.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 67 
                 1803.24 
                 2145.24 
                 pass 
                 93.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 68 
                 1692.06 
                 2034.06 
                 pass 
                 83.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 69 
                 1792.15 
                 2134.15 
                 pass 
                 83.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 70 
                 1703.94 
                 2045.94 
                 pass 
                 92.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 71 
                 1771.03 
                 2227.03 
                 pass 
                 92.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 72 
                 1876.13 
                 2446.13 
                 pass 
                 87.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 73 
                 1961.24 
                 2531.24 
                 pass 
                 85.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 74 
                 1979.26 
                 2549.26 
                 pass 
                 88 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 75 
                 1812.04 
                 2268.04 
                 pass 
                 89.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 76 
                 1764.97 
                 2220.07 
                 pass 
                 85.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 77 
                 1800.68 
                 2148.96 
                 pass 
                 85.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 78 
                 1749.02 
                 1977.02 
                 pass 
                 88.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 79 
                 1781.02 
                 1989.02 
                 pass 
                 82.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 80 
                 1676.93 
                 1904.93 
                 pass 
                 89.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 81 
                 1670 
                 2012 
                 pass 
                 88.1 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 82 
                 1654.83 
                 1896.83 
                 pass 
                 89.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 83 
                 1514.86 
                 1856.86 
                 pass 
                 81 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 84 
                 157.97 
                 1815.97 
                 pass 
                 92.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 85 
                 1565.86 
                 1679.86 
                 pass 
                 81.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 86 
                 1497.73 
                 1611.73 
                 pass 
                 89.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 87 
                 1502.74 
                 1844.74 
                 pass 
                 84.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 88 
                 1449.69 
                 1905.69 
                 pass 
                 86.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 89 
                 1492.76 
                 1946.76 
                 pass 
                 97.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 90 
                 1597.88 
                 2053.86 
                 pass 
                 81.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 91 
                 1577.79 
                 1805.79 
                 pass 
                 92.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 92 
                 1641.9 
                 1755.9 
                 pass 
                 87.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 93 
                 1697.95 
                 1925.95 
                 pass 
                 86 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 94 
                 1810.09 
                 2266.09 
                 pass 
                 86.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 95 
                 1894.24 
                 2578.24 
                 pass 
                 84.3 
                 50 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                 96 
                 1815.1 
                 2385.1 
                 pass 
                 95.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 97 
                 1711.97 
                 2281.97 
                 pass 
                 85.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 98 
                 1834.93 
                 2204.93 
                 pass 
                 86.45 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 99 
                 1847.80 
                 2217.89 
                 pass 
                 86.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 100  
                 1738.07 
                 2648.07 
                 pass 
                 87.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 101  
                 1759.18 
                 2557.16 
                 pass 
                 82 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 102  
                 1750.13 
                 2548.13 
                 pass 
                 82.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 103  
                 1776.11 
                 2578.11 
                 pass 
                 86.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 104  
                 1754.   
                 2324.04 
                 pass 
                 81.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 105  
                 1717.9 
                 2287.9 
                 pass 
                 82.6 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 106  
                 1778 
                 2234 
                 pass 
                 87.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 107  
                 1778.03 
                 2120.03 
                 pass 
                 91.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 108  
                 1739.01 
                 2309.01 
                 pass 
                 94 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 109  
                 1893.   
                 2253.97 
                 pass 
                 89 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 110  
                 17   
                 2179.28 
                 pass 
                 81.7 
                 50 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 111  
                 
                   
                 
                 2289.84 
                 pass 
                 84.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 112  
                 1687.83 
                 1639.52 
                 pass 
                 81.9 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 113  
                 
                   
                 
                 1812.67 
                 pass 
                 82.4 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 114  
                 
                   
                 
                 1817.65 
                 pass 
                 82.3 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 115  
                 1697.83 
                 1825.83 
                 pass 
                 81.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 116  
                 1743.89 
                 
                   
                 
                 pass 
                 86.1 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 117  
                 
                   
                 
                 
                   
                 
                 pass 
                 89.2 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 118  
                 1714.82 
                 
                   
                 
                 pass 
                 94.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 119  
                 1759.81 
                 2101.61 
                 pass 
                 94.5 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 120  
                 
                   
                 
                 2828.61 
                 pass 
                 93.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 121  
                 
                   
                 
                 
                   
                 
                 pass 
                 96.8 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 122  
                 1580.75 
                 1788.75 
                 pass 
                 92 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 123  
                 1320.44 
                 1548.44 
                 pass 
                 82.7 
                 50 
                 Y 
               
               
                   
                   
               
               
                   
                 Comments: 
               
               
                   
                 1) C   isomerization of protein 
               
               
                   
                 2) no HPLC possible-MALDI performed 
               
               
                   
                 3) dissolved in CMSO 
               
               
                   
                 4) dissolved in TFA/water 
               
               
                   
                 5) dissolved in ACN-   
               
               
                   
                     indicates data missing or illegible when filed 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 HIV-1 Consensus B Rev (NIH AIDS Reagent 6445) 
               
               
                 DATA SHEET 
               
               
                 HIV-1 Consensus B REV (15-mer) Peptides - Complete Set (Cat# 6445, Lot# 7) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 Peptide 
                   
               
               
                 Cat # 
                 Peptide Name 
                 Sublot # 
                 Lot # 
                 HPLC Purity 
                 Content 
                 Solubility Data 
               
               
                   
               
               
                 5991 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5991 
                 91.4% 
                 77.6% 
                 1 mg/ml in water 
               
               
                   
                 Peptide MAGRSGDSDEELLKT 
               
               
                   
               
               
                 5992 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5992 
                 89.1% 
                 75.5% 
                 1 mg/ml in water 
               
               
                   
                 Peptide SGDSDEELLKTVRLI 
               
               
                   
               
               
                 5993 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5993 
                 85.2% 
                 85.5% 
                 1 mg/ml in water 
               
               
                   
                 Peptide DEELLKTVRLIKFLY 
               
               
                   
               
               
                 5994 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5994 
                 92.5% 
                 80.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide LKTVRLIKFLYQSNP 
               
               
                   
               
               
                 5995 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5995 
                 89.7% 
                 80.3% 
                 1 mg/ml in water 
               
               
                   
                 Peptide RLIKPLYQSNPPPSP 
               
               
                   
               
               
                 5996 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5996 
                 95.3% 
                 89.1% 
                 1 mg/ml in water 
               
               
                   
                 Peptide FLYQSNPPPSPEGTR 
               
               
                   
               
               
                 5997 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5997 
                 93.2% 
                 65.5% 
                 1 mg/ml in water 
               
               
                   
                 Peptide SNPPPSPEGTRQARR 
               
               
                   
               
               
                 5998 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5998 
                 80.3% 
                 67.3% 
                 1 mg/ml in water 
               
               
                   
                 Peptide PSPEGTRQARRNRRR 
               
               
                   
               
               
                 5999 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 5999 
                 94.5% 
                 73.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide GTRQARRNRRRRWRE 
               
               
                   
               
               
                 6000 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6000 
                 89.7% 
                 67.8% 
                 1 mg/ml in water 
               
               
                   
                 Peptide ARRNRRRRWRERGRQ 
               
               
                   
               
               
                 6001 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6001 
                 91.7% 
                 67.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide RRRRWRERQRQIRSI 
               
               
                   
               
               
                 6002 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6002 
                 89.3% 
                 77.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide WRERQRQIRSISGWI 
               
               
                   
               
               
                 6003 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6003 
                 82.8% 
                 74.9% 
                 1 mg/ml in water 
               
               
                   
                 Peptide QRQIRSISGWILSTY 
               
               
                   
               
               
                 6004 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6004 
                 93.0% 
                 88.7% 
                 1 mg/ml in water 
               
               
                   
                 Peptide RSISGWILSTYLGRP 
               
               
                   
               
               
                 6005 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6005 
                 91.9% 
                 86.1% 
                 1 mg/ml in water 
               
               
                   
                 Peptide GWILSTYLGRPAEPV 
               
               
                   
               
               
                 6006 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6006 
                 85.0% 
                 87.5% 
                 1 mg/ml in water 
               
               
                   
                 Peptide STYLGRPAEPVPLQL 
               
               
                   
               
               
                 6007 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6007 
                 83.8% 
                 82.9% 
                 1 mg/ml in water 
               
               
                   
                 Peptide GRPAEPVPLQLPPLE 
               
               
                   
               
               
                 6008 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6008 
                 84.2% 
                 89.1% 
                 1 mg/ml in water 
               
               
                   
                 Peptide EPVPLQLPPLERLTL 
               
               
                   
               
               
                 6009 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6009 
                 85.4% 
                 85.2% 
                 1 mg/ml in water 
               
               
                   
                 Peptide LQLPPLERLTLDCNE 
               
               
                   
               
               
                 6010 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6010 
                 74.8% 
                 82.8% 
                 1 mg/ml in water 
               
               
                   
                 Peptide PLERLTLDCNEDCGT 
               
               
                   
               
               
                 6011 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6011 
                 83.4% 
                 82.7% 
                 1 mg/ml in water 
               
               
                   
                 Peptide LTLDCNEDCGTSGTQ 
               
               
                   
               
               
                 6012 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6012 
                 82.1% 
                 87.4% 
                 1 mg/ml in water 
               
               
                   
                 Peptide CNEDCGTSGTQGVGS 
               
               
                   
               
               
                 6013 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6013 
                 89.9% 
                 88.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide CGTSGTQGVGSPQIL 
               
               
                   
               
               
                 6014 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6014 
                 90.5% 
                 91.0% 
                 1 mg/ml in water 
               
               
                   
                 Peptide GTQGVGSPQILVESP 
               
               
                   
               
               
                 6015 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6015 
                 81.8% 
                 84.5% 
                 1 mg/ml in water 
               
               
                   
                 Peptide VGSPQILVESPAVLE 
               
               
                   
               
               
                 6016 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6016 
                 82.3% 
                 75.1% 
                 1 mg/ml in water 
               
               
                   
                 Peptide QILVESPAVLESGTK 
               
               
                   
               
               
                 6017 
                 HIV-1 Consensus B REV (15-mer) 
                 5 
                 6017 
                 89.2% 
                 85.2% 
                 1 mg/ml in water 
               
               
                   
                 Peptide ESPAVLESGTKEE 
               
               
                   
               
               
                 NOTE: 
               
               
                 Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the pepside does not begin to precipitate out of solution. 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 6 
               
               
                   
               
               
                 Consensus B Env (NIH AIDS reagent 9480) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Data for Cat# 9480 
                   
                   
                   
               
               
                 Lot 140223 and #12540 Lot 140347 
                 Solubility 
                 Solvent 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                   
                 Cat # 
                 Peptide 
                 Sequence 
                 mg/ml 
                 Water 
                 PBS 
                 10% Acetic Acid 
                 DMSO 
               
               
                   
               
               
                 1 
                 8763 
                 HIV-1 Con B Env 
                 MRVKGIRKNYQHLWR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 2 
                 8764 
                 HIV-1 Con B Env 
                 GIRKNYQHLWRWGTM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 3 
                 8765 
                 HIV-1 Con B Env 
                 NYQHLWRWGTMLLGM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 4 
                 8766 
                 HIV-1 Con B Env 
                 LWRWGTMLLGMLMIC 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 5 
                 8767 
                 HIV-1 Con B Env 
                 GTMLLGMLMICSAAE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 6 
                 8768 
                 HIV-1 Con B Env 
                 LGMLMICSAAEKLWV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 7 
                 8769 
                 HIV-1 Con B Env 
                 MICSAAEKLWVTVYY 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 8 
                 8770 
                 HIV-1 Con B Env 
                 AAEKLWVTVYYGVPV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 9 
                 8771 
                 HIV-1 Con B Env 
                 LWVTVYYGVPVWKEA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 10 
                 8772 
                 HIV-1 Con B Env 
                 VYYGVPVWKEATTTL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 11 
                 8773 
                 HIV-1 Con B Env 
                 VPVWKEATTTLFCAS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 12 
                 8774 
                 HIV-1 Con B Env 
                 KEATTTLFCASDAKA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 13 
                 8775 
                 HIV-1 Con B Env 
                 TTLFCASDAKAYDTE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 14 
                 8776 
                 HIV-1 Con B Env 
                 CASDAKAYDTEVHNV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 15 
                 8777 
                 HIV-1 Con B Env 
                 AKAYDTEVHNVWATH 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 16 
                 8778 
                 HIV-1 Con B Env 
                 DTEVHNVWATHACVP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 17 
                 8779 
                 HIV-1 Con B Env 
                 HNVWATHACVPTDPN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 18 
                 8780 
                 HIV-1 Con B Env 
                 ATHACVPTDPNPQEV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 19 
                 8781 
                 HIV-1 Con B Env 
                 CVPTDPNPQEVVLEN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 20 
                 8782 
                 HIV-1 Con B Env 
                 DPNPQEVVLENVTEN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 21 
                 8783 
                 HIV-1 Con B Env 
                 QEVVLENVTENFNMW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 22 
                 8784 
                 HIV-1 Con B Env 
                 LENVTENFNMWKNNM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 23 
                 8785 
                 HIV-1 Con B Env 
                 TENFNMWKNNMVEQM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 24 
                 8786 
                 HIV-1 Con B Env 
                 NMWKNNMVEQMHEDI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 25 
                 8787 
                 HIV-1 Con B Env 
                 NNMVEQMHEDIISLW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 26 
                 8788 
                 HIV-1 Con B Env 
                 EQMHEDIISLWDQSL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 27 
                 8789 
                 HIV-1 Con B Env 
                 EDIISLWDQSLKPCV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 28 
                 8790 
                 HIV-1 Con B Env 
                 SLWDQSLKPCVKLTP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 29 
                 8791 
                 HIV-1 Con B Env 
                 QSLKPCVKLTPLCVT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 30 
                 8792 
                 HIV-1 Con B Env 
                 PCVKLTPLCVTLNCT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 31 
                 8793 
                 HIV-1 Con B Env 
                 LTPLCVTLNCTDLMN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 32 
                 8794 
                 HIV-1 Con B Env 
                 CVTLNCTDLMNATNT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 33 
                 8795 
                 HIV-1 Con B Env 
                 NCTDLMNATNTTNSS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 34 
                 8796 
                 HIV-1 Con B Env 
                 LMNATNTTNSSSGEK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 35 
                 8797 
                 HIV-1 Con B Env 
                 TNTTNSSSGEKMEKG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 36 
                 8798 
                 HIV-1 Con B Env 
                 NSSSGEKMEKGEIKN 
                 0.25 
                 − 
                 − 
                 − 
               
               
                   
               
               
                 37 
                 8799 
                 HIV-1 Con B Env 
                 GEKMEKGEIKNCSFN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 38 
                 8800 
                 HIV-1 Con B Env 
                 EKGEIKNCSFNITTS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 39 
                 8801 
                 HIV-1 Con B Env 
                 IKNCSFNITTSIRDK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 40 
                 8802 
                 HIV-1 Con B Env 
                 SFNITTSIRDKVQKE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 41 
                 8803 
                 HIV-1 Con B Env 
                 TTSIRDKVQKEYALF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 42 
                 8804 
                 HIV-1 Con B Env 
                 RDKVQKEYALFYKLD 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 43 
                 8805 
                 HIV-1 Con B Env 
                 QKEYALFYKLDVVPI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 44 
                 8806 
                 HIV-1 Con B Env 
                 ALFYKLDVVPIDNDN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 45 
                 8807 
                 HIV-1 Con B Env 
                 KLDVVPIDNDNTSSY 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 46 
                 8808 
                 HIV-1 Con B Env 
                 VPIDNDNTSSYRLIS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 47 
                 8809 
                 HIV-1 Con B Env 
                 NDNTSSYRLISCNTS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 48 
                 8810 
                 HIV-1 Con B Env 
                 SSYRLISCNTSVITQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 49 
                 8811 
                 HIV-1 Con B Env 
                 LISCNTSVITQACPK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 50 
                 8812 
                 HIV-1 Con B Env 
                 NTSVITQACPKVSFE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 51 
                 8813 
                 HIV-1 Con B Env 
                 ITQACPKVSFEPIPI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 52 
                 8814 
                 HIV-1 Con B Env 
                 CPKVSFEPIPIHYCA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 53 
                 8815 
                 HIV-1 Con B Env 
                 SFEPIPIHYCAPAGF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 54 
                 8816 
                 HIV-1 Con B Env 
                 IPIHYCAPAGFAILK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 55 
                 8817 
                 HIV-1 Con B Env 
                 YCAPAGFAILKCNDK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 56 
                 8818 
                 HIV-1 Con B Env 
                 AGFAILKCNDKKFNG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 57 
                 8819 
                 HIV-1 Con B Env 
                 ILKCNDKKFNGTGPC 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 58 
                 8820 
                 HIV-1 Con B Env 
                 NDKKFNGTGPCTNVS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 59 
                 8821 
                 HIV-1 Con B Env 
                 FNGTGPCTNVSTVQC 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 60 
                 8822 
                 HIV-1 Con B Env 
                 GPCTNVSTVQCTHGI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 61 
                 8823 
                 HIV-1 Con B Env 
                 NVSTVQCTHGIRPVV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 62 
                 8824 
                 HIV-1 Con B Env 
                 VQCTHGIRPVVSTQL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 63 
                 8825 
                 HIV-1 Con B Env 
                 HGIRPVVSTQLLLNG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 64 
                 8826 
                 HIV-1 Con B Env 
                 PVVSTQLLLNGSLAE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 65 
                 8827 
                 HIV-1 Con B Env 
                 TQLLLNGSLAEEEVV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 66 
                 8828 
                 HIV-1 Con B Env 
                 LNGSLAEEEVVIRSE 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 67 
                 8829 
                 HIV-1 Con B Env 
                 LAEEEVVIRSENFTN 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 68 
                 8830 
                 HIV-1 Con B Env 
                 EVVIRSENFTNNAKT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 69 
                 8831 
                 HIV-1 Con B Env 
                 RSENFTNNAKTIIVQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 70 
                 8832 
                 HIV-1 Con B Env 
                 FTNNAKTIIVQLNES 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 71 
                 8833 
                 HIV-1 Con B Env 
                 AKTIIVQLNESVEIN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 72 
                 8834 
                 HIV-1 Con B Env 
                 IVQLNESVEINCTRP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 73 
                 8835 
                 HIV-1 Con B Env 
                 NESVEINCTRPNNNT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 74 
                 8836 
                 HIV-1 Con B Env 
                 EINCTRPNNNTRKSI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 75 
                 8837 
                 HIV-1 Con B Env 
                 TRPNNNTRKSIHIGP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 76 
                 8838 
                 HIV-1 Con B Env 
                 NNTRKSIHIGPGRAF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 77 
                 8839 
                 HIV-1 Con B Env 
                 KSIHIGPGRAFYTTG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 78 
                 8840 
                 HIV-1 Con B Env 
                 IGPGRAFYTTGEIIG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 79 
                 8841 
                 HIV-1 Con B Env 
                 RAFYTTGEIIGDIRQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 80 
                 8842 
                 HIV-1 Con B Env 
                 TTGEIIGDIRQAHCN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 81 
                 8843 
                 HIV-1 Con B Env 
                 IIGDIRQAHCNISRA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 82 
                 8844 
                 HIV-1 Con B Env 
                 IRQAHCNISRAKWNN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 83 
                 8845 
                 HIV-1 Con B Env 
                 HCNISRAKWNNTLKQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 84 
                 8846 
                 HIV-1 Con B Env 
                 SRAKWNNTLKQIVKK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 85 
                 8847 
                 HIV-1 Con B Env 
                 WNNTLKQIVKKLREQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 86 
                 8848 
                 HIV-1 Con B Env 
                 LKQIVKKLREQFGNK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 87 
                 8849 
                 HIV-1 Con B Env 
                 VKKLREQFGNKTIVF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 88 
                 8850 
                 HIV-1 Con B Env 
                 REQFGNKTIVFNQSS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 89 
                 8851 
                 HIV-1 Con B Env 
                 GNKTIVFNQSSGGDP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 90 
                 8852 
                 HIV-1 Con B Env 
                 IVFNQSSGGDPEIVM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 91 
                 8853 
                 HIV-1 Con B Env 
                 QSSGGDPEIVMHSFN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 92 
                 8854 
                 HIV-1 Con B Env 
                 GDPEIVMHSFNCGGE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 93 
                 8855 
                 HIV-1 Con B Env 
                 IVMHSFNCGGEFFYC 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 94 
                 8856 
                 HIV-1 Con B Env 
                 SFNCGGEFFYCNTTQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 95 
                 8857 
                 HIV-1 Con B Env 
                 GGEFFYCNTTQLFNS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 96 
                 8858 
                 HIV-1 Con B Env 
                 FYCNTTQLFNSTWNV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 97 
                 8859 
                 HIV-1 Con B Env 
                 TTQLFNSTWNVNGTW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 98 
                 8860 
                 HIV-1 Con B Env 
                 FNSTWNVNGTWNNNT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 99 
                 8861 
                 HIV-1 Con B Env 
                 WNVNGTWNNNTEGND 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 100 
                 8862 
                 HIV-1 Con B Env 
                 GTWNNNTEGNDTITL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 101 
                 8863 
                 HIV-1 Con B Env 
                 NNTEGNDTITLPCRI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 102 
                 8864 
                 HIV-1 Con B Env 
                 GNDTITLPCRIKQII 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 103 
                 8865 
                 HIV-1 Con B Env 
                 ITLPCRIKQIINMWQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 104 
                 8866 
                 HIV-1 Con B Env 
                 CRIKQIINMWQEVGK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 105 
                 8867 
                 HIV-1 Con B Env 
                 QIINMWQEVGKAMYA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 106 
                 8868 
                 HIV-1 Con B Env 
                 MWQEVGKAMYAPPIR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 107 
                 8869 
                 HIV-1 Con B Env 
                 VGKAMYAPPIRGQIR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 108 
                 8870 
                 HIV-1 Con B Env 
                 MYAPPIRGQIRCSSN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 109 
                 8871 
                 HIV-1 Con B Env 
                 PIRGQIRCSSNITGL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 110 
                 8872 
                 HIV-1 Con B Env 
                 QIRCSSNITGLLLTR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 111 
                 8873 
                 HIV-1 Con B Env 
                 SSNITGLLLTRDGGN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 112 
                 8874 
                 HIV-1 Con B Env 
                 TGLLLTRDGGNNNTN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 113 
                 8875 
                 HIV-1 Con B Env 
                 LTRDGGNNNTNETEI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 114 
                 8876 
                 HIV-1 Con B Env 
                 GGNNNTNETEIFRPG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 115 
                 8877 
                 HIV-1 Con B Env 
                 NTNETEIFRPGGGDM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 116 
                 8878 
                 HIV-1 Con B Env 
                 TEIFRPGGGDMRDNW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 117 
                 8879 
                 HIV-1 Con B Env 
                 RPGGGDMRDNWRSEL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 118 
                 8880 
                 HIV-1 Con B Env 
                 GDMRDNWRSELYKYK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 119 
                 8881 
                 HIV-1 Con B Env 
                 DNWRSELYKYKVVKI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 120 
                 8882 
                 HIV-1 Con B Env 
                 SELYKYKVVKIEPLG 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 121 
                 8883 
                 HIV-1 Con B Env 
                 KYKVVKIEPLGVAPT 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 122 
                 8884 
                 HIV-1 Con B Env 
                 VKIEPLGVAPTKAKR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 123 
                 8885 
                 HIV-1 Con B Env 
                 PLGVAPTKAKRRVVQ 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 124 
                 8886 
                 HIV-1 Con B Env 
                 APTKAKRRVVQREKR 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 125 
                 8887 
                 HIV-1 Con B Env 
                 AKRRVVQREKRAVGI 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 126 
                 8888 
                 HIV-1 Con B Env 
                 VVQREKRAVGIGAMF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 127 
                 8889 
                 HIV-1 Con B Env 
                 EKRAVGIGAMFLGFL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 128 
                 8890 
                 HIV-1 Con B Env 
                 VGIGAMFLGFLGAAG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 129 
                 8891 
                 HIV-1 Con B Env 
                 AMFLGFLGAAGSTMG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 130 
                 8892 
                 HIV-1 Con B Env 
                 GFLGAAGSTMGAASM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 131 
                 8893 
                 HIV-1 Con B Env 
                 AAGSTMGAASMTLTV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 132 
                 8894 
                 HIV-1 Con B Env 
                 TMGAASMTLTVQARQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 133 
                 8895 
                 HIV-1 Con B Env 
                 ASMTLTVQARQLLSG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 134 
                 8896 
                 HIV-1 Con B Env 
                 LTVQARQLLSGIVQQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 135 
                 8897 
                 HIV-1 Con B Env 
                 ARQLLSGIVQQQNNL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 136 
                 8898 
                 HIV-1 Con B Env 
                 LSGIVQQQNNLLRAI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 137 
                 8899 
                 HIV-1 Con B Env 
                 VQQQNNLLRAIEAQQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 138 
                 8900 
                 HIV-1 Con B Env 
                 NNLLRAIEAQQHLLQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 139 
                 8901 
                 HIV-1 Con B Env 
                 RAIEAQQHLLQLTVW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 140 
                 8902 
                 HIV-1 Con B Env 
                 AQQHLLQLTVWGIKQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 141 
                 8903 
                 HIV-1 Con B Env 
                 LLQLTVWGIKQLQAR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 142 
                 8904 
                 HIV-1 Con B Env 
                 TVWGIKQLQARVLAV 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 143 
                 8905 
                 HIV-1 Con B Env 
                 IKQLQARVLAVERYL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 144 
                 8906 
                 HIV-1 Con B Env 
                 QARVLAVERYLKDQQ 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 145 
                 8907 
                 HIV-1 Con B Env 
                 LAVERYLKDQQLLGI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 146 
                 8908 
                 HIV-1 Con B Env 
                 RYLKDQQLLGIWGCS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 147 
                 8909 
                 HIV-1 Con B Env 
                 DQQLLGIWGCSGKLI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 148 
                 8910 
                 HIV-1 Con B Env 
                 LGIWGCSGKLICTTT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 149 
                 8911 
                 HIV-1 Con B Env 
                 GCSGKLICTTTVPWN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 150 
                 8912 
                 HIV-1 Con B Env 
                 KLICTTTVPWNASWS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 151 
                 8913 
                 HIV-1 Con B Env 
                 TTTVPWNASWSNKSL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 152 
                 8914 
                 HIV-1 Con B Env 
                 PWNASWSNKSLDEIW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 153 
                 8915 
                 HIV-1 Con B Env 
                 SWSNKSLDEIWDNMT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 154 
                 8916 
                 HIV-1 Con B Env 
                 KSLDEIWDNMTWMEW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 155 
                 8917 
                 HIV-1 Con B Env 
                 EIWDNMTWMEWEREI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 156 
                 8918 
                 HIV-1 Con B Env 
                 NMTWMEWEREIDNYT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 157 
                 8919 
                 HIV-1 Con B Env 
                 MEWEREIDNYTSLIY 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 158 
                 8920 
                 HIV-1 Con B Env 
                 REIDNYTSLIYTLIE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 159 
                 8921 
                 HIV-1 Con B Env 
                 NYTSLIYTLIEESQN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 160 
                 8922 
                 HIV-1 Con B Env 
                 LIYTLIEESQNQQEK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 161 
                 8923 
                 HIV-1 Con B Env 
                 LIEESQNQQEKNEQE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 162 
                 8924 
                 HIV-1 Con B Env 
                 SQNQQEKNEQELLEL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 163 
                 8925 
                 HIV-1 Con B Env 
                 QEKNEQELLELDKWA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 164 
                 8926 
                 HIV-1 Con B Env 
                 EQELLELDKWASLWN 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 165 
                 8927 
                 HIV-1 Con B Env 
                 LELDKWASLWNWFDI 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 166 
                 8928 
                 HIV-1 Con B Env 
                 KWASLWNWFDITNWL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 167 
                 8929 
                 HIV-1 Con B Env 
                 LWNWFDITNWLWYIK 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 168 
                 8930 
                 HIV-1 Con B Env 
                 FDITNWLWYIKIFIM 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 169 
                 8931 
                 HIV-1 Con B Env 
                 NWLWYIKIFIMIVGG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 170 
                 8932 
                 HIV-1 Con B Env 
                 YIKIFIMIVGGLIGL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 171 
                 8933 
                 HIV-1 Con B Env 
                 FIMIVGGLIGLRIVF 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 172 
                 8934 
                 HIV-1 Con B Env 
                 VGGLIGLRIVFAVLS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 173 
                 8935 
                 HIV-1 Con B Env 
                 IGLRIVFAVLSIVNR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 174 
                 8936 
                 HIV-1 Con B Env 
                 IVFAVLSIVNRVRQG 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 175 
                 8937 
                 HIV-1 Con B Env 
                 VLSIVNRVRQGYSPL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 176 
                 8938 
                 HIV-1 Con B Env 
                 VNRVRQGYSPLSFQT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 177 
                 8939 
                 HIV-1 Con B Env 
                 RQGYSPLSFQTRLPA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 178 
                 8940 
                 HIV-1 Con B Env 
                 SPLSFQTRLPAPRGP 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 179 
                 8941 
                 HIV-1 Con B Env 
                 FQTRLPAPRGPDRPE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 180 
                 8942 
                 HIV-1 Con B Env 
                 LPAPRGPDRPEGIEE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 181 
                 8943 
                 HIV-1 Con B Env 
                 RGPDRPEGIEEEGGE 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 182 
                 8944 
                 HIV-1 Con B Env 
                 RPEGIEEEGGERDRD 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 183 
                 8945 
                 HIV-1 Con B Env 
                 IEEEGGERDRDRSGR 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 184 
                 8946 
                 HIV-1 Con B Env 
                 GGERDRDRSGRLVDG 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 185 
                 8947 
                 HIV-1 Con B Env 
                 DRDRSGRLVDGFLAL 
                 0.25 
                 − 
                 + 
                 − 
                 + 
               
               
                   
               
               
                 186 
                 8948 
                 HIV-1 Con B Env 
                 SGRLVDGFLALIWDD 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 187 
                 8949 
                 HIV-1 Con B Env 
                 VDGFLALIWDDLRSL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 188 
                 8950 
                 HIV-1 Con B Env 
                 LALIWDDLRSLCLFS 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 189 
                 8951 
                 HIV-1 Con B Env 
                 WDDLRSLCLFSYHRL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 190 
                 8952 
                 HIV-1 Con B Env 
                 RSLCLFSYHRLRDLL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 191 
                 8953 
                 HIV-1 Con B Env 
                 LFSYHRLRDLLLIVT 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 192 
                 8954 
                 HIV-1 Con B Env 
                 HRLRDLLLIVTRIVE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 193 
                 8955 
                 HIV-1 Con B Env 
                 DLLLIVTRIVELLGR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 194 
                 8956 
                 HIV-1 Con B Env 
                 IVTRIVELLGRRGWE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 195 
                 8957 
                 HIV-1 Con B Env 
                 IVELLGRRGWEVLKY 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 196 
                 8958 
                 HIV-1 Con B Env 
                 LGRRGWEVLKYWWNL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 197 
                 8959 
                 HIV-1 Con B Env 
                 GWEVLKYWWNLLQYW 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 198 
                 8960 
                 HIV-1 Con B Env 
                 LKYWWNLLQYWSQEL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 199 
                 8961 
                 HIV-1 Con B Env 
                 WNLLQYWSQELKNSA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 200 
                 8962 
                 HIV-1 Con B Env 
                 QYWSQELKNSAVSLL 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 201 
                 8963 
                 HIV-1 Con B Env 
                 QELKNSAVSLLNATA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 202 
                 8964 
                 HIV-1 Con B Env 
                 NSAVSLLNATAIAVA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 203 
                 8965 
                 HIV-1 Con B Env 
                 SLLNATAIAVAEGTD 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 204 
                 8966 
                 HIV-1 Con B Env 
                 ATAIAVAEGTDRVIE 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 205 
                 8967 
                 HIV-1 Con B Env 
                 AVAEGTDRVIEVVQR 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 206 
                 8968 
                 HIV-1 Con B Env 
                 GTDRVIEVVQRACRA 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 207 
                 8969 
                 HIV-1 Con B Env 
                 VIEVVQRACRAILH1 
                 0.25 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 208 
                 8970 
                 HIV-1 Con B Env 
                 VQRACRAILHIPRRI 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 209 
                 8971 
                 HIV-1 Con B Env 
                 CRAILHIPRRIRQGL 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 210 
                 8972 
                 HIV-1 Con B Env 
                 LHIPRRIRQGLERAL 
                 0.25 
                 + 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 211 
                 8973 
                 HIV-1 Con B Env 
                 RRIRQGLERALL 
                 0.25 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
            
           
           
               
            
               
                 Molecular Weight and Purity Data: 
               
               
                 Catalog #9480 Lot 140223 and #12540 Lot 140347 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 MW (1) 
                   
                 MW (2) 
               
               
                   
                   
                   
                   
                   
                 detected 
                   
                 detected 
               
               
                   
                 JPT-# 
                 Sequence 
                 Peptide Name 
                 Batch# 
                 [g/mol] 
                 MW (1) label 
                 [g/mol] 
               
               
                   
               
               
                 1 
                 23651_294 
                 H-MRVKGIRKNYQHLWR-OH 
                 8763_HIV-1 Con B Env_001 
                 270114F-04 
                 — 
                 — 
                 993.4 
               
               
                   
               
               
                 2 
                 23651_295 
                 H-GIRKNYQHLWRWGTM-OH 
                 8764_HIV-1 Con B Env_002 
                 270114F-06 
                 — 
                 — 
                 976.6 
               
               
                   
               
               
                 3 
                 23651_296 
                 H-NYQHLWRWGTMLLGM-OH 
                 8765_HIV-1 Con B Env_003 
                 270114F-08 
                 1906.2 
                 [M + H]+ 
                 953.7 
               
               
                   
               
               
                 4 
                 23651_297 
                 H-LWRWGTMLLGMLMIC-OH 
                 8766_HIV-1 Con B Env_004 
                 270114F-10 
                 1824.7 
                 [M + H]+ 
                 912.7 
               
               
                   
               
               
                 5 
                 23651_298 
                 H-GTMLLGMLMICSAAE-OH 
                 8767_HIV-1 Con B Env_005 
                 270114F-12 
                 1540.01 
                 [M + H]+ 
                 1562.55 
               
               
                   
               
               
                 6 
                 23651_299 
                 H-LGMLMICSAAEKLWV-OH 
                 8768_HIV-1 Con B Env_006 
                 270114F-14 
                 1665.7 
                 [M + H]+ 
                 833.0 
               
               
                   
               
               
                 7 
                 23651_300 
                 H-MICSAAEKLWVTVYY-OH 
                 8769_HIV-1 Con B Env_007 
                 270114F-16 
                 1777.8 
                 [M + H]+ 
                 889.0 
               
               
                   
               
               
                 8 
                 23651_301 
                 H-AAEKLWVTVYYGVPV-OH 
                 8770_HIV-1 Con B Env_008 
                 270114F-18 
                 1695.7 
                 [M + H]+ 
                 848.1 
               
               
                   
               
               
                 9 
                 23651_302 
                 H-LWVTVYYGVPVWKEA-OH 
                 8771_HIV-1 Con B Env_009 
                 270114F-20 
                 1809.8 
                 [M + H]+ 
                 905.6 
               
               
                   
               
               
                 10 
                 23651_303 
                 H-VYYGVPVWKEATTTL-OH 
                 8772_HIV-1 Con B Env_010 
                 270114F-22 
                 1726.8 
                 [M + H]+ 
                 64.1 
               
               
                   
               
               
                 11 
                 23651_304 
                 H-VPVWKEATTTLFCAS-OH 
                 8773_HIV-1 Con B Env_011 
                 270114F-24 
                 1654.2 
                 [M + H]+ 
                 827.2 
               
               
                   
               
               
                 12 
                 23651_305 
                 H-KEATTTLFCASDAKA-OH 
                 8774_HIV-1 Con B Env_012 
                 270114F-26 
                 1558.6 
                 [M + H]+ 
                 779.0 
               
               
                   
               
               
                 13 
                 23651_306 
                 H-TTLFCASDAKAYDTE-OH 
                 8775_HIV-1 Con B Env_013 
                 270114F-28 
                 1636.6 
                 [M + H]+ 
                 818.5 
               
               
                   
               
               
                 14 
                 23651_307 
                 H-CASDAKAYDTEVHNV-OH 
                 8776_HIV-1 Con B Env_014 
                 270114F-30 
                 1624.6 
                 [M + H]+ 
                 812.0 
               
               
                   
               
               
                 15 
                 23651_308 
                 H-AKAYDTEVHNVWATH-OH 
                 8777_HIV-1 Con B Env_015 
                 270114F-32 
                 1743.1 
                 [M + H]+ 
                 871.7 
               
               
                   
               
               
                 16 
                 23651_309 
                 H-DTEVHNVWATHACVP-OH 
                 8778_HIV-1 Con B Env_016 
                 270114F-34 
                 1679.3 
                 [M + H]+ 
                 840.2 
               
               
                   
               
               
                 17 
                 23651_310 
                 H-HNVWATHACVPTDPN-OH 
                 8779_HIV-1 Con B Env_017 
                 270114F-36 
                 1662.7 
                 [M + H]+ 
                 831.5 
               
               
                   
               
               
                 18 
                 23651_311 
                 H-ATHACVPTDPNPQEV-OH 
                 8780_HIV-1 Con B Env_018 
                 270114F-38 
                 1578.6 
                 [M + H]+ 
                 790.0 
               
               
                   
               
               
                 19 
                 23651_312 
                 H-CVPTDPNPQEVVLEN-OH 
                 8781_HIV-1 Con B Env_019 
                 270114F-40 
                 1655.6 
                 [M + H]+ 
                 827.5 
               
               
                   
               
               
                 20 
                 23651_313 
                 H-DPNPQEVVLENVTEN-OH 
                 8782_HIV-1 Con B Env_020 
                 270114F-42 
                 1696.8 
                 [M + H]+ 
                 849.0 
               
               
                   
               
               
                 21 
                 23651_314 
                 H-QEVVLENVTENFNMW-OH 
                 8783_HIV-1 Con B Env_021 
                 270114F-44 
                 1853.7 
                 [M + H]+ 
                 927.0 
               
               
                   
               
               
                 22 
                 23651_315 
                 H-LENVTENFNMWKNNM-OH 
                 8784_HIV-1 Con B Env_022 
                 270114F-46 
                 1885.7 
                 [M + H]+ 
                 942.6 
               
               
                   
               
               
                 23 
                 23651_316 
                 H-TENFNMWKNNMVEQM-OH 
                 8785_HIV-1 Con B Env_023 
                 270114F-48 
                 1915.7 
                 [M + H]+ 
                 959.0 
               
               
                   
               
               
                 24 
                 23651_317 
                 H-NMWKNNMVEQMHEDI-OH 
                 8786_HIV-1 Con B Env_024 
                 300114C3 
                 — 
                 — 
                 960.0 
               
               
                   
               
               
                 25 
                 23651_318 
                 H-NNMVEQMHEDIISLW-OH 
                 8787_HIV-1 Con B Env_025 
                 300114C4 
                 1860.7 
                 [M + H]+ 
                 930.0 
               
               
                   
               
               
                 26 
                 23651_319 
                 H-EQMHEDIISLWDQSL-OH 
                 8788_HIV-1 Con B Env_026 
                 300114C5 
                 1845.6 
                 [M + H]+ 
                 922.5 
               
               
                   
               
               
                 27 
                 23651_320 
                 H-EDIISLWDQSLKPCV-OH 
                 8789_HIV-1 Con B Env_027 
                 300114C6 
                 1746.7 
                 [M + H]+ 
                 873.5 
               
               
                   
               
               
                 28 
                 23651_321 
                 H-SLWDQSLKPCVKLTP-OH 
                 8790_HIV-1 Con B Env_028 
                 300114C10 
                 1716.8 
                 [M + H]+ 
                 858.0 
               
               
                   
               
               
                 29 
                 23651_322 
                 H-QSLKPCVKLTPLCVT-OH 
                 8791_HIV-1 Con B Env_029 
                 310114B4 
                 1630.7 
                 [M + H]+ 
                 815.6 
               
               
                   
               
               
                 30 
                 23651_323 
                 H-PCVKLTPLCVTLNCT-OH 
                 8792_HIV-1 Con B Env_030 
                 310114B5 
                 1604.7 
                 [M + H]+ 
                 803.0 
               
               
                   
               
               
                 31 
                 23651_324 
                 H-LTPLCVTLNCTDLMN-OH 
                 8793_HIV-1 Con B Env_031 
                 310114B6 
                 1651.7 
                 [M + H]+ 
                 826.5 
               
               
                   
               
               
                 32 
                 23651_325 
                 H-CVTLNCTDLMNATNT-OH 
                 8794_HIV-1 Con B Env_032 
                 310114B7 
                 1615.6 
                 [M + H]+ 
                 807.5 
               
               
                   
               
               
                 33 
                 23651_326 
                 H-NCTDLMNATNTTNSS-OH 
                 8795_HIV-1 Con B Env_033 
                 310114B11 
                 1588.5 
                 [M + H]+ 
                 974.0 
               
               
                   
               
               
                 34 
                 23651_327 
                 H-LMNATNTTNSSSGEK-OH 
                 8796_HIV-1 Con B Env_034 
                 310114C11 
                 1555.6 
                 [M + H]+ 
                 778.0 
               
               
                   
               
               
                 35 
                 23651_328 
                 H-TNTTNSSSGEKMEKG-OH 
                 8797_HIV-1 Con B Env_035 
                 310114C12 
                 1570.6 
                 [M + H]+ 
                 786.0 
               
               
                   
               
               
                 36 
                 23651_329 
                 H-NSSSGEKMEKGEIKN-OH 
                 8798_HIV-1 Con B Env_036 
                 310114Y-15 
                 1639.9 
                 [M + H]+ 
                 816.6 
               
               
                   
               
               
                 37 
                 23651_330 
                 H-GEKMEKGEIKNCSFN-OH 
                 8799_HIV-1 Con B Env_037 
                 310114Y-17 
                 1713.7 
                 [M + H]+ 
                 857.5 
               
               
                   
               
               
                 38 
                 23651_331 
                 H-EKGEIKNCSFNITTS-OH 
                 8800_HIV-1 Con B Env_038 
                 310114Y-19 
                 1670.7 
                 [M + H]+ 
                 836.0 
               
               
                   
               
               
                 39 
                 23651_332 
                 H-IKNCSFNITTSIRDK-OH 
                 8801_HIV-1 Con B Env_039 
                 310114Y-22 
                 1739.8 
                 [M + H]+ 
                 870.6 
               
               
                   
               
               
                 40 
                 22651_333 
                 H-SFNITTSIRDKVQKE-OH 
                 8802_HIV-1 Con B Env_040 
                 310114Y-23 
                 1765.7 
                 [M + H]+ 
                 883.6 
               
               
                   
               
               
                 41 
                 22651_334 
                 H-TTSIRDKVQKEVALF-OH 
                 8803_HIV-1 Con B Env_041 
                 310114Y-25 
                 — 
                 — 
                 900.1 
               
               
                   
               
               
                 42 
                 22651_335 
                 H-ROKVQKEYALFYKLD-OH 
                 8804_HIV-1 Con B Env_042 
                 310114Y-27 
                 1917.3 
                 [M + H]+ 
                 959.2 
               
               
                   
               
               
                 43 
                 22651_336 
                 H-QKEYALFYKLDVVPI-OH 
                 8805_HIV-1 Con B Env_043 
                 310114Y-29 
                 1827.8 
                 [M + H]+ 
                 913.6 
               
               
                   
               
               
                 44 
                 22651_337 
                 H-ALFYKLDVVPIDNDN-OH 
                 8806_HIV-1 Con B Env_044 
                 310114Y-31 
                 1736.3 
                 [M + H]+ 
                 868.7 
               
               
                   
               
               
                 45 
                 22651_338 
                 H-KLDVVPIDNDNTSSV-OH 
                 8807_HIV-1 Con B Env_045 
                 310114Y-33 
                 1680.7 
                 [M + H]+ 
                 840.5 
               
               
                   
               
               
                 46 
                 22651_339 
                 H-VPIONDNTSSYRLIS-OH 
                 8808_HIV-1 Con B Env_046 
                 310114Y-35 
                 1693.7 
                 [M + H]+ 
                 847.5 
               
               
                   
               
               
                 47 
                 22651_340 
                 H-NDNTSSYRLISCNTS-OH 
                 8809_HIV-1 Con B Env_047 
                 030214Z-18 
                 1675.6 
                 [M + H]+ 
                 838.0 
               
               
                   
               
               
                 48 
                 22651_341 
                 H-SSYRLISONTSVITQ-OH 
                 8810_HIV-1 Con B Env_048 
                 030214Z-20 
                 1673.7 
                 [M + H]+ 
                 836.6 
               
               
                   
               
               
                 49 
                 22651_342 
                 H-LISCNTSVITQACPK-OH 
                 8811_HIV-1 Con B Env_049 
                 030214Z-22 
                 1578.7 
                 [M + H]+ 
                 789.6 
               
               
                   
               
               
                 50 
                 22651_343 
                 H-NTSVITQACPKVSFE-OH 
                 8812_HIV-1 Con B Env_050 
                 030214Z-24 
                 1625.7 
                 [M + H]+ 
                 812.5 
               
               
                   
               
               
                 51 
                 22651_344 
                 H-ITQACPKVSFEPIPI-OH 
                 8813_HIV-1 Con B Env_051 
                 030214Z-26 
                 1643.7 
                 [M + H]+ 
                 822.1 
               
               
                   
               
               
                 52 
                 22651_345 
                 H-CPKVSFEPIPIHYCA-OH 
                 8814_HIV-1 Con B Env_052 
                 050214V-01 
                 1704.7 
                 [M + H]+ 
                 853.0 
               
               
                   
               
               
                 53 
                 22651_346 
                 H-SFEPIPIHYCAPAGF-OH 
                 8815_HIV-1 Con B Env_053 
                 050214V-02 
                 1650.2 
                 [M + H]+ 
                 825.2 
               
               
                   
               
               
                 54 
                 22651_347 
                 H-IPIHYCAPAGFAILK-OH 
                 8816_HIV-1 Con B Env_054 
                 050214V-03 
                 1615.3 
                 [M + H]+ 
                 807.7 
               
               
                   
               
               
                 55 
                 22651_348 
                 H-YCAPAGFAILKCNDK-OH 
                 8817_HIV-1 Con B Env_055 
                 050214V-04 
                 1614.7 
                 [M + H]+ 
                 807.5 
               
               
                   
               
               
                 56 
                 22651_349 
                 H-AGFAILKCNDKKFNG-OH 
                 8818_HIV-1 Con B Env_056 
                 050214V-05 
                 1627.2 
                 [M + H]+ 
                 813.7 
               
               
                   
               
               
                 57 
                 22651_350 
                 H-ILKCNDKKFNGTGPC-OH 
                 8819_HIV-1 Con B Env_057 
                 050214V-06 
                 1638.7 
                 [M + H]+ 
                 819.5 
               
               
                   
               
               
                 58 
                 22651_351 
                 H-NDKKFNGTGPCTNVS-OH 
                 8820_HIV-1 Con B Env_058 
                 050214V-07 
                 1582.5 
                 [M + H]+ 
                 791.5 
               
               
                   
               
               
                 59 
                 22651_352 
                 H-FNGTGPCTNVSTVQC-OH 
                 8821_HIV-1 Con B Env_059 
                 050214V-08 
                 1529.6 
                 [M + H]+ 
                 764.5 
               
               
                   
               
               
                 60 
                 22651_353 
                 H-GPCTNVSTVQCTHGI-OH 
                 8822_HIV-1 Con B Env_060 
                 050214V-09 
                 1517.6 
                 [M + H]+ 
                 759.0 
               
               
                   
               
               
                 61 
                 22651_354 
                 H-NVSTVQCTHGIRPVV-OH 
                 8823_HIV-1 Con B Env_061 
                 050214V-10 
                 1610.7 
                 [M + H]+ 
                 805.5 
               
               
                   
               
               
                 62 
                 22651_355 
                 H-VQCTHGIRPVVSTQL-OH 
                 8824_HIV-1 Con B Env_062 
                 050214V-11 
                 1638.4 
                 [M + H]+ 
                 819.7 
               
               
                   
               
               
                 63 
                 22651_356 
                 H-HGIRPVVSTQLLLNG-OH 
                 8825_HIV-1 Con B Env_063 
                 050214V-12 
                 1605.8 
                 [M + H]+ 
                 802.6 
               
               
                   
               
               
                 64 
                 22651_357 
                 H-PVVSTQLLLNGSLAE-OH 
                 8826_HIV-1 Con B Env_064 
                 050214V-13 
                 1542.7 
                 [M + H]+ 
                 771.0 
               
               
                   
               
               
                 65 
                 22651_358 
                 H-TQLLLNGSLAEEEVV-OH 
                 8827_HIV-1 Con B Env_065 
                 050214V-14 
                 1615.7 
                 [M + H]+ 
                 808.5 
               
               
                   
               
               
                 66 
                 22651_359 
                 H-LNGSLAEEEVVIRSE-OH 
                 8828_HIV-1 Con B Env_066 
                 050214V-15 
                 1645.7 
                 [M + H]+ 
                 823.0 
               
               
                   
               
               
                 67 
                 22651_360 
                 H-LAEEEVVIRSENFTN-OH 
                 8829_HIV-1 Con B Env_067 
                 050214V-16 
                 1751.7 
                 [M + H]+ 
                 875.6 
               
               
                   
               
               
                 68 
                 22651_361 
                 H-EVVIRSENFTNNAKT-OH 
                 8830_HIV-1 Con B Env_068 
                 050214V-17 
                 1721.7 
                 [M + H]+ 
                 861.5 
               
               
                   
               
               
                 69 
                 22651_362 
                 H-RSENFTNNAKTIIVQ-OH 
                 8631_HIV-1 Con B Env_069 
                 050214V-18 
                 1734.8 
                 [M + H]+ 
                 868.1 
               
               
                   
               
               
                 70 
                 22651_363 
                 H-FTNNAKTIIVCLNES-OH 
                 8832_HIV-1 Con B Env_070 
                 050214V-19 
                 1693.7 
                 [M + H]+ 
                 846.5 
               
               
                   
               
               
                 71 
                 22651_364 
                 H-AKTIIVQLNESVEIN-OH 
                 8833_HIV-1 Con B Env_071 
                 050214V-20 
                 1672.60 
                 [M + H]+ 
                 1695.08 
               
               
                   
               
               
                 72 
                 22651_365 
                 H-IVQLNESVEINCTRP-OH 
                 8834_HIV-1 Con B Env_072 
                 050214V-21 
                 1715.7 
                 [M + H]+ 
                 858.0 
               
               
                   
               
               
                 73 
                 22651_366 
                 H-NESVEINCTRPNNNT-OH 
                 8835_HIV-1 Con B Env_073 
                 050214V-22 
                 1705.6 
                 [M + H]+ 
                 853.0 
               
               
                   
               
               
                 74 
                 22651_367 
                 H-EINCTRPNNNTRKSI-OH 
                 8836_HIV-1 Con B Env_074 
                 050214V-23 
                 1759.8 
                 [M + H]+ 
                 880.6 
               
               
                   
               
               
                 75 
                 22651_368 
                 H-TRPNNNTRKSIHIGP-OH 
                 8837_HIV-1 Con B Env_075 
                 050214V-24 
                 — 
                 — 
                 853.1 
               
               
                   
               
               
                 76 
                 22651_369 
                 H-NNTRKSIHIGPGRAF-OH 
                 8838_HIV-1 Con B Env_076 
                 050214V-25 
                 — 
                 — 
                 834.6 
               
               
                   
               
               
                 77 
                 22651_370 
                 H-KSIHIGPGRAFYTTG-OH 
                 8839_HIV-1 Con B Env_077 
                 050214V-26 
                 1605.7 
                 [M + H]+ 
                 803.0 
               
               
                   
               
               
                 78 
                 22651_371 
                 H-IGPGRAFYTTGEIIG-OH 
                 8840_HIV-1 Con B Env_078 
                 050214V-27 
                 1551.7 
                 [M + H]+ 
                 776.6 
               
               
                   
               
               
                 79 
                 22651_372 
                 H-RAFYTTGEIIGDlRQ-OH 
                 8841_HIV-1 Con B Env_079 
                 050214V-28 
                 1740.7 
                 [M + H]+ 
                 870.6 
               
               
                   
               
               
                 80 
                 22651_373 
                 H-TTGEIIGDIRQAHCN-OH 
                 8842_HIV-1 Con B Env_080 
                 050214V-29 
                 1629.2 
                 [M + H]+ 
                 814.7 
               
               
                   
               
               
                 81 
                 22651_374 
                 H-IIGDIRQAHCNISRA-OH 
                 8843_HIV-1 Con B Env_081 
                 050214V-30 
                 1669.2 
                 [M + H]+ 
                 834.2 
               
               
                   
               
               
                 82 
                 22651_375 
                 H-IRQAKCNISRAKWNN-OH 
                 8844_HIV-1 Con B Env_082 
                 050214V-31 
                 — 
                 — 
                 906.1 
               
               
                   
               
               
                 83 
                 22651_376 
                 H-HCNISRAKWNNTLKQ-OH 
                 8845_HIV-1 Con B Env_083 
                 050214V-32 
                 1813.8 
                 [M + H]+ 
                 907.1 
               
               
                   
               
               
                 84 
                 22651_377 
                 H-SRAKWNNTLKQIVKK-OH 
                 8846_HIV-1 Con B Env_084 
                 050214V-33 
                 1814.9 
                 [M + H]+ 
                 907.7 
               
               
                   
               
               
                 85 
                 22651_378 
                 H-WNNTLKQIVKKLREQ-OH 
                 8847_HIV-1 Con B Env_085 
                 050214V-34 
                 — 
                 — 
                 949.7 
               
               
                   
               
               
                 86 
                 22651_379 
                 H-LKQIVKKLREQFGNK-OH 
                 8848_HIV-1 Con B Env_086 
                 050214V-35 
                 1829.0 
                 [M + H]+ 
                 915.6 
               
               
                   
               
               
                 87 
                 22651_380 
                 H-VKKLREQFGNKTIVF-OH 
                 8849_HIV-1 Con B Env_087 
                 050214V-36 
                 1806.9 
                 [M + H]+ 
                 904.2 
               
               
                   
               
               
                 88 
                 22651_381 
                 H-REQFGNKTIVFNQSS-OH 
                 8850_HIV-1 Con B Env_088 
                 050214V-37 
                 1754.8 
                 [M + H]+ 
                 878.0 
               
               
                   
               
               
                 89 
                 22651_382 
                 H-GNKTIVFNQSSGGDP-OH 
                 8851_HIV-1 Con B Env_089 
                 050214V-38 
                 1520.6 
                 [M + H]+ 
                 761.0 
               
               
                   
               
               
                 90 
                 22651_383 
                 H-IVFNQSSGGDPEIVM-OH 
                 8852_HIV-1 Con B Env_090 
                 050214V-39 
                 1593.6 
                 [M + H]+ 
                 797.0 
               
               
                   
               
               
                 91 
                 22651_384 
                 H-QSSGGDPEIVMHSFN-OH 
                 8853_HIV-1 Con B Env_091 
                 050214V-40 
                 1606.5 
                 [M + H]+ 
                 803.0 
               
               
                   
               
               
                 92 
                 22651_385 
                 H-GDPEIVMHSFNCGGE-OH 
                 8854_HIV-1 Con B Env_092 
                 050214V-41 
                 1593.5 
                 [M + H]+ 
                 796.5 
               
               
                   
               
               
                 93 
                 22651_386 
                 H-IVMHSFNCGGEFFYC-OH 
                 8855_HIV-1 Con B Env_093 
                 050214V-42 
                 1756.6 
                 [M + H]+ 
                 877.9 
               
               
                   
               
               
                 94 
                 22651_387 
                 H-SFNCGGEFFVCNTTQ-OH 
                 8856_HIV-1 Con B Env_094 
                 050214V-43 
                 1717.6 
                 [M + H]+ 
                 859.5 
               
               
                   
               
               
                 95 
                 22651_388 
                 H-GGEFFYCNTTQLFNS-OH 
                 8857_HIV-1 Con B Env_095 
                 050214V-44 
                 1729.6 
                 [M + H]+ 
                 864.5 
               
               
                   
               
               
                 96 
                 22651_389 
                 H-FYCNTTQLFNSTWNV-OH 
                 8858_HIV-1 Con B Env_096 
                 050214V-45 
                 1838.7 
                 [M + H]+ 
                 919.6 
               
               
                   
               
               
                 97 
                 22651_390 
                 H-TTQLFNSTWNVNGTW-OH 
                 8859_HIV-1 Con B Env_097 
                 050214V-46 
                 1769.9 
                 [M + H]+ 
                 885.1 
               
               
                   
               
               
                 98 
                 22651_391 
                 H-FNSTWNVNGTWNNNT-OH 
                 8860_HIV-1 Con B Env_098 
                 050214V-47 
                 1769.7 
                 [M + H]+ 
                 885.5 
               
               
                   
               
               
                 99 
                 22651_392 
                 H-WNVNGTWNNNTEGND-OH 
                 8861_HIV-1 Con B Env_099 
                 050214V-48 
                 1734.6 
                 [M + H]+ 
                 868.0 
               
               
                   
               
               
                 100 
                 22651_393 
                 H-GTWNNNTEGNDTITL-OH 
                 8862_HIV-1 Con B Env_100 
                 060214Y-18 
                 1651.6 
                 [M + H]+ 
                 825.5 
               
               
                   
               
               
                 101 
                 22651_394 
                 H-NNTEGNDTITLPCRI-OH 
                 8863_HIV-1 Con B Env_101 
                 060214Y-20 
                 1662.7 
                 [M + H]+ 
                 831.0 
               
               
                   
               
               
                 102 
                 22651_395 
                 H-GNDTITLPCRIKQII-OH 
                 8864_HIV-1 Con B Env_102 
                 060214Y-22 
                 1686.2 
                 [M + H]+ 
                 843.2 
               
               
                   
               
               
                 103 
                 22651_396 
                 H-ITLPCRIKQIINMWQ-OH 
                 8865_HIV-1 Con B Env_103 
                 060214C8 
                 1858.3 
                 [M + H]+ 
                 929.3 
               
               
                   
               
               
                 104 
                 22651_397 
                 H-CRIKQIINMWQEVGK-OH 
                 8866_HIV-1 Con B Env_104 
                 060214C10 
                 1848.2 
                 [M + H]+ 
                 924.0 
               
               
                   
               
               
                 105 
                 22651_398 
                 H-QIINMWQEVGKAMYA-OH 
                 8867_HIV-1 Con B Env_105 
                 060214C12 
                 1781.7 
                 [M + H]+ 
                 891.5 
               
               
                   
               
               
                 106 
                 22651_399 
                 H-MWQEVGKAMYAPPIR-OH 
                 8868_HIV-1 Con B Env_106 
                 140214C5 
                 1776.8 
                 [M + H]+ 
                 889.1 
               
               
                   
               
               
                 107 
                 22651_400 
                 H-VGKAMYAPPIRGQIR-OH 
                 8869_HIV-1 Con B Env_107 
                 140214C7 
                 1657.3 
                 [M + H]+ 
                 829.3 
               
               
                   
               
               
                 108 
                 22651_401 
                 H-MYAPPIRGQIRCSSN-OH 
                 8870_HIV-1 Con B Env_108 
                 140214C9 
                 1692.7 
                 [M + H]+ 
                 847.0 
               
               
                   
               
               
                 109 
                 22651_402 
                 H-PIRGQIRCSSNITGL-OH 
                 8871_HIV-1 Con B Env_109 
                 140214C11 
                 — 
                 — 
                 808.1 
               
               
                   
               
               
                 110 
                 22651_403 
                 H-QIRCSSNITGLLLTR-OH 
                 8872_HIV-1 Con B Env_110 
                 140214B9 
                 1675.8 
                 [M + H]+ 
                 838.1 
               
               
                   
               
               
                 111 
                 22651_404 
                 H-SSNITGLLLTRDGGN-OH 
                 8373_HIV-1 Con B Env_111 
                 110214G-03 
                 1518.4 
                 [M + H]+ 
                 759.7 
               
               
                   
               
               
                 112 
                 22651_405 
                 H-TGLLLTRDGGNNNTN-OH 
                 8874_HIV-1 Con B Env_112 
                 110214G-05 
                 1560.7 
                 [M + H]+ 
                 780.5 
               
               
                   
               
               
                 113 
                 22651_406 
                 H-LTRDGGNNNTNETEI-OH 
                 8875_HIV-1 Con B Env_113 
                 110214G-07 
                 1648.6 
                 [M + H]+ 
                 824.5 
               
               
                   
               
               
                 114 
                 22651_407 
                 H-GGNNNTNETEIFRPG-OH 
                 8676_HIV-1 Con B Env_114 
                 110214G-09 
                 1621.6 
                 [M + H]+ 
                 810.5 
               
               
                   
               
               
                 115 
                 22651_408 
                 H-NTNETEIFRPGGGDM-OH 
                 8877_HIV-1 Con B Env_115 
                 110214G-11 
                 1639.6 
                 [M + H]+ 
                 819.5 
               
               
                   
               
               
                 116 
                 22651_409 
                 H-TEIFRPGGGDMRDNW-OH 
                 8878_HIV-1 Con B Env_116 
                 110214G-13 
                 — 
                 — 
                 876.0 
               
               
                   
               
               
                 117 
                 22651_410 
                 H-RPGGGDMRDNWRSEL-OH 
                 8679_HIV-1 Con B Env_117 
                 110214G-15 
                 1745.9 
                 [M + H]+ 
                 873.5 
               
               
                   
               
               
                 118 
                 22651_411 
                 H-GDMRDNWRSELYKYK-OH 
                 8880_HIV-1 Con B Env_118 
                 110214G-17 
                 — 
                 — 
                 981.1 
               
               
                   
               
               
                 119 
                 22651_412 
                 H-DNWRSELYKYKVVKI-OH 
                 8881_HIV-1 Con B Env_119 
                 110214G-19 
                 — 
                 — 
                 971.5 
               
               
                   
               
               
                 120 
                 22651_413 
                 H-SELYKYKVVKIEPLG-OH 
                 8882_HIV-1 Con B Env_120 
                 110214G-21 
                 1767.9 
                 [M + H]+ 
                 883.7 
               
               
                   
               
               
                 121 
                 22651_414 
                 H-KYKVVKIEPLGVAPT-OH 
                 8883_HIV-1 Con B Env_121 
                 110214G-23 
                 1642.8 
                 [M + H]+ 
                 821.6 
               
               
                   
               
               
                 122 
                 22651_415 
                 H-VKIEPLGVAPTKAKR-OH 
                 8884_HIV-1 Con B Env_122 
                 110214G-25 
                 1606.8 
                 [M + H]+ 
                 804.1 
               
               
                   
               
               
                 123 
                 22651_416 
                 H-PLGVAPTKAKRRVVQ-OH 
                 8885_HIV-1 Con B Env_123 
                 110214V-02 
                 1620.9 
                 [M + H]+ 
                 810.6 
               
               
                   
               
               
                 124 
                 22651_417 
                 H-APTKAKRRVVQREKR-OH 
                 8886_HIV-1 Con B Env_124 
                 110214V-04 
                 — 
                 — 
                 912.2 
               
               
                   
               
               
                 125 
                 22651_418 
                 H-AKRRVVQREKRAVGI-OH 
                 8887_HIV-1 Con B Env_125 
                 110214V-06 
                 — 
                 — 
                 883.7 
               
               
                   
               
               
                 126 
                 22651_419 
                 H-VVQREKRAVGIGAMF-OH 
                 8888_HIV-1 Con B Env_126 
                 110214V-08 
                 1662.8 
                 [M + H]+ 
                 831.1 
               
               
                   
               
               
                 127 
                 22651_420 
                 H-EKRAMGLGAMFLGFL-OH 
                 8889_HIV-1 Con B Env_127 
                 110214V-10 
                 1610.7 
                 [M + H]+ 
                 805.1 
               
               
                   
               
               
                 128 
                 22651_421 
                 H-VGIGAMFLGFLGAAG-OH 
                 8890_HIV-1 Con B Env_128 
                 110214V-12 
                 1380.7 
                 [M + H]+ 
                 891.0 
               
               
                   
               
               
                 129 
                 22651_422 
                 H-AMFLGFLGAAGSTMG-OH 
                 8891_HIV-1 Con B Env_129 
                 110214V-14 
                 1480.9 
                 [M + H]+ 
                 718.5 
               
               
                   
               
               
                 130 
                 22651_423 
                 H-GFLGAAGEIMGAASM-OH 
                 8892_HIV-1 Con B Env_130 
                 110214V-16 
                 1326.4 
                 [M + H]+ 
                 565.0 
               
               
                   
               
               
                 131 
                 22651_424 
                 H-AAGSTMGAASMTLTV-OH 
                 8893_HIV-1 Con B Env_131 
                 110214V-15 
                 1368.5 
                 [M + H]+ 
                 635.0 
               
               
                   
               
               
                 132 
                 22651_425 
                 H-TMGAASMTLIVQARQ-OH 
                 8894_HIV-1 Con B Env_132 
                 110214V-20 
                 1565.7 
                 [M + H]+ 
                 783.5 
               
               
                   
               
               
                 133 
                 22651_426 
                 H-ASMTLTVOARQLLSG-OH 
                 8895_HIV-1 Con B Env_133 
                 110214V-22 
                 1576.5 
                 [M + H]+ 
                 788.8 
               
               
                   
               
               
                 134 
                 22651_427 
                 H-LTVQARQLLSGIVQQ-OH 
                 8896_HIV-1 Con B Env_134 
                 110214V-24 
                 1655.7 
                 [M + H]+ 
                 817.6 
               
               
                   
               
               
                 135 
                 22651_428 
                 H-ARQLLSGIVQGQNNL-OH 
                 8897_HIV-1 Con B Env_135 
                 110214V-25 
                 1631.8 
                 [M + H]+ 
                 841.6 
               
               
                   
               
               
                 136 
                 22651_429 
                 H-LSGIVQQQNNLLRAI-OH 
                 8898_HIV-1 Con B Env_136 
                 110214V-25 
                 1666.3 
                 [M + H]+ 
                 834.1 
               
               
                   
               
               
                 137 
                 22651_430 
                 H-VQQQNNLLRAIEAQQ-OH 
                 8899_HIV-1 Con B Env_137 
                 110214V-30 
                 1754.6 
                 [M + H]+ 
                 827.5 
               
               
                   
               
               
                 138 
                 22651_431 
                 H-NNLLRAIEAQQHLIQ-OH 
                 8900_HIV-1 Con B Env_138 
                 110214V-32 
                 1762.8 
                 [M + H]+ 
                 851.1 
               
               
                   
               
               
                 139 
                 22651_432 
                 H-RAIEAQQHLLQLTVW-OH 
                 8901_HIV-1 Con B Env_139 
                 110214V-34 
                 1807.1 
                 [M + H]+ 
                 903.7 
               
               
                   
               
               
                 140 
                 22651_433 
                 H-AQQHLLQLTVWGIKQ-OH 
                 8902_HIV-1 Con B Env_140 
                 110214V-36 
                 1763.8 
                 [M + H]+ 
                 882.1 
               
               
                   
               
               
                 141 
                 22651_434 
                 H-LLQLTVWGIKQLQAR-OH 
                 8903_HIV-1 Con B Env_141 
                 110214V-35 
                 1768.2 
                 [M + H]+ 
                 834.2 
               
               
                   
               
               
                 142 
                 22651_435 
                 H-TVWGIKCLQARVLAV-OH 
                 8904_HIV-1 Con B Env_142 
                 110214V-40 
                 1682.9 
                 [M + H]+ 
                 341.2 
               
               
                   
               
               
                 143 
                 22651_436 
                 H-IKQLOARVLAVERYL-OH 
                 8905_HIV-1 Con B Env_143 
                 110214V-42 
                 1800.0 
                 [M + H]+ 
                 900.7 
               
               
                   
               
               
                 144 
                 22651_437 
                 H-QARVIAVERVLKQQQ-OH 
                 8906_HIV-1 Con B Env_144 
                 110214V-44 
                 — 
                 — 
                 909.2 
               
               
                   
               
               
                 145 
                 22651_438 
                 H-RYVERYLKDQQLLGI-OH 
                 8907_HIV-1 Con B Env_145 
                 110214V-46 
                 1760.7 
                 [M + H]+ 
                 890.2 
               
               
                   
               
               
                 146 
                 22651_439 
                 H-RYVERYLKDQQLLGI-OH 
                 8908_HIV-1 Con B Env_146 
                 110214V-48 
                 1780.2 
                 [M + H]+ 
                 891.1 
               
               
                   
               
               
                 147 
                 22651_440 
                 H-OQQLLGFWGCSGKLI-OH 
                 8909_HIV-1 Con B Env_147 
                 180214V-02 
                 1631.7 
                 [M + H]+ 
                 816.0 
               
               
                   
               
               
                 148 
                 22651_441 
                 H-LGIWGCSGKLICTIT-OH 
                 8910_HIV-1 Con B Env_148 
                 180214V-04 
                 1553.3 
                 [M + H]+ 
                 777.1 
               
               
                   
               
               
                 149 
                 22651_442 
                 H-GCSGKLKIITTTVPWN-OH 
                 8911_HIV-1 Con B Env_149 
                 180214V-06 
                 1580.7 
                 [M + H]+ 
                 790.5 
               
               
                   
               
               
                 150 
                 22651_443 
                 H-KLICTTTVPWNASWS-OH 
                 8912_HIV-1 Con B Env_150 
                 180214V-08 
                 1707.7 
                 [M + H]+ 
                 854.0 
               
               
                   
               
               
                 151 
                 22651_444 
                 H-TITVPWNASWSNKSL-OH 
                 8913_HIV-1 Con B Env_151 
                 180214V-10 
                 1592.7 
                 [M + H]+ 
                 845.5 
               
               
                   
               
               
                 152 
                 22651_445 
                 H-PWNASWSNKSLDDW-OH 
                 8914_HIV-1 Con B Env_152 
                 180214V-12 
                 1633.1 
                 [M + H]+ 
                 917.5 
               
               
                   
               
               
                 153 
                 22651_446 
                 H-SWSNKSLDEIWDNMT-OH 
                 8915_HIV-1 Con B Env_153 
                 180214V-14 
                 1826.7 
                 [M + H]+ 
                 914.0 
               
               
                   
               
               
                 154 
                 22651_447 
                 H-KSLDEIWDNMTWMEW-OH 
                 8916_HIV-1 Con B Env_154 
                 180214V-16 
                 1986.0 
                 [M + H]+ 
                 983.0 
               
               
                   
               
               
                 155 
                 22651_448 
                 H-EIWDNMTWMIWEREI-OH 
                 8917_HIV-1 Con B Env_155 
                 180214V-18 
                 2069.8 
                 [M + H]+ 
                 1035.1 
               
               
                   
               
               
                 156 
                 22651_449 
                 H-HMTWMEWEREIDNVT-OH 
                 8918_HIV-1 Con B Env_156 
                 180214V-20 
                 — 
                 — 
                 1009.3 
               
               
                   
               
               
                 157 
                 22651_450 
                 H-MEWEREIDNYISLSY-OH 
                 8919_HIV-1 Con B Env_157 
                 180214V-27 
                 1962.8 
                 [M + H]+ 
                 981.3 
               
               
                   
               
               
                 158 
                 22651_451 
                 H-REIDNYTSLSNTBE-OH 
                 8920_HIV-1 Con B Env_158 
                 180214V-24 
                 1842.9 
                 [M + H]+ 
                 922.1 
               
               
                   
               
               
                 159 
                 22651_452 
                 H-NYISUYTUEESQN-OH 
                 8921_HIV-1 Con B Env_159 
                 180214V-28 
                 1768.3 
                 [M + H]+ 
                 894.6 
               
               
                   
               
               
                 160 
                 22651_453 
                 H-LNTUEESQNQQEK-OH 
                 8922_HIV-1 Con B Env_160 
                 180214V-28 
                 1636.8 
                 [M + H]+ 
                 915.6 
               
               
                   
               
               
                 161 
                 22651_454 
                 H-LIEESQNQQEBNEQE-OH 
                 8923_HIV-1 Con B Env_161 
                 180214V-30 
                 1847.7 
                 [M + H]+ 
                 923.3 
               
               
                   
               
               
                 162 
                 22651_455 
                 H-SQNQQEKNEQQIEL-OH 
                 8924_HIV-1 Con B Env_162 
                 180214V-32 
                 1829.8 
                 [M + H]+ 
                 915.6 
               
               
                   
               
               
                 163 
                 22651_456 
                 H-QEKNEQELLELOKWA-OH 
                 8925_HIV-1 Con B Env_163 
                 180214V-34 
                 1871.9 
                 [M + H]+ 
                 937.2 
               
               
                   
               
               
                 164 
                 22651_457 
                 H-EQELLELDKWASLWN-OH 
                 8926_HIV-1 Con B Env_164 
                 180214V-38 
                 1874.6 
                 [M + H]+ 
                 937.8 
               
               
                   
               
               
                 165 
                 22651_458 
                 H-ELDKWASIWNWFDI-OH 
                 8927_HIV-1 Con B Env_165 
                 180214V-38 
                 3937.3 
                 [M + H]+ 
                 969.2 
               
               
                   
               
               
                 166 
                 22651_459 
                 H-LWASLWNWFWTNWL-OH 
                 8928_HIV-1 Con B Env_166 
                 180214V-40 
                 1981.3 
                 [M + H]+ 
                 991.0 
               
               
                   
               
               
                 167 
                 22651_460 
                 H-LWMWFOMNWDAYIK-OH 
                 8929_HIV-1 Con B Env_167 
                 180214V-42 
                 2100.8 
                 [M + H]+ 
                 1050.1 
               
               
                   
               
               
                 168 
                 22651_461 
                 H-DITNWLWYIKIRM-OH 
                 8930_HIV-1 Con B Env_168 
                 180214V-44 
                 2000.8 
                 [M + H]+ 
                 1002.5 
               
               
                   
               
               
                 169 
                 22651_462 
                 H-NWLWMKAMNGG-OH 
                 8931_HIV-1 Con B Env_169 
                 180214V-48 
                 1855.30 
                 [M + H]+ 
                 — 
               
               
                   
               
               
                 170 
                 22651_463 
                 H-VIKIFIMIMVGGLIG-OH 
                 8932_HIV-1 Con B Env_170 
                 180214V-48 
                 1649.9 
                 [M + H]+ 
                 825.7 
               
               
                   
               
               
                 171 
                 22651_464 
                 H-FIMIVGGLIGIRIVF-OH 
                 8833_HIV-1 Con B Env_171 
                 130214Z-02 
                 1648.9 
                 [M + H]+ 
                 824.5 
               
               
                   
               
               
                 172 
                 22651_465 
                 H-VGGLIGLRIVFAVLS-OH 
                 8834_HIV-1 Con B Env_172 
                 130214Z-04 
                 1514.8 
                 [M + H]+ 
                 737.6 
               
               
                   
               
               
                 173 
                 22651_466 
                 H-IGLRIVFAVLSIVNR-OH 
                 8835_HIV-1 Con B Env_173 
                 130214Z-06 
                 3671.3 
                 [M + H]+ 
                 835.8 
               
               
                   
               
               
                 174 
                 22651_467 
                 H-IVFAVLSIVNRYRGG-OH 
                 8836_HIV-1 Con B Env_174 
                 130214Z-03 
                 1672.8 
                 [M + H]+ 
                 836.2 
               
               
                   
               
               
                 175 
                 22651_468 
                 H-VLSIVNRVRQGYSPI-OH 
                 8837_HIV-1 Con B Env_175 
                 130214Z-10 
                 1700.8 
                 [M + H]+ 
                 851.1 
               
               
                   
               
               
                 176 
                 22651_469 
                 H-VNRYFQGYSPLSFQT-OH 
                 8838_HIV-1 Con B Env_176 
                 130214Z-12 
                 1751.8 
                 [M + H]+ 
                 876.6 
               
               
                   
               
               
                 177 
                 22651_470 
                 H-RQGYSPLSFQTRLPA-OH 
                 8839_HIV-1 Con B Env_177 
                 130214Z-14 
                 1722.2 
                 [M + H]+ 
                 861.3 
               
               
                   
               
               
                 178 
                 22651_471 
                 H-SPLSFQTRIPAPRGP-OH 
                 8840_HIV-1 Con B Env_178 
                 170214Y-04 
                 1625.7 
                 [M + H]+ 
                 8126.6 
               
               
                   
               
               
                 179 
                 22651_472 
                 H-FQTRLPAPRGPDRPE-OH 
                 8841_HIV-1 Con B Env_179 
                 170214Y-05 
                 1739.2 
                 [M + H]+ 
                 869.3 
               
               
                   
               
               
                 180 
                 22651_473 
                 H-LPAPRGPORPEGIEE-OH 
                 8842_HIV-1 Con B Env_180 
                 170214Y-08 
                 1632.8 
                 [M + H]+ 
                 817.0 
               
               
                   
               
               
                 181 
                 22651_474 
                 H-RGPDEPEGIEEGGGE-OH 
                 8843_HIV-1 Con B Env_181 
                 170214Y-10 
                 1627.5 
                 [M + H]+ 
                 814.0 
               
               
                   
               
               
                 182 
                 22651_475 
                 H-RPEGIEEEGGERDRD-OH 
                 8844_HIV-1 Con B Env_182 
                 170214Y-12 
                 — 
                 — 
                 872.5 
               
               
                   
               
               
                 183 
                 22651_476 
                 H-IEEEGGERDRDSSGR-OH 
                 8845_HIV-1 Con B Env_183 
                 170214Y-14 
                 — 
                 — 
                 881.0 
               
               
                   
               
               
                 184 
                 22651_477 
                 H-GGERDSDRSGRIVDG-OH 
                 8846_HIV-1 Con B Env_184 
                 170214Y-15 
                 1649.1 
                 [M + H]+ 
                 878.0 
               
               
                   
               
               
                 185 
                 22651_478 
                 H-DRDRSGRLVDGFLAL-OH 
                 8847_HIV-1 Con B Env_185 
                 170214Y-18 
                 1690.3 
                 [M + H]+ 
                 845.7 
               
               
                   
               
               
                 186 
                 22651_479 
                 H-SGRLVDGFIAIIWDD-OH 
                 8848_HIV-1 Con B Env_186 
                 170214Y-20 
                 1678.7 
                 [M + H]+ 
                 839.0 
               
               
                   
               
               
                 187 
                 22651_480 
                 H-VDGFLALIWDDLASL-OH 
                 8849_HIV-1 Con B Env_187 
                 210214R-03 
                 1734.8 
                 [M + H]+ 
                 867.1 
               
               
                   
               
               
                 188 
                 22651_481 
                 H-LALIWDDLRSLCLFS-OH 
                 8850_HIV-1 Con B Env_188 
                 210214R-05 
                 1765.4 
                 [M + H]+ 
                 883.3 
               
               
                   
               
               
                 189 
                 22651_482 
                 H-WDDLASLCLFSYHRL-OH 
                 8851_HIV-1 Con B Env_189 
                 210214R-07 
                 1926.2 
                 [M + H]+ 
                 963.1 
               
               
                   
               
               
                 190 
                 22651_483 
                 H-RSLCLFSYHRLRDIL-OH 
                 8852_HIV-1 Con B Env_190 
                 210214R-08 
                 — 
                 — 
                 947.0 
               
               
                   
               
               
                 191 
                 22651_484 
                 H-LFSYERLRDLILIVT-OH 
                 8853_HIV-1 Con B Env_191 
                 210214R-11 
                 1859.9 
                 [M + H]+ 
                 830.2 
               
               
                   
               
               
                 192 
                 22651_485 
                 H-HRLRQLLLIVERIVE-OH 
                 8854_HIV-1 Con B Env_192 
                 210214R-13 
                 — 
                 — 
                 922.7 
               
               
                   
               
               
                 193 
                 22651_486 
                 H-DLLLIVYARVELLGR-OH 
                 8855_HIV-1 Con B Env_193 
                 210214R-15 
                 1725.4 
                 [M + H]+ 
                 862.4 
               
               
                   
               
               
                 194 
                 22651_487 
                 H-IVTRIVELLGREGWE-OH 
                 8856_HIV-1 Con B Env_194 
                 210214R-17 
                 — 
                 — 
                 839.2 
               
               
                   
               
               
                 195 
                 22651_488 
                 H-IVELLGRRGWEVLKY-OH 
                 8857_HIV-1 Con B Env_195 
                 210214R-19 
                 1632.9 
                 [M + H]+ 
                 916.2 
               
               
                   
               
               
                 196 
                 22651_489 
                 H-LGRRGWEVLKYWWNL-OH 
                 8858_HIV-1 Con B Env_196 
                 210214R-21 
                 1977.0 
                 [M + H]+ 
                 938.7 
               
               
                   
               
               
                 197 
                 22651_490 
                 H-GWEVLKVWWMLLQYW-OH 
                 8859_HIV-1 Con B Env_197 
                 210214R-23 
                 — 
                 — 
                 1043.1 
               
               
                   
               
               
                 198 
                 22651_491 
                 H-LKYWWNLLQVWSQEL-OH 
                 8860_HIV-1 Con B Env_198 
                 210214R-25 
                 2072.2 
                 [M + H]+ 
                 1036.2 
               
               
                   
               
               
                 199 
                 22651_492 
                 H-WNLLQVWSQELKNSA-OH 
                 8861_HIV-1 Con B Env_199 
                 210214R-27 
                 1881.8 
                 [M + H]+ 
                 941.0 
               
               
                   
               
               
                 200 
                 22651_493 
                 H-QYWSQELKNSAVSLL-OH 
                 8862_HIV-1 Con B Env_200 
                 210214R-29 
                 1767.8 
                 [M + H]+ 
                 384.0 
               
               
                   
               
               
                 201 
                 22651_494 
                 H-QELKNSAVSLINATA-OH 
                 8863_HIV-1 Con B Env_201 
                 210214R-31 
                 1559.3 
                 [M + H]+ 
                 780.2 
               
               
                   
               
               
                 202 
                 22651_495 
                 H-NSAVSLLNATAIAVA-OH 
                 8864_HIV-1 Con B Env_202 
                 210214R-33 
                 1414.2 
                 [M + H]+ 
                 708.1 
               
               
                   
               
               
                 203 
                 22651_496 
                 H-SLINATAIAVAGGTD-OH 
                 8865_HIV-1 Con B Env_203 
                 210214R-35 
                 1446.2 
                 [M + H]+ 
                 724.0 
               
               
                   
               
               
                 204 
                 22651_497 
                 H-ATAIAVAEGTDRVIE-OH 
                 8866_HIV-1 Con B Env_204 
                 210214R-37 
                 1515.7 
                 [M + H]+ 
                 758.5 
               
               
                   
               
               
                 205 
                 22651_498 
                 H-AVAEGTDRVIEVVQR-OH 
                 8867_HIV-1 Con B Env_205 
                 210214R-38 
                 1641.8 
                 [M + H]+ 
                 821.6 
               
               
                   
               
               
                 206 
                 22651_499 
                 H-GTDRVIEVVQFACRA-OH 
                 8868_HIV-1 Con B Env_206 
                 210214R-41 
                 1673.3 
                 [M + H]+ 
                 837.2 
               
               
                   
               
               
                 207 
                 22651_500 
                 H-VIEVVQRACRAELHI-OH 
                 8869_HIV-1 Con B Env_207 
                 210214R-43 
                 1720.4 
                 [M + H]+ 
                 850.8 
               
               
                   
               
               
                 208 
                 22651_501 
                 H-VQRACRAILHIFRFI-OH 
                 8870_HIV-1 Con B Env_208 
                 210214R-45 
                 — 
                 — 
                 901.7 
               
               
                   
               
               
                 209 
                 22651_502 
                 H-CRAILHIPRRIRQGL-OH 
                 8871_HIV-1 Con B Env_209 
                 210214R-47 
                 — 
                 — 
                 901.7 
               
               
                   
               
               
                 210 
                 22651_503 
                 H-LHIPRRIRQGLERAL-OH 
                 8872_HIV-1 Con B Env_210 
                 210214Z-02 
                 — 
                 — 
                 914.7 
               
               
                   
               
               
                 211 
                 22651_504 
                 H-RRIFQGLERALL-OH 
                 8373_HIV-1 Con B Env_211 
                 19021482 
                 — 
                 — 
                 741.1 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 Theor. 
                   
                 Exp. MW 
                   
                   
                   
                   
               
               
                   
                   
                   
                 MW (3) 
                   
                 MW 
                 Theor. 
                 vs. 
               
               
                   
                   
                 MW (2) 
                 detected 
                 MW (3) 
                 (average) 
                 MW + TFA 
                 Theor. 
                   
                 Amount 
               
               
                   
                   
                 label 
                 [g/mol] 
                 label 
                 [g/mol] 
                 [g/mol] 
                 MW 
                 Purity [%] 
                 [mg] 
                 Purified 
                 Comment 
               
               
                   
                   
               
               
                   
                   1 
                 [M + 2H]2+ 
                 662.8 
                 [M + 3H]3+ 
                 1985.38 
                 2783.38 
                 pass 
                 85.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                   2 
                 [M + 2H]2+ 
                 649.7 
                 [M + 3H]3+ 
                 1946.25 
                 2516.25 
                 pass 
                 87.8 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                   3 
                 [M + 2H]2+ 
                 — 
                 — 
                 1906.24 
                 2248.24 
                 pass 
                 87.1 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                   4 
                 [M + 2H]2+ 
                 — 
                 — 
                 1824.34 
                 2052.34 
                 pass 
                 80.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                   5 
                 [M + 2H]2+ 
                 1584.37 
                 [M + 2Na]2+ 
                 1540.92 
                 1654.92 
                 pass 
                 approx. 80 
                 65.0 
                 N 
                 2) 
               
               
                   
                   
               
               
                   
                   6 
                 [M + 2H]2+ 
                 555.8 
                 [M + 3H]3+ 
                 1665.09 
                 1893.09 
                 pass 
                 90.0 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                   7 
                 [M + 2H]2+ 
                 1777.56 
                 [M + H]+ 
                 1777.12 
                 2005.12 
                 pass 
                 approx. 80 
                 65.0 
                 N 
                 1) 
               
               
                   
                   
               
               
                   
                   8 
                 [M + 2H]2+ 
                 565.8 
                 [M + 3H]3+ 
                 1694.98 
                 1922.98 
                 pass 
                 94.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                   9 
                 [M + 2H]2+ 
                 604.2 
                 [M + 3H]3+ 
                 1810.11 
                 2038.11 
                 pass 
                 87.2 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  10 
                 [M + 2H]2+ 
                 576.4 
                 [M + 3H]3+ 
                 1726.97 
                 1954.97 
                 pass 
                 88.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  11 
                 [M + 2H]2+ 
                 — 
                 — 
                 1652.91 
                 1880.91 
                 pass 
                 85.9 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  12 
                 [M + 2H]2+ 
                 519.8 
                 [M + 3H]3+ 
                 1556.74 
                 1898.74 
                 pass 
                 87.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  13 
                 [M + 2H]2+ 
                 — 
                 — 
                 1635.76 
                 1863.76 
                 pass 
                 84.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  14 
                 [M + 2H]2+ 
                 541.9 
                 [M + 3H]3+ 
                 1622.72 
                 1964.72 
                 pass 
                 89.4 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  15 
                 [M + 2H]2+ 
                 581.7 
                 [M + 3H]3+ 
                 1741.86 
                 2197.86 
                 pass 
                 85.3 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  16 
                 [M + 2H]2+ 
                 — 
                 — 
                 1678.82 
                 2020.82 
                 pass 
                 82.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  17 
                 [M + 2H]2+ 
                 555.0 
                 [M + 3H]3+ 
                 1661.80 
                 2003.80 
                 pass 
                 88.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  18 
                 [M + 2H]2+ 
                 527.2 
                 [M + 3H]3+ 
                 1578.71 
                 1806.71 
                 pass 
                 93.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  19 
                 [M + 2H]2+ 
                 — 
                 — 
                 1653.81 
                 1653.81 
                 pass 
                 91.1 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  20 
                 [M + 2H]2+ 
                 566.5 
                 [M + 3H]3+ 
                 1696.76 
                 1696.76 
                 pass 
                 86.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  21 
                 [M + 2H]2+ 
                 — 
                 — 
                 1852.01 
                 1852.01 
                 pass 
                 80.5 
                 66.0 
                 Y 
                 5) 
               
               
                   
                   
               
               
                   
                  22 
                 [M + 2H]2+ 
                 628.9 
                 [M + 3H]3+ 
                 1884.07 
                 1884.07 
                 pass 
                 93.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  23 
                 [M + 2H]2+ 
                 639.5 
                 [M + 3H]3+ 
                 1916.13 
                 1916.13 
                 pass 
                 95.5 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  24 
                 [M + 2H]2+ 
                 640.5 
                 [M + 3H]3+ 
                 1919.14 
                 1919.14 
                 pass 
                 94.8 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  25 
                 [M + 2H]2+ 
                 620.5 
                 [M + 3H]3+ 
                 1859.08 
                 1859.08 
                 pass 
                 85.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  26 
                 [M + 2H]2+ 
                 615.5 
                 [M + 3H]3+ 
                 1844.02 
                 1844.02 
                 pass 
                 82.9 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  27 
                 [M + 2H]2+ 
                 582.9 
                 [M + 3H]3+ 
                 1746.01 
                 1746.01 
                 pass 
                 89.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  28 
                 [M + 2H]2+ 
                 572.6 
                 [M + 3H]3+ 
                 1715.04 
                 2057.04 
                 pass 
                 87.1 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  29 
                 [M + 2H]2+ 
                 544.2 
                 [M + 3H]3+ 
                 1630.03 
                 1972.03 
                 pass 
                 88.1 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  30 
                 [M + 2H]2+ 
                 535.7 
                 [M + 3H]3+ 
                 1604.99 
                 1832.99 
                 pass 
                 88.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  31 
                 [M + 2H]2+ 
                 — 
                 — 
                 1650.97 
                 1764.97 
                 pass 
                 82.4 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  32 
                 [M + 2H]2+ 
                 — 
                 — 
                 1613.81 
                 1727.81 
                 pass 
                 81.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  33 
                 [M + 2H]2+ 
                 — 
                 — 
                 1586.64 
                 1700.64 
                 pass 
                 80.4 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  34 
                 [M + 2H]2+ 
                 — 
                 — 
                 1554.62 
                 1782.62 
                 pass 
                 84.6 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  35 
                 [M + 2H]2+ 
                 524.5 
                 [M + 3H]3+ 
                 1570.61 
                 1912.61 
                 pass 
                 84.4 
                 65.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                  36 
                 [M + 2H]2+ 
                 546.7 
                 [M + 3H]3+ 
                 1637.75 
                 2093.75 
                 pass 
                 85.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  37 
                 [M + 2H]2+ 
                 572.2 
                 [M + 3H]3+ 
                 1713.91 
                 2169.91 
                 pass 
                 87.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  38 
                 [M + 2H]2+ 
                 557.8 
                 [M + 3H]3+ 
                 1670.83 
                 2012.83 
                 pass 
                 95.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  39 
                 [M + 2H]2+ 
                 580.8 
                 [M + 3H]3+ 
                 1740.00 
                 2196.00 
                 pass 
                 89.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  40 
                 [M + 2H]2+ 
                 589.6 
                 [M + 3H]3+ 
                 1765.97 
                 2221.97 
                 pass 
                 81.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  41 
                 [M + 2H]2+ 
                 600.5 
                 [M + 3H]3+ 
                 1799.05 
                 2255.05 
                 pass 
                 90.5 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  42 
                 [M + 2H]2+ 
                 639.7 
                 [M + 3H]3+ 
                 1916.21 
                 2486.21 
                 pass 
                 91.6 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  43 
                 [M + 2H]2+ 
                 609.5 
                 [M + 3H]3+ 
                 1826.17 
                 2168.17 
                 pass 
                 95.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  44 
                 [M + 2H]2+ 
                 — 
                 — 
                 1735.96 
                 1963.96 
                 pass 
                 86.0 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  45 
                 [M + 2H]2+ 
                 — 
                 — 
                 1679.80 
                 1907.80 
                 pass 
                 86.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  46 
                 [M + 2H]2+ 
                 565.5 
                 [M + 3H]3+ 
                 1693.84 
                 1921.84 
                 pass 
                 85.4 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  47 
                 [M + 2H]2+ 
                 — 
                 — 
                 1674.76 
                 1902.76 
                 pass 
                 85.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  48 
                 [M + 2H]2+ 
                 558.1 
                 [M + 3H]3+ 
                 1671.89 
                 1899.89 
                 pass 
                 88.0 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  49 
                 [M + 2H]2+ 
                 526.9 
                 [M + 3H]3+ 
                 1577.87 
                 1805.87 
                 pass 
                 91.2 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  50 
                 [M + 2H]2+ 
                 542.3 
                 [M + 3H]3+ 
                 1623.89 
                 1851.83 
                 pass 
                 85.5 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  51 
                 [M + 2H]2+ 
                 548.5 
                 [M + 3H]3+ 
                 1642.98 
                 1870.98 
                 pass 
                 93.8 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  52 
                 [M + 2H]2+ 
                 568.8 
                 [M + 3H]3+ 
                 1704.05 
                 2046.05 
                 pass 
                 90.5 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  53 
                 [M + 2H]2+ 
                 — 
                 — 
                 1648.92 
                 1876.92 
                 pass 
                 87.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  54 
                 [M + 2H]2+ 
                 — 
                 — 
                 1614.00 
                 1956.00 
                 pass 
                 84.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  55 
                 [M + 2H]2+ 
                 538.8 
                 [M + 3H]3+ 
                 1613.92 
                 1955.92 
                 pass 
                 91.7 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  56 
                 [M + 2H]2+ 
                 — 
                 — 
                 1625.90 
                 2081.90 
                 pass 
                 92.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  57 
                 [M + 2H]2+ 
                 546.8 
                 [M + 3H]3+ 
                 1637.92 
                 2093.92 
                 pass 
                 89.1 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  58 
                 [M + 2H]2+ 
                 528.2 
                 [M + 3H]3+ 
                 1581.70 
                 1923.70 
                 pass 
                 89.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  59 
                 [M + 2H]2+ 
                 — 
                 — 
                 1527.67 
                 1641.67 
                 pass 
                 81.6 
                 66.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                  60 
                 [M + 2H]2+ 
                 — 
                 — 
                 1516.69 
                 1744.69 
                 pass 
                 91.2 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  61 
                 [M + 2H]2+ 
                 5375 
                 [M + 3H]3+ 
                 1609.85 
                 1951.85 
                 pass 
                 86.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  62 
                 [M + 2H]2+ 
                 — 
                 — 
                 1637.91 
                 1979.91 
                 pass 
                 89.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  63 
                 [M + 2H]2+ 
                 535.5 
                 [M + 3H]3+ 
                 1603.88 
                 1945.88 
                 pass 
                 87.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  64 
                 [M + 2H]2+ 
                 — 
                 — 
                 1540.77 
                 1654.77 
                 pass 
                 90.4 
                 66.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                  65 
                 [M + 2H]2+ 
                 — 
                 — 
                 1614.79 
                 1728.79 
                 pass 
                 92.8 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  66 
                 [M + 2H]2+ 
                 549.1 
                 [M + 3H]3+ 
                 1644.78 
                 1872.78 
                 pass 
                 94.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  67 
                 [M + 2H]2+ 
                 — 
                 — 
                 1749.87 
                 1977.87 
                 pass 
                 93.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  68 
                 [M + 2H]2+ 
                 574.8 
                 [M + 3H]3+ 
                 1721.86 
                 2063.86 
                 pass 
                 88.0 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  69 
                 [M + 2H]2+ 
                 579.2 
                 [M + 3H]3+ 
                 1734.91 
                 2076.91 
                 pass 
                 95.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  70 
                 [M + 2H]2+ 
                 — 
                 — 
                 1691.88 
                 1919.88 
                 pass 
                 94.6 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  71 
                 [M + Na]+ 
                 1717.22 
                 [M + 2Na]2+ 
                 1670.90 
                 1898.90 
                 pass 
                 approx. 80 
                 66.0 
                 Y 
                 2) 
               
               
                   
                   
               
               
                   
                  72 
                 [M + 2H]2+ 
                 572.5 
                 [M + 3H]3+ 
                 1714.94 
                 1942.94 
                 pass 
                 92.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  73 
                 [M + 2H]2+ 
                 — 
                 — 
                 1704.76 
                 1932.76 
                 pass 
                 87.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  74 
                 [M + 2H]2+ 
                 587.5 
                 [M + 3H]3+ 
                 1759.94 
                 2215.94 
                 pass 
                 81.6 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                  75 
                 [M + 2H]2+ 
                 569.2 
                 [M + 3H]3+ 
                 1704.90 
                 2274.90 
                 pass 
                 85.9 
                 72.0 
                 Y 
               
               
                   
                   
               
               
                   
                  76 
                 [M + 2H]2+ 
                 556.9 
                 [M + 3H]3+ 
                 1667.89 
                 2237.89 
                 pass 
                 93.2 
                 74.0 
                 Y 
               
               
                   
                   
               
               
                   
                  77 
                 [M + 2H]2+ 
                 535.8 
                 [M + 3H]3+ 
                 1604.83 
                 2060.83 
                 pass 
                 87.0 
                 74.0 
                 Y 
               
               
                   
                   
               
               
                   
                  78 
                 [M + 2H]2+ 
                 — 
                 — 
                 1551.76 
                 1779.76 
                 pass 
                 86.9 
                 73.0 
                 Y 
               
               
                   
                   
               
               
                   
                  79 
                 [M + 2H]2+ 
                 580.9 
                 [M + 3H]3+ 
                 1739.95 
                 2081.95 
                 pass 
                 84.7 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                  80 
                 [M + 2H]2+ 
                 543.5 
                 [M + 3H]3+ 
                 1627.78 
                 1969.78 
                 pass 
                 84.5 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                  81 
                 [M + 2H]2+ 
                 556.7 
                 [M + 3H]3+ 
                 1666.93 
                 2122.93 
                 pass 
                 91.1 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  82 
                 [M + 2H]2+ 
                 604.6 
                 [M + 3H]3+ 
                 1811.05 
                 2381.05 
                 pass 
                 92.7 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  83 
                 [M + 2H]2+ 
                 605.3 
                 [M + 3H]3+ 
                 1813.05 
                 2383.05 
                 pass 
                 85.4 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  84 
                 [M + 2H]2+ 
                 605.7 
                 [M + 3H]3+ 
                 1814.14 
                 2498.14 
                 pass 
                 96.0 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  85 
                 [M + 2H]2+ 
                 633.6 
                 [M + 3H]3+ 
                 1898.21 
                 2468.21 
                 pass 
                 96.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  86 
                 [M + 2H]2+ 
                 610.7 
                 [M + 3H]3+ 
                 1829.20 
                 2513.20 
                 pass 
                 92.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  87 
                 [M + 2H]2+ 
                 603.3 
                 [M + 3H]3+ 
                 1807.15 
                 2377.15 
                 pass 
                 89.6 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  88 
                 [M + 2H]2+ 
                 585.8 
                 [M + 3H]3+ 
                 1754.91 
                 2096.91 
                 pass 
                 89.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  89 
                 [M + 2H]2+ 
                 — 
                 — 
                 1520.61 
                 1748.61 
                 pass 
                 91.4 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  90 
                 [M + 2H]2+ 
                 — 
                 — 
                 1592.78 
                 1706.78 
                 pass 
                 93.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  91 
                 [M + 2H]2+ 
                 — 
                 — 
                 1604.71 
                 1832.71 
                 pass 
                 88.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  92 
                 [M + 2H]2+ 
                 — 
                 — 
                 1591.72 
                 1819.72 
                 pass 
                 82.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  93 
                 [M + 2H]2+ 
                 — 
                 — 
                 1754.03 
                 1982.03 
                 pass 
                 81.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  94 
                 [M + 2H]2+ 
                 1718.10 
                 [M + 3H]3+ 
                 1717.34 
                 1831.84 
                 pass 
                 approx. 80 
                 69.0 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                  95 
                 [M + 2H]2+ 
                 — 
                 — 
                 1727.86 
                 1841.86 
                 pass 
                 92.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                  96 
                 [M + 2H]2+ 
                 — 
                 — 
                 1838.01 
                 1952.01 
                 pass 
                 89.8 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  97 
                 [M + 2H]2+ 
                 — 
                 — 
                 1768.87 
                 1882.87 
                 pass 
                 87.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                  98 
                 [M + 2H]2+ 
                 — 
                 — 
                 1768.78 
                 1882.78 
                 pass 
                 85.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                  99 
                 [M + 2H]2+ 
                 — 
                 — 
                 1734.67 
                 1848.67 
                 pass 
                 92.1 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 100 
                 [M + 2H]2+ 
                 — 
                 — 
                 1649.65 
                 1763.65 
                 pass 
                 87.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 101 
                 [M + 2H]2+ 
                 554.5 
                 [M + 3H]3+ 
                 1660.80 
                 1888.80 
                 pass 
                 84.9 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 102 
                 [M + 2H]2+ 
                 — 
                 — 
                 1685.01 
                 2027.01 
                 pass 
                 86.3 
                 6.0 
                 Y 
               
               
                   
                   
               
               
                   
                 103 
                 [M + 2H]2+ 
                 620.0 
                 [M + 3H]3+ 
                 1857.30 
                 2199.30 
                 pass 
                 82.5 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 104 
                 [M + 2H]2+ 
                 616.3 
                 [M + 3H]3+ 
                 1846.22 
                 2302.22 
                 pass 
                 81.0 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 105 
                 [M + 2H]2+ 
                 594.8 
                 [M + 3H]3+ 
                 1782.09 
                 2010.09 
                 pass 
                 85.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 106 
                 [M + 2H]2+ 
                 593.2 
                 [M + 3H]3+ 
                 1777.13 
                 2119.13 
                 pass 
                 93.3 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 107 
                 [M + 2H]2+ 
                 553.3 
                 [M + 3H]3+ 
                 1657.02 
                 2113.02 
                 pass 
                 95.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 108 
                 [M + 2H]2+ 
                 565.2 
                 [M + 3H]3+ 
                 1692.99 
                 2034.99 
                 pass 
                 89.1 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 109 
                 [M + 2H]2+ 
                 539.2 
                 [M + 3H]3+ 
                 1614.89 
                 1956.89 
                 pass 
                 88.7 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 110 
                 [M + 2H]2+ 
                 559.3 
                 [M + 3H]3+ 
                 1674.98 
                 2016.98 
                 pass 
                 80.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 111 
                 [M + 2H]2+ 
                 — 
                 — 
                 1517.65 
                 1745.65 
                 pass 
                 91.2 
                 67.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                 112 
                 [M + 2H]2+ 
                 — 
                 — 
                 1559.63 
                 1787.63 
                 pass 
                 90.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 113 
                 [M + 2H]2+ 
                 550.2 
                 [M + 3H]3+ 
                 1647.64 
                 1875.64 
                 pass 
                 92.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 114 
                 [M + 2H]2+ 
                 — 
                 — 
                 1619.64 
                 1847.64 
                 pass 
                 85.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 115 
                 [M + 2H]2+ 
                 — 
                 — 
                 1637.72 
                 1865.72 
                 pass 
                 91.6 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 116 
                 [M + 2H]2+ 
                 584.5 
                 [M + 3H]3+ 
                 1750.90 
                 2092.90 
                 pass 
                 83.5 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 117 
                 [M + 2H]2+ 
                 582.5 
                 [M + 3H]3+ 
                 1745.89 
                 2201.89 
                 pass 
                 84.7 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 118 
                 [M + 2H]2+ 
                 654.7 
                 [M + 3H]3+ 
                 1961.18 
                 2531.18 
                 pass 
                 89.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 119 
                 [M + 2H]2+ 
                 647.9 
                 [M + 3H]3+ 
                 1941.25 
                 2511.25 
                 pass 
                 94.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 120 
                 [M + 2H]2+ 
                 589.7 
                 [M + 3H]3+ 
                 1766.10 
                 2222.10 
                 pass 
                 97.3 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 121 
                 [M + 2H]2+ 
                 548.5 
                 [M + 3H]3+ 
                 1642.00 
                 2098.00 
                 pass 
                 95.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 122 
                 [M + 2H]2+ 
                 536.6 
                 [M + 3H]3+ 
                 1606.96 
                 2176.96 
                 pass 
                 93.4 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 123 
                 [M + 2H]2+ 
                 541.0 
                 [M + 3H]3+ 
                 1619.97 
                 2189.97 
                 pass 
                 92.9 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 124 
                 [M + 2H]2+ 
                 608.7 
                 [M + 3H]3+ 
                 1823.17 
                 2735.17 
                 pass 
                 94.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 125 
                 [M + 2H]2+ 
                 589.5 
                 [M + 3H]3+ 
                 1766.12 
                 2564.12 
                 pass 
                 96.5 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 126 
                 [M + 2H]2+ 
                 554.5 
                 [M + 3H]3+ 
                 1660.99 
                 2116.99 
                 pass 
                 97.6 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 127 
                 [M + 2H ]2+ 
                 537.2 
                 [M + 3H]3+ 
                 1606.96 
                 1950.96 
                 pass 
                 96.0 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 128 
                 [M + 2H ]2+ 
                 1403.00 
                 [M + 3H]3+ 
                 1380.67 
                 1494.67 
                 pass 
                 Approx. 80 
                 67.0 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 129 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1430.70 
                 1544.70 
                 pass 
                 86.7 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 130 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1328.52 
                 1442.52 
                 pass 
                 91.7 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 131 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1366.57 
                 1482.57 
                 pass 
                 83.6 
                 56.0 
                 Y 
                 4) 
               
               
                   
                   
               
               
                   
                 132 
                 [M + 2H ]2+ 
                 522.8 
                 [M + 3H]3+ 
                 1569.81 
                 1793.81 
                 pass 
                 93.3 
                 67.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                 133 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1575.84 
                 1803.84 
                 pass 
                 83.3 
                 68.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                 134 
                 [M + 2H ]2+ 
                 532.2 
                 [M + 3H]3+ 
                 1693.94 
                 1881.94 
                 pass 
                 87.5 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 135 
                 [M + 2H ]2+ 
                 561.6 
                 [M + 3H]3+ 
                 1681.91 
                 1908.91 
                 pass 
                 96.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 136 
                 [M + 2H ]2+ 
                 556.5 
                 [M + 3H]3+ 
                 1666.34 
                 1894.94 
                 pass 
                 91.7 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 137 
                 [M + 2H ]2+ 
                 585.3 
                 [M + 3H]3+ 
                 1753.94 
                 1930.94 
                 pass 
                 97.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 138 
                 [M + 2H ]2+ 
                 587.8 
                 [M + 3H]3+ 
                 1781.01 
                 2103.01 
                 pass 
                 99.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 139 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1806.09 
                 2148.09 
                 pass 
                 89.1 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 140 
                 [M + 2H ]2+ 
                 588.5 
                 [M + 3H]3+ 
                 1763.06 
                 2109.06 
                 pass 
                 92.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 141 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1787.14 
                 2103.14 
                 pass 
                 90.1 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 142 
                 [M + 2H ]2+ 
                 561.8 
                 [M + 3H]3+ 
                 1652.03 
                 2024.03 
                 pass 
                 93.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 143 
                 [M + 2H ]2+ 
                 601.0 
                 [M + 3H]3+ 
                 1806.18 
                 2256.18 
                 pass 
                 90.7 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 144 
                 [M + 2H ]2+ 
                 676.8 
                 [M + 3H]3+ 
                 1817.08 
                 2273.08 
                 pass 
                 94.8 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 145 
                 [M + 2H ]2+ 
                 587.2 
                 [M + 3H]3+ 
                 1759.08 
                 2101.08 
                 pass 
                 93.6 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 146 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1780.08 
                 2322.08 
                 pass 
                 91.6 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 147 
                 [M + 2H ]2+ 
                 544.5 
                 [M + 3H]3+ 
                 1630.92 
                 1858.92 
                 pass 
                 87.8 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 148 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1552.89 
                 1780.85 
                 pass 
                 82.6 
                 73.0 
                 Y 
               
               
                   
                   
               
               
                   
                 149 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1579.83 
                 1807.83 
                 pass 
                 82.4 
                 71.0 
                 Y 
               
               
                   
                   
               
               
                   
                 150 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1706.96 
                 1934.96 
                 pass 
                 81.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 151 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1681.84 
                 1913.84 
                 pass 
                 85.6 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 152 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1832.98 
                 2050.98 
                 pass 
                 83.0 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 153 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1825.95 
                 2053.95 
                 pass 
                 81.9 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 154 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1984.20 
                 2222.20 
                 pass 
                 84.8 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 155 
                 [M + 2H ]2+ 
                 — 
                 — 
                 2068.27 
                 2298.27 
                 pass 
                 83.9 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 156 
                 [M + 2H ]2+ 
                 679.4 
                 [M + 3H]3+ 
                 2018.17 
                 2246.17 
                 pass 
                 81.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 157 
                 [M + 2H ]2+ 
                 664.8 
                 [M + 3H]3+ 
                 1962.15 
                 2190.15 
                 pass 
                 87.8 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 158 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1843.06 
                 2071.06 
                 pass 
                 92.8 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 159 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1787.93 
                 1901.93 
                 pass 
                 81.4 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 160 
                 [M + 2H ]2+ 
                 612.9 
                 [M + 3H]3+ 
                 1836.01 
                 1054.01 
                 pass 
                 85.8 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 161 
                 [M + 2H ]2+ 
                 616.3 
                 [M + 3H]3+ 
                 1849.86 
                 2073.85 
                 pass 
                 88.2 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 162 
                 [M + 2H ]2+ 
                 610.8 
                 [M + 3H]3+ 
                 1829.91 
                 2057.91 
                 pass 
                 90.9 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 163 
                 [M + 2H ]2+ 
                 625.3 
                 [M + 3H]3+ 
                 1873.02 
                 2216.02 
                 pass 
                 93.4 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 164 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1874.06 
                 2307.06 
                 pass 
                 91.1 
                 71.0 
                 Y 
               
               
                   
                   
               
               
                   
                 165 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1936.19 
                 2164.19 
                 pass 
                 80.8 
                 71.0 
                 Y 
               
               
                   
                   
               
               
                   
                 166 
                 [M + 2H ]2+ 
                 — 
                 — 
                 1980.24 
                 2205.24 
                 pass 
                 89.9 
                 71.0 
                 Y 
               
               
                   
                   
               
               
                   
                 167 
                 [M + 2H ]2+ 
                 700.5 
                 [M + 3H]3+ 
                 2098.42 
                 2328.42 
                 pass 
                 93.3 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 168 
                 [M + 2H ]2+ 
                 660.8 
                 [M + 3H]3+ 
                 2002.43 
                 2231.42 
                 pass 
                 83.2 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 169 
                 — 
                 — 
                 — 
                 1853.29 
                 2081.29 
                 pass 
                 approx. 20-80 
                 68.0 
                 Y 
                 2) 
               
               
                   
                   
               
               
                   
                 170 
                 [M + 2H]2+ 
                 1672.77 
                 [M + Na]+ 
                 1650.14 
                 1878.14 
                 pass 
                 approx. 80 
                 68.0 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 171 
                 [M + 2H]2+ 
                 1648.75 
                 [M + H]+ 
                 1648.13 
                 1879.13 
                 pass 
                 approx. 80) 
                 67.0 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 172 
                 [M + 2H]2+ 
                 1514.30 
                 [M + H]+ 
                 1513.89 
                 1741.89 
                 pass 
                 approx. 80 
                 68.0 
                 Y 
                 1) 
               
               
                   
                   
               
               
                   
                 173 
                 [M + 2H]2+ 
                 — 
                 — 
                 1670.08 
                 2012.08 
                 pass 
                 85.3 
                 67.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                 174 
                 [M + 2H]2+ 
                 558.0 
                 [M + 3H]3+ 
                 1671.02 
                 2013.02 
                 pass 
                 95.5 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 175 
                 [M + 2H]2+ 
                 567.9 
                 [M + 3H]3+ 
                 1701.01 
                 2043.01 
                 pass 
                 89.8 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 176 
                 [M + 2H]2+ 
                 584.8 
                 [M + 3H]3+ 
                 1751.97 
                 2093.97 
                 pass 
                 88.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 177 
                 [M + 2H]2+ 
                 — 
                 — 
                 1720.97 
                 2062.97 
                 pass 
                 87.9 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 178 
                 [M + 2H]2+ 
                 543.3 
                 [M + 3H]3+ 
                 2623.90 
                 1985.90 
                 pass 
                 95.4 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 179 
                 [M + 2H]2+ 
                 550.0 
                 [M + 3H]3+ 
                 1736.97 
                 2192.97 
                 pass 
                 90.0 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 180 
                 [M + 2H]2+ 
                 545.2 
                 [M + 3H]3+ 
                 1632.80 
                 1974.80 
                 pass 
                 91.1 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 181 
                 [M + 2H]2+ 
                 543.1 
                 [M + 3H]3+ 
                 1626.64 
                 1965.64 
                 pass 
                 88.5 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 182 
                 [M + 2H]2+ 
                 562.2 
                 [M + 3H]3+ 
                 1743.75 
                 2193.75 
                 pass 
                 90.4 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 183 
                 [M + 2H]2+ 
                 587.8 
                 [M + 3H]3+ 
                 1780.79 
                 2330.79 
                 pass 
                 9085.4   
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 184 
                 [M + 2H]2+ 
                 549.2 
                 [M + 3H]3+ 
                 1646.73 
                 2214.73 
                 pass 
                 97.1 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 185 
                 [M + 2H]2+ 
                 564.3 
                 [M + 3H]3+ 
                 1689.91 
                 7145.91 
                 pass 
                 89.2 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 186 
                 [M + 2H]2+ 
                 — 
                 — 
                 1676.90 
                 1904.90 
                 pass 
                 85.0 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 187 
                 [M + 2H]2+ 
                 578.5 
                 [M + 3H]3+ 
                 1743.04 
                 1961.01 
                 pass 
                 88.9 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 188 
                 [M + 2H]2+ 
                 — 
                 — 
                 1765.12 
                 1993.12 
                 pass 
                 83.7 
                 69.0 
                 Y 
               
               
                   
                   
               
               
                   
                 189 
                 [M + 2H]2+ 
                 642.3 
                 [M + 3H]3+ 
                 1924.23 
                 2380.23 
                 pass 
                 91.7 
                 70.0 
                 Y 
               
               
                   
                   
               
               
                   
                 190 
                 [M + 2H]2+ 
                 631.6 
                 [M + 3H]3+ 
                 2892.28 
                 2462.28 
                 pass 
                 86.1 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 191 
                 [M + 2H]2+ 
                 620.7 
                 [M + 3H]3+ 
                 1855.26 
                 2315.26 
                 pass 
                 87.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 192 
                 [M + 2H]2+ 
                 616.3 
                 [M + 3H]3+ 
                 1846.25 
                 2416.25 
                 pass 
                 82.7 
                 65.0 
                 Y 
               
               
                   
                   
               
               
                   
                 193 
                 [M + 2H]2+ 
                 — 
                 — 
                 1723.13 
                 2065.13 
                 pass 
                 94.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 194 
                 [M + 2H]2+ 
                 600.0 
                 [M + 3H]3+ 
                 1787.12 
                 2253.12 
                 pass 
                 85.9 
                 86.0 
                 Y 
               
               
                   
                   
               
               
                   
                 195 
                 [M + 2H]2+ 
                 611.4 
                 [M + 3H]3+ 
                 1831.18 
                 2287.18 
                 pass 
                 87.8 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 196 
                 [M + 2H]2+ 
                 659.7 
                 [M + 3H]3+ 
                 1976.30 
                 2432.30 
                 pass 
                 90.3 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 197 
                 [M + 2H]2+ 
                 — 
                 — 
                 2054.39 
                 2312.39 
                 pass 
                 93.9 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 198 
                 [M + 2H]2+ 
                 — 
                 — 
                 2070.37 
                 2298.37 
                 pass 
                 84.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 199 
                 [M + 2H]2+ 
                 627.5 
                 [M + 3H]3+ 
                 1880.08 
                 2108.08 
                 pass 
                 92.0 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 200 
                 [M + 2H]2+ 
                 589.5 
                 [M + 3H]3+ 
                 1769.98 
                 1933.98 
                 pass 
                 91.4 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 201 
                 [M + 2H]2+ 
                 — 
                 — 
                 1556.74 
                 1786.74 
                 pass 
                 84.9 
                 6SXI 
                 Y 
               
               
                   
                   
               
               
                   
                 202 
                 [M + 2H]2+ 
                 — 
                 — 
                 1414.62 
                 1528.62 
                 pass 
                 80.4 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 203 
                 [M + 2H]2+ 
                 — 
                 — 
                 1445.58 
                 1559.58 
                 pass 
                 83.7 
                 67.0 
                 Y 
                 3) 
               
               
                   
                   
               
               
                   
                 204 
                 [M + 2H]2+ 
                 — 
                 — 
                 1515.67 
                 1743.67 
                 pass 
                 90.0 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 205 
                 [M + 2H]2+ 
                 548.3 
                 [M + 3H]3+ 
                 1641.83 
                 1983.83 
                 pass 
                 88.2 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 206 
                 [M + 2H]2+ 
                 558.6 
                 [M + 3H]3+ 
                 1672.92 
                 2325.92 
                 pass 
                 87.6 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 207 
                 [M + 2H]2+ 
                 574.2 
                 [M + 3H]3+ 
                 1720.11 
                 2176.11 
                 pass 
                 89.1 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 208 
                 [M + 2H]2+ 
                 601.7 
                 [M + 3H]3+ 
                 1802.24 
                 2486.24 
                 pass 
                 82.0 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 209 
                 [M + 2H]2+ 
                 601.7 
                 [M + 3H]3+ 
                 1800.24 
                 7436.24 
                 pass 
                 82.3 
                 67.0 
                 Y 
               
               
                   
                   
               
               
                   
                 210 
                 [M + 2H]2+ 
                 610.3 
                 [M + 3H]3+ 
                 1828.21 
                 2512.21 
                 pass 
                 91.3 
                 66.0 
                 Y 
               
               
                   
                   
               
               
                   
                 211 
                 [M + 2H]2+ 
                 494.5 
                 [M + 3H]3+ 
                 1480.79 
                 2050.79 
                 pass 
                 97.3 
                 68.0 
                 Y 
               
               
                   
                   
               
               
                   
                 Comments: 
               
               
                   
                 1) estimated on ESI/MAID: 
               
               
                   
                 2) estimated on MALD: 
               
               
                   
                 3) dissolved in ACN/H2O 
               
               
                   
                 4) dissolved in TFA/H2O 
               
               
                   
                 5) dissolved in DMSO 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                 HIV-1 Consensus B Tat (NIH AIDS Reagent 5138) 
               
               
                 DATA SHEET 
               
               
                 HIV-1 Consensus 8 Tat (15-mer) peptides - Complete Set (Cat# 5138, Lot# 11) 
               
            
           
           
               
               
            
               
                   
                 Solubility Data 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                 Molecular 
                   
                 Peptide 
                   
                   
                 10% 
                   
               
               
                   
                   
                   
                   
                 Weight 
                 Purity 
                 Content 
                   
                   
                 Acetic 
               
               
                 CAT # 
                 Peptide Name 
                 SEQUENCE 
                 LOT # 
                 g/mol 
                 [%] 
                 [%] 
                 Water 
                 PBS 
                 Acid 
                 DMSO 
               
               
                   
               
               
                 5113 
                 HIV-1 Clade B consensus tat 
                 MEPVDPRLEPWKHPG 
                 070034 
                 1786.85 
                 &gt;80% 
                 90% 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 5114 
                 HIV-1 Clade B consensus tat 
                 DPRLEPWKHPGSQPK 
                 070035 
                 1770.88 
                 &gt;80% 
                 90% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5115 
                 HIV-1 Clade B consensus tat 
                 EPWKHPGSQPKTACT 
                 070036 
                 1665.77 
                 &gt;80% 
                 90% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5116 
                 HIV-1 Clade B consensus tat 
                 HPGSQPKTACTNCYC 
                 070037 
                 1608.63 
                 &gt;80% 
                 90% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5117 
                 HIV-1 Clade B consensus tat 
                 QPKTACTNCYCKKCC 
                 070038 
                 1692.67 
                 &gt;80% 
                 80% 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 5118 
                 HIV-1 Clade B consensus tat 
                 ACINCYCKKCCFHCQ 
                 070039 
                 1753.62 
                 &gt;80% 
                 80% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5119 
                 HIV-1 Clade B consensus tat 
                 CYCKKCCFHCQVCFI 
                 070040 
                 1826.71 
                 &gt;80% 
                 85% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5120 
                 HIV-1 Clade B consensus tat 
                 KCCFHCQVCFITKGL 
                 070041 
                 1728.78 
                 &gt;80% 
                 90% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5121 
                 HIV-1 Clade B consensus tat 
                 HCQVCFITKGLGISY 
                 070042 
                 1667.79 
                 &gt;80% 
                 95% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5122 
                 HIV-1 Clade B consensus tat 
                 CFITKGLGISYGRKK 
                 070043 
                 1669.89 
                 &gt;80% 
                 80% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5123 
                 HIV-1 Clade B consensus tat 
                 KGLGISYGRKKRRQR 
                 070044 
                 1802.04 
                 &gt;80% 
                 70% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5124 
                 HIV-1 Clade B consensus tat 
                 ISYGRKKRRQRRRAP 
                 070045 
                 1927.12 
                 &gt;80% 
                 75% 
                 − 
                 − 
                 − 
                 + 
               
               
                   
               
               
                 5125 
                 HIV-1 Clade B consensus tat 
                 RKKRRQRRRAPQDSQ 
                 070046 
                 1965.11 
                 &gt;80% 
                 85% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5126 
                 HIV-1 Clade B consensus tat 
                 RQRRRAPQDSQTHQV 
                 070047 
                 1861.97 
                 &gt;80% 
                 90% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5127 
                 HIV-1 Clade B consensus tat 
                 RAPQDSGTHQVSLSK 
                 070048 
                 1680.84 
                 &gt;80% 
                 90% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5128 
                 HIV-1 Clade B consensus tat 
                 DSQTHQVSLSKQPAS 
                 070049 
                 1611.77 
                 &gt;80% 
                 85% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5129 
                 HIV-1 Clade B consensus tat 
                 HQVSLSKQPASGPRG 
                 070050 
                 1618.83 
                 &gt;80% 
                 70% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5130 
                 HIV-1 Clade B consensus tat 
                 LSKQPASQPRGDPTG 
                 070050 
                 1618.83 
                 &gt;80% 
                 70% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5131 
                 HIV-1 Clade B consensus tat 
                 PASQPRGDPTGPKES 
                 070052 
                 1522.71 
                 &gt;80% 
                 85% 
                 − 
                 + 
                 + 
                 + 
               
               
                   
               
               
                 5132 
                 HIV-1 Clade B consensus tat 
                 PRGDPTGPKESKKKV 
                 070053 
                 1622.87 
                 &gt;80% 
                 70% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5133 
                 HIV-1 Clade B consensus tat 
                 PTGPKESKKKVERET 
                 070054 
                 1712.90 
                 &gt;80% 
                 75% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5134 
                 HIV-1 Clade B consensus tat 
                 KESKKKVERETETDP 
                 070055 
                 1802.90 
                 &gt;80% 
                 85% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 5135 
                 HIV-1 Clade B consensus tat 
                 KKVERETETDPVDQ 
                 070056 
                 1544.75 
                 &gt;80% 
                 95% 
                 − 
                 − 
                 + 
                 + 
               
               
                   
               
               
                 Determination of solubility: appr. 0.25 mg of the respective peptide was incubcted with 1 ml of solvent. 
               
               
                 Solubility was assessed by visual inspection of the resulting solution/suspension. 
               
               
                 “+”: complete dissolution 
               
               
                 “−”: incomplete dissolution 
               
               
                 NOTE: 
               
               
                 Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted witn aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution.